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ABSTRACT 
 Women are exposed to numerous endogenous and exogenous hormones across the 
lifespan. In the last several decades, the prescription of novel hormonal contraceptives and 
hormone therapies (HTs) have resulted in aging women that have a unique hormone 
exposure history; little is known about the impact of these hormone exposures on short- 
and long- term brain health. The goal of my dissertation was to understand how lifetime 
hormone exposures shape the female cognitive phenotype using several innovative 
approaches, including a new human spatial working memory task, the human radial arm 
maze (HRAM), and several rodent menopause models with variants of clinically used 
hormone treatments. Using the HRAM (chapter 2) and established human 
neuropsychological tests, I determined males outperformed females with high endogenous 
or exogenous estrogen levels on visuospatial tasks and the spatial working memory HRAM 
(chapter 3). Evaluating the synthetic estrogen in contraceptives, ethinyl estradiol (EE), I 
found a high EE dose impaired spatial working memory in ovariectomized (Ovx) rats, 
medium and high EE doses reduced choline-acetyltransferace-immunoreactive neuron 
population estimates in the basal forebrain following Ovx (chapter 4), and low EE impaired 
spatial cognition in ovary-intact rats (chapter 5). Assessing the impact of several clinically-
used HTs, I identified a window of opportunity around ovarian follicular depletion outside 
of which the HT conjugated equine estrogens (CEE) was detrimental to spatial memory 
(chapter 6), as well as therapeutic potentials for synthetic contraceptive hormones (chapter 
9) and bioidentical estradiol (chapter 7) during and after the transition to menopause. 
Chapter 6 and 7 findings, that estradiol and Ovx benefitted cognition after the menopause 
transition, but CEE did not, are perhaps due to the negative impact of ovarian-produced, 
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androstenedione-derived estrone; indeed, blocking androstenedione’s conversion to estrone 
prevented its cognitive impairments (chapter 8). Finally, I determined that EE combined 
with the popular progestin levonorgestrel benefited spatial memory during the transition to 
menopause, a profile not seen with estradiol, levonorgestrel, or EE alone (chapter 9). This 
work identifies several cognitively safe, and enhancing, hormonal treatment options at 
different time points throughout female aging, revealing promising avenues toward 
optimizing female health.
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CHAPTER 1: GENERAL INTRODUCTION 
 Throughout the lifespan, women are exposed to constant shifts in hormones. In 
addition to constant exposure to endogenous hormones, which are hormones that are 
naturally produced by an organism, there is also the possibility of exposure to exogenous 
hormones, or hormones that originate from outside of the organism. Women’s 
reproductive hormones, in particular, undergo many endogenously- and exogenously- 
triggered changes, including those that happen during perinatal development, puberty, 
with use of hormonal contraceptives, during pregnancy, throughout the transition to 
menopause, and with HT. Reproductive hormones such as estrogens, androgens, 
progesterone, and others, are responsible for the regulation of countless body functions in 
addition to their reproductive functions, including temperature, bone density, body fat 
composition and deposition, metabolism, and brain function. The breadth of hormone 
exposures women experience is impressive, and includes both natural and synthetic 
hormones. Moreover, several changes in hormone use trends across the past few decades 
contribute to an aging generation with a previously unrepresented hormonal history. The 
known pervasive and interactive effects each of these hormones has on brain and body 
function mean that these changing hormone use trends are likely to produce a unique 
generation of aging females.  
 Fortunately, scientists now have access to several important tools necessary to 
methodically investigate the effects that these hormone exposures have on brain function 
and cognition. Rodent behavioral research affords the opportunity to model many of the 
hormonal states that women experience throughout the lifespan. The rodent estrous cycle 
is remarkably similar to the human menstrual cycle, providing a model of the human 
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reproductive lifespan. Through surgical removal of the ovaries in rodents (ovariectomy; 
Ovx) we can model oophorectomy, a procedure that approximately 600,000 women 
undergo each year in the Unites States (ACOG, 2008; Rocca et al., 2009), as well as 
isolate the effects of individual ovarian hormones on the brain and body (Mennenga and 
Bimonte-Nelson, 2013). Treatment with the industrial chemical 4-vinylcyclohexene 
diepoxide (VCD) accelerates the process of atresia in ovarian follicles, producing a 
follicle-deplete, ovary-intact rodent with a hormone profile similar to that following 
human menopause (Mayer, et al., 2004, 2005; Acosta et al., 2009, 2010; Mennenga and 
Bimonte-Nelson, 2013). Both Ovx and VCD treatment can be manipulated independently 
of aging, allowing investigation into age-dependent and –independent effects of 
reproductive hormones.  
 17β-Estradiol (E2) is the most potent naturally circulating estrogen in women and 
rats, followed by estrone  (E1) and estriol, in order of receptor affinity. Ethinyl estradiol 
(EE), a synthetic form of E2, is the most common estrogen in hormonal contraceptives 
(Shively, 1998), and is the only estrogen used in the contraceptive pill. National surveys 
estimate that 10.6 million women between 2006-2010 (Jones et al., 2012), and 17.3% of 
all women between 2006-2008 (Mosher and Jones, 2010), used oral contraceptives. Over 
30 contraceptive formulations contain EE (Curtis et al., 2005; Hoffman et al., 2012) and 
EE is also found in hormone therapies (HTs) for menopausal women, such as Estinyl™ 
and Femhrt™ (Curtis et al., 2005; Hoffman et al., 2012). Understanding the cognitive 
impact of estrogens is critical, as exposure to exogenous estrogens occurs throughout the 
lifespan through both hormonal contraceptives and HTs. While EE is a synthetic 
analogue to E2, these estrogens have different pharmacological profiles (Coelingh 
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Bennink et al., 2004). Additionally, EE is more biologically active than E2 (Dickson and 
Eisenfeld, 1981) and cannot be converted to E1 or other weaker estrogens (Fotherby, 
1996), whereas E2 can (Prokai-Tatrai, et al., 2005). These estrogens also exhibit different 
binding profiles across species (Paradiso et al., 2001).  
Estrogen Receptors (ERs) are highly expressed in several cognitive brain regions, 
including the basal forebrain (BF) (Shughrue et al., 1999), which contains cholinergic 
cell bodies that project to the hippocampus (McEwen, 2001; Gibbs, 2010). These 
projections are known to be intimately involved in spatial learning and memory (Luine et 
al., 1986) and are required for E2 to benefit cognition in rodents (Gibbs, 2002, 2007); 
however, no studies have evaluated the impact of EE on this system. Although EE is 
among the most commonly prescribed estrogens for contraception, and is prescribed to 
women from puberty to post-menopause, most preclinical research on the cognitive 
impact of estrogens does not include EE (for reviews see: Bimonte-Nelson et al., 2010; 
Acosta et al., 2013).  
Optimizing Hormonal Contraceptive Use During Young Adulthood 
In human contraceptive users, no impact of EE-containing contraceptives was 
found on several tests of memory and concentration (Silber et al., 1987). Mordecai et al. 
(2008) found enhanced verbal memory during the active, compared to the inactive phase 
of oral contraceptives, although benefits were not seen on visuospatial measures. 
Although each of the contraceptive formulations used in these studies contained EE, 
other aspects of the formulations differed, including dose and which progestin was 
included. Thus, it is difficult to decipher whether or to what extent EE was responsible 
for these effects. In studies investigating EE as a HT, cognitive effects seem to depend on 
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memory domain as well. In aged ovariectomized (Ovx) rhesus monkeys, EE improved 
spatial working memory (Lacreuse et al., 2002), but impaired face recognition (Lacreuse 
and Herndon, 2003), and had no impact on executive function (Lacreuse et al., 2004). An 
fMRI study of menopausal women found EE-containing HTs increased frontal cortex 
activation during a working memory task (Smith, et al., 2006).  
We performed an experiment in human participants to unite human and rodent 
cognitive research methodology and to determine whether a human analogue of a rodent 
testing paradigm produces a similar pattern of errors to that seen in rodents (see Table 1 
for an overview of experiments). We also sought to determine whether established tasks 
that measure different domains of cognition in humans would account for unique portions 
of variance in HRAM scores. In experiment 1 (chapter 2), we tested whether a human 
radial arm maze (HRAM) could be a useful and valid measure of human spatial working 
memory. In experiment 2 (chapter 3), we then divided our participants according to 
hormonal status to determine whether sex, menstrual phase, or hormonal contraceptive 
use were associated with differences in performance on each of these tasks. Following the 
collection of these data, experiment 3 (chapter 4) was then performed to test the cognitive 
and neurobiological effects of daily administration of EE in Ovx rodents, to determine 
whether we could reproduce our human findings in rodents. Experiment 3 (chapter 4) 
utilized Ovx female rats with no circulating ovarian hormones in addition to the EE 
delivered exogenously by daily injections. While the Ovx model is a powerful tool that 
allows isolation of the cognitive effects of a single hormone, an animal model using 
ovary-intact female rats is necessary, given that most women retain their ovaries for the 
majority of their lives. Thus, experiment 4 (chapter 5) evaluated the effects of EE 
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administration in ovary-intact animals to determine how EE affects cognition when 
ovaries are present.  
Optimizing the Cognitive Impact of Hormone Therapy in a Rodent Model of Natural 
Menopause 
 Around the fifth decade of life, women’s eggs stop maturing, ovulation and 
menstruation become irregular, and eventually the menses cease; this natural irregularity 
and gradual cessation of the menses is known as menopause (NAMS; Curtis et al., 2005; 
Hoffman et al., 2012). With the halting of ovulation, ovarian production of estrogen and 
progesterone drastically decrease, resulting in several undesirable health consequences. 
Common issues faced by women undergoing menopause include hot flashes, bone 
density loss, cardiovascular changes, atrophy of vaginal tissue, and cognitive decline 
(Curtis et al., 2005; Hoffman et al., 2012). While human life expectancy is increasing, 
menopause onset has remained stable and can begin as early as age 40, meaning that 
women are living increasingly larger proportions of their lives in this hypo-estrogenic 
state (NAMS). Many women utilize estrogen-containing HT, which can alleviate several 
symptoms associated with menopause. Conjugated equine estrogens (CEE, tradename 
Premarin®, Prempro with the synthetic progestin Medroxyprogesterone acetate; MPA) 
were the most commonly prescribed estrogen component of HT in the US (Hersh et al., 
2004). Fourteen million women in the US were estimated to use CEE in 2005, and CEE 
has been prescribed as HT since 1942 (Stefanick, 2005). CEE contains several estrogens, 
including many that are not naturally produced by women, trace amounts of E2, and over 
50% E1 sulfate (E1S; Gleason et al., 2005), which is desulfated in the liver, converting it 
to E1. In many women, CEE HT is effective at attenuating or preventing symptoms of 
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menopause, including hot flashes, vaginal atrophy, and decreased bone density (Curtis et 
al., 2005); however, whether CEE reduces the cognitive decline associated with 
menopause remains unclear. The large Women’s Health Initiative Memory Study 
(WHIMS) reported that CEE alone produced no change in risk of developing mild 
cognitive impairment (MCI) and marginally increased risk of probable dementia; CEE 
plus progestin treatment produced no change in MCI risk and increased the risk of 
probable dementia in menopausal women (Espeland et al., 2004; Shumaker et al., 2004), 
findings which prompted many women to discontinue their HT use altogether (ACOG, 
2011). 
Using the Ovx rodent as a model of surgical hormone loss, our and other 
laboratories have shown that E2 HT can benefit performance in multiple cognitive 
domains, including spatial reference memory, a form of long term memory for 
information that stays constant (Bimonte and Denenberg 1999; Gibbs, 2000; Bimonte-
Nelson et al., 2006; Talboom et al., 2008), and spatial working memory, a form of short 
term memory for information that is updated (Bimonte and Denenberg, 1999). Our lab 
has also shown that CEE HT can benefit spatial working and reference memory in rats 
whose ovaries had been surgically removed via Ovx (Acosta et al., 2009). The Ovx 
model is an excellent tool to study the estimated 600,000 women per year who have 
undergone surgically induced menopause (ACOG, 2008; Rocca et al., 2009), and it is the 
gold standard for isolating the effects of exogenously administered ovarian hormones 
(Mennenga & Bimonte-Nelson, 2013); however, the Ovx model has limited 
generalizability to the majority of women who have undergone natural, transitional 
menopause and retained their follicle-deplete ovaries. Importantly, reproductive 
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senescence in women differs from reproductive senescence in female rats. The aging rat 
does not experience menopause; it experiences estropause, which includes several 
hormonal states indicative of irregular ovulation. Natural menopause can be more closely 
modeled in the rodent via the industrial chemical 4-vinylcyclohexene diepoxide (VCD). 
Treatment with VCD accelerates the natural process of atresia in the finite primary and 
primordial follicle pool, producing a gradual loss of follicles (Flaws et al., 1994; 
Springer, McAsey, et al., 1996; Springer, Tilly, et al., 1996; Borman, et al., 1999; Kao et 
al., 1999; Hu et al., 2002; Mayer, et al., 2002, 2004, 2005), leading to ovarian failure, and 
a drastic decrease in ovarian-derived E2 and progesterone (Hirshfield, 1991; Springer et 
al., 1996: Mayer, et al., 2004, 2005). Thus, treatment with VCD results in an ovary-intact, 
follicle-deplete rat with a hormone profile similar to that of a naturally menopausal 
woman.  
 Using the VCD and Ovx models, our lab was able to asses how CEE HT would 
impact cognition with transitional, versus abrupt, hormone loss. We showed that CEE 
improves performance on a spatial working and reference memory task following 
surgical menopause, but impairs performance on this task when administered following a 
VCD-induced transitional hormone loss and follicle-deplete ovaries were retained 
(Acosta et al., 2010). In surgically menopausal rats, CEE enhanced reference memory 
and two measures of working memory on the trial with the highest working memory 
load, similar to our previous findings. In contrast, VCD-treated rats showed the opposite 
effect, with errors increasing on these measures following CEE treatment. Further, CEE-
treated Ovx rats showed better memory retention across an 8-hr delay relative to oil-
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treated Ovx rats, while CEE exerted no retention benefit in transitionally menopausal 
rats.  
There is accumulating evidence that a ‘window of opportunity’ for HT initiation 
following hormone loss exists. Clinical studies demonstrating a limited window of time 
during which HT can exert positive effects have given rise to the window of opportunity 
hypothesis (Resnick & Henderson, 2002; Zandi et al., 2002; MacLennan et al., 2006; 
Maki, 2006; Maki & Sundermann, 2009; Khoo et al., 2010). For example, recent reports 
have found that, in naturally menopausal women, HT initiated prior to menopause was 
beneficial to cognitive performance, while HT initiated post-menopause was detrimental 
(Greendale et al., 2009), and use of HT initiated during perimenopause has been shown to 
enhance memory and hippocampal activation, as detected by fMRI, in women (Maki et 
al., 2011). Several preclinical rodent studies also support the window of opportunity 
hypothesis for beneficial effects of HT on cognition (Gibbs, 2000; Daniel et al., 2006; 
Bohacek & Daniel, 2010) and brain health (Bohacek et al., 2008; Bohacek & Daniel, 
2009). In middle-aged Ovx rats, E2 given immediately, but not 5 months after Ovx, 
enhanced spatial working memory on a land radial-arm maze (Daniel et al., 2006) and 
enhanced performance on the five-choice serial reaction time task (Bohacek & Daniel, 
2010). Additionally, E2 given immediately or three months, but not 10 months, after Ovx 
enhanced delayed-match-to-position performance (Gibbs, 2000).  
Thus, clinical and preclinical findings concur that the beneficial effects of 
estrogen HT may be dependent on early initiation. However, there have been no 
preclinical rodent studies evaluating this question utilizing a model of transitional 
menopause. In our previous study demonstrating detrimental effects of CEE in 
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transitionally menopausal ovary-intact rats (Acosta et al. 2010), CEE treatment initiation 
took place after follicular depletion had ensued. We then asked whether giving CEE at 
the onset of follicular depletion would still impair memory. The goals of experiment 5 
(chapter 6) were to determine whether the cognitive impact of CEE HT is influenced by 
the timing of treatment initiation relative to the onset of follicular depletion, or the 
duration of treatment.  
Our lab has collected an abundance of data that lead us to suspect that other 
estrogens may be capable of producing a more favorable cognitive outcome following 
follicular depletion. Androstenedione is an androgen that is produced by the ovaries and 
can be converted to E1 via the aromatase enzyme. In several studies, we have found an 
association between elevated circulating androstenedione levels and number of errors on 
the WRAM (Acosta et al., 2009; 2010; Camp et al. 2012). We have also shown that 
exogenous delivery of E1 to Ovx animals produces memory impairment (Engler-
Chiurazzi et al., 2012), providing some insight into the possible hormonal mechanism 
underlying the negative cognitive effects of CEE following VCD treatment. These data 
suggest that androstenedione, the primary hormone released by follicle-deplete ovaries, 
may be impairing memory through its conversion to E1, via the aromatase enzyme. 
Administration of CEE, primarily composed of E1 sulfate, may exacerbate already 
impaired cognition by further increasing levels of E1. Mounting evidence suggests that 
CEE is not optimal for naturally menopausal women with an already imbalanced 
hormonal background. A HT that restores hormonal balance during and after the 
transition to menopause, such as E2, may provide cognitive benefits. Experiment 6 
(chapter 7) was conducted to determine how E2 administration to follicle-deplete rats 
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would impact cognition compared to Ovx, which is the only treatment that has thus far 
been shown to improve memory following VCD-induced follicular depletion in rodents 
(Acosta et al., 2009b). 
Hormonal Mechanisms Underlying the Cognitive Consequences of Natural Hormone 
Loss 
 With reproductive senescence, there is a drastic loss of ovarian-derived estrogen 
and progesterone, and the androgen androstenedione becomes the principal hormone 
released by the ovaries (Timaras et al., 1995). This androgen-rich hormone milieu is also 
seen in a rodent model of natural menopause via treatment with VCD. Accumulating 
evidence in the female rat suggests that androstenedione has a negative impact on 
cognition. Following a series of studies in which we found an association between higher 
levels of endogenously-produced androstenedione and poorer memory (Acosta et al., 
2009b, 2010), we demonstrated that exogenous androstenedione administration to Ovx 
animals impaired spatial reference memory, working memory, and memory retention 
(Camp et al., 2012).  
Understanding the effects of androstenedione on the brain and its function is 
critically important to understanding the cognitive impact of natural menopause; ovarian-
derived androstenedione is present in menopausal women who maintain their ovaries, an 
effect observed for at least ten years after menopause ensues (Fogle et al., 2007). Drugs 
that block the activity of the aromatase enzyme (Santen et al., 2009), which catalyzes the 
conversion of androstenedione to E1, are some of the tools used to treat metastatic breast 
cancer prevalent in menopausal women (Glück et al., 2013), as well as manage estrogen-
dependent endometrial carcinoma (Gao et al., 2014). In a subsequent study, we sought to 
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decipher the hormonal mechanisms underlying the negative cognitive impact of 
androstenedione using a rat model. Androstenedione could be exerting cognitive effects 
through a multitude of mechanistic pathways; it is a direct precursor to testosterone via 
the 17β-hydroxysteroid dehydrogenase (17β-HSD) enzyme, and to E1 via the aromatase 
enzyme, and it binds to androgen receptors (Horton & Tait, 1966; Jasuja et al., 2005). In 
the rodent model, testosterone administration has been shown to enhance spatial working 
memory (Bimonte-Nelson et al., 2003b), spatial reference memory (Benice & Raber, 
2009), and performance on avoidance tasks (Flood et al., 1995; Edinger et al., 2004). 
Moreover, higher relative levels of testosterone are associated with better spatial ability 
in women, while lower relative levels of salivary testosterone were related to better 
spatial ability in men (Gouchie & Kimura, 1991). We have previously shown that E1 
administration in Ovx rats produces cognitive impairments (Engler-Chiurazzi et al., 
2012). Given these results, we hypothesized that androstenedione’s conversion to E1, 
rather than its actions on the androgen receptor, underlies its negative cognitive impact.  
In experiment 7 (chapter 8), we systematically evaluate whether 
androstenedione’s conversion to E1, or its effects on the androgen receptor, are 
responsible for its negative cognitive effects in the surgically menopausal young adult rat. 
We utilize pharmacological manipulations that either block androstenedione’s conversion 
to E1, or block androstenedione’s androgenic effects by blocking activation of the 
androgen receptor. Anastrozole, a non-steroidal aromatase inhibitor, or flutamide, a non-
steroidal anti-androgen, were co-administered with androstenedione to determine whether 
androstenedione impairs memory via its conversion to E1, or via its action on the 
androgen receptor, respectively. A secondary purpose of this study was to test the effects 
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of anastrozole given alone. Aromatase inhibitors such as anastrozole are used to treat and 
prevent recurrence of breast cancer (Santen et al., 2009). Elucidating the impact of 
aromatase and estrogen metabolism on the brain and its function is critical to our 
understanding of the systems-level alterations that occur with changes in both 
endogenous and exogenous steroid hormones. 
Modeling Current Trends in Hormone Therapy 
Since the early 2000’s, HT prescription trends have shifted; the heavily publicized 
WHI and WHIMS results showing no cognitive benefits of CEE HT, and potential 
increased cognitive and health risks, prompted women to ask for alternative, safer HT 
regimens (ACOG, 2011; Endocrine Society, 2015). In response to this demand, many 
FDA-approved bioidentical E2-containing HTs are now available in the United States. In 
addition to these FDA-approved HT formulations, this demand has also opened a market 
for non-FDA-approved, custom compounded estrogen/estrogen+progestogen 
formulations. These formulations have gained popularity in the clinic; new estimates state 
that 28%-68% of HT prescriptions now fall under this category (NAMS, 2015a, 2015b), 
and these regimens have raised major health concerns amongst physicians, as they are not 
governmentally regulated, and may contain unsafe levels of various hormones (Endocrine 
Society, 2015; NAMS, 2015a, 2015b). 
Another popular hormonal option for women beginning the transition to 
menopause is a hormonal contraceptive regimen, to regulate the menses (Curtis et al., 
2005; Hoffman et al., 2012). It is still unknown how EE or any of the synthetic progestins 
utilized in hormonal contraceptives affect cognition in a rodent model of transitional 
menopause, although many physicians are now recommending these formulations for 
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prevention of unwanted pregnancies during the transition to menopause (Ikhena & 
Johnson, 2012). Other work from our lab has shown that treatment with MPA induces 
long-lasting cognitive impairments (Braden et al., 2010; 2011), and ongoing work in our 
laboratory suggests that a clinically relevant dose of another available progestin, 
levonorgestrel (levo), produces a favorable cognitive impact in young Ovx rats.  
Findings from this dissertation suggest that EE-containing hormonal 
contraceptives may be a promising HT candidate for use during the menopause transition. 
Although low-dose EE negatively impacted memory in young-adult ovary-intact rodents 
in chapter 5, as well as in young adult women in chapter 3, we did not see an impact of 
low-dose EE in animals that had undergone Ovx in chapter 4. The results from this 
dissertation broadly suggest that the cognitive effects of estrogens are dependent on the 
hormonal profile of the user. EE’s lack of conversion to E1 makes it a promising 
candidate for use by naturally menopausal women, and the necessary synthetic progestin 
may serve to replace the progestogenic stimulation lost with menopause. FDA-approved 
hormonal contraceptives may serve several functions, including alleviating non-cognitive 
symptoms of menopause, masking irregular hormone fluctuations, and preventing 
unwanted pregnancies during the transition to menopause. Hormonal contraceptives also 
do not incur the same cancer risks as traditional HTs, and may actually reduce the risk of 
ovarian and endometrial cancer (Hoffman et al., 2012). For experiment 8 (chapter 9) we 
tested the cognitive impact of the estrogens E2 and EE, as well as the synthetic progestin 
levo, and the combinations of each estrogen with levo during follicular depletion, to 
model clinically prescribed formulations of combined contraceptives and FDA-approved 
HTs that are currently prescribed (Curtis et al., 2005; Hoffman et al., 2012).  
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Overarching Aims of This Dissertation 
 The overarching purpose of my graduate work was to further scientific 
understanding of how various hormone exposures across the lifespan impact the 
trajectory of learning and memory throughout aging. I have addressed this goal by 
systematically modeling current hormone use trends in rodents via menopause induction 
models (both surgical and transitional) and by manipulating endogenous and exogenous 
estrogens, progestogens, and androgens. Through this dissertation research, I have 
discovered that endogenous and exogenous ovarian hormones impact the brain and its 
functions, work that, I hope, will translate to enriching brain health in women. Moreover, 
underscoring the translational approach of my work, I helped lead a team which created a 
human radial arm maze, thereby allowing gains in interdisciplinary understanding of 
hormonal effects on spatial learning and memory. Throughout the chapters of this 
dissertation, I aimed to model, as closely as possible, the current hormone use trends 
prevalent in women’s healthcare today. The current aging generation is the first to have 
had exposure to hormonal contraceptives during young adulthood, and has also 
experienced several distinctive iterations of HT use trends during and after menopause; 
each of these major shifts in lifetime hormone exposures have produced an aging 
generation with a unique hormone history. It is my hope that the work in this dissertation 
allows insight into the cognitive impact of each of these various hormone exposures 
across the lifespan, therefore contributing to our understanding of the aging profile of 
current and future generations.  
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CHAPTER 2: NAVIGATING TO NEW FRONTIERS IN BEHAVIORAL 
NEUROSCIENCE: TRADITIONAL NEUROPSYCHOLOGICAL TESTS PREDICT 
HUMAN PERFORMANCE ON A RODENT-INSPIRED RADIAL ARM MAZE 
Introduction 
 Spatial learning and memory, the ability to encode, store, and retrieve information 
about route navigation and object locations (Barnes et al., 1997), has been a major focus in 
the field of neuroscience since Tolman famously asserted that rodents utilize cognitive 
maps of their environments to navigate mazes (Tolman, 1948). Several decades and many 
landmark findings later, an abundance of rodent research probing the many facets of spatial 
navigation and numerous useful tools for measuring spatial learning and memory have 
been amassed (see Bimonte-Nelson et al., 2010 for review). In rodents, one of the most 
commonly used and widely recognized tests of spatial memory is the radial-arm maze 
(RAM) (Jarrard, 1993; Olton & Samuelson, 1976), which consists of a circular arena, from 
which multiple arms radiate outward. Rewards are typically located at the end of each arm, 
or a subset of the arms, depending on the specific task protocol, and the maze is surrounded 
by plentiful extra-maze environmental cues to aid in spatial navigation. The maze relies on 
positive and/or negative reinforcement to motivate animals to efficiently locate each reward 
using the fewest arm entries possible.  
 In the RAM task, rewards are typically not replaced once they have been located 
within each testing session, resulting in increasing task difficulty (i.e., the number of spatial 
locations the animal must avoid for successful performance) across trials, within each 
testing session. In the animal research literature, working memory is considered to be a 
form of short-term memory and is classically defined as information that is worked with, 
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kept ‘online’, and updated. In the RAM, working memory demand is elevated with each 
trial; once a reward is located at the end of an arm, the animal must then remember to avoid 
that arm on future trials for optimal task performance. This complexity makes the RAM a 
valuable instrument for evaluating the ability to handle a systematic increase in working 
memory load. It is well documented in both rats and mice that RAM errors increase within 
each day as trials progress and working memory demand escalates; however, errors 
decrease across multiple testing sessions as animals learn the task (Bimonte-Nelson et al., 
2003; Bimonte & Denenberg, 1999; Camp et al., 2012; Hyde et al., 1998; Jarrard, 1993; 
Olton & Samuelson, 1976).  
 Evidence supports the assertion that, in humans, spatial learning and memory 
involves multiple complex cognitive processes similar to those measured in rodents. For 
example, in order to form a cognitive spatial map, humans also acquire knowledge about 
environmental cues (Shelton & McNamara, 2004; Taylor & Tversky, 1992). Additionally, 
human neuroimaging studies have discovered cell analogues to rodent place cells in the 
hippocampus, providing support for brain mechanisms similar to those of rats when 
mediating navigation through space (Ekstrom et al., 2003), further supporting the idea that 
humans, like rats, utilize a “cognitive map” of their environment. Many effective tasks 
have been developed to tap visuospatial ability, episodic memory, and working memory 
capacity in humans in both experimental and clinical settings. Tasks measuring general 
intelligence in humans, a domain that has yet to be defined or tested in rodents, have also 
been widely developed.  
 Rodent assessments of spatial memory are often also assessments of episodic 
memory, working memory capacity, as well as visuospatial ability. Rodent models have 
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been critical to our understanding of spatial learning and memory, the brain regions and 
mechanisms that confer navigational skills, and potential therapies and pharmacological 
treatments to improve quality of life in populations suffering from cognitive impairments. 
Rodent RAM research, specifically, has produced a wealth of translational knowledge by 
allowing for pharmacological, genetic, and environmental manipulations that are not 
ethically or logistically possible in human populations. Data collected with the rodent RAM 
have led researchers toward numerous discoveries and new directions with the potential to 
enrich and optimize cognitive function in humans; use of this paradigm is essential to 
decipher the infinitely complex neural mechanisms associated with learning and memory, 
as well as the influence of aging, disease, environmental changes, and countless other 
factors. It is generally thought that rodent performance on the RAM depends on 
visuospatial ability, working memory capacity, and an intact episodic memory, but not 
general intelligence. These same cognitive domains are readily evaluated in humans; 
however, it remains unclear whether working definitions of these cognitive domains in 
rodent and human research are functionally equivalent. The extent to which rodent RAM 
research is directly translational to human learning and memory persists as a key scientific 
question. 
 One approach to this immensely complex and dynamic issue is to create an 
intermediate testing instrument by adapting experimental paradigms from animals to 
humans. The aim of the present study was just that—to use a direct and literal translational 
approach to design a human task that measures the ability to remember and utilize 
information about spatial locations in a real world, walk-though environment, modeled 
after rodent RAMs. A complementary team of scientists with expertise in rodent maze 
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learning, human perception and memory, navigational behavior, and diagnostic clinical 
neuropsychology was assembled to construct an 11-arm, walk-through human RAM 
(HRAM), aiming to make the task as similar as possible to the rodent RAM. Performance 
on the HRAM was compared to performance on a battery of tests tapping cognitive 
domains that are hypothesized to underlie spatial learning and memory; namely, spatial 
reasoning ability, episodic memory, working memory, and general intelligence. The 
HRAM allowed me to translate and compare navigational error patterns, exactly as 
measured in rodent RAM studies, to performance on a battery of standard 
neuropsychological and cognitive tests in human participants. 
 My primary goal was to determine whether the HRAM produces a similar pattern of 
errors to that seen in rodents both within and across testing sessions. I expected to see 
HRAM errors change as a function of WM load and testing session. Specifically, I 
predicted that HRAM performance would decline as working memory demand became 
elevated within each testing session, but that performance would improve across testing 
sessions, similar to the pattern of performance seen in rodents. An additional goal of this 
study was to explore the relationship between HRAM performance and performance on 
commonly used neuropsychological and cognitive tests. In order to better understand the 
relationship between some of the most commonly used rodent and human methodology, I 
aimed to determine how much variance in HRAM performance could be predicted by 
scores on standard tests of visuospatial ability, working memory, episodic memory, and 
general intellectual ability. Because RAM performance relies on working memory and 
knowledge of spatial locations, I hypothesized that participants’ scores on tests (defined in 
Methods section) of working memory capacity (OSpan, RSpan, RotSpan, SymSpan), and 
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visuospatial ability (MRT, JLAP) would predict performance on the HRAM. I also tested 
whether performance on a measure of episodic memory (RAVLT) would predict HRAM 
performance. I also wanted to investigate whether a measure of general intelligence would 
predict performance on the HRAM. The final goal of this project was to determine whether 
tasks that measure different domains of cognition in humans would account for unique 
portions of variance in HRAM scores, that is, whether each class of tests (i.e., working 
memory capacity tasks, visuospatial ability tasks, episodic memory tasks) contributed 
distinctly to overall prediction of HRAM performance. I aimed to assess the extent to 
which the addition of neuropsychological tests to a standard battery of cognitive tests 
would improve prediction of human ability to navigate and learn in a real-world 
environment. I predicted that performance on each group of tasks would account for unique 
variance in our HRAM task. The overarching goal of this study was to help expand 
knowledge of both human and rodent cognition, to allow broader interpretations of existing 
data in both species, and to facilitate translational connections between animal laboratory, 
human laboratory, and human clinical research domains. 
Materials and Methods 
Participants 
A total of 157 participants (54 men and 103 women) were recruited from several 
psychology courses at Arizona State University. Mean age was 21.29 years (sd=3.75, 
range=18-47). Mean educational level in years was 14.43 (sd=1.29, 13-18 years range). 
There were no sex differences in age, education, or self-reported college GPA. 
Participation in the study was an option for extra credit in those courses. All procedures 
were approved by an Institutional Review Board for use of human participants in 
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research. Names were used only to assign course credit; all performance or questionnaire 
data were de-identified. All participants had normal or corrected to normal vision and no 
other obvious physical difficulties with the potential to affect their performance in the 
maze. 
Human Radial Arm Maze 
We developed and constructed a novel human radial-arm-maze (HRAM) to fit 
human proportions. A schematic and pictures of the HRAM are shown in figure 1. The 
maze frame consisted of a circular wooden center platform, 3.0 meters in diameter, 11 
vertical pillars equally spaced around the center platform (standing 2.3 meters tall), and a 
circular ring around the top to stabilize the pillars. To create the walls of each arm, both 
ends of a solid black tarp were attached to sequential pillars at the edge of the center 
platform, and then wrapped around a heavy 2-meter tall cylinder forming the ends of 
each arm. The complete maze had 11 equally spaced arms extending from the center area, 
each 5 meters long by 1 meter wide, resulting in a total maze width of 13 meters. An 11-
arm design was employed to create an asymmetrical arm pattern, thereby decreasing the 
chances for systematic strategies. This arrangement also allowed us to compare 
processing capacity of humans and rodents, which has classically been described by 
Miller as 7 ± 2 items of information in humans (Miller, 1956). More recent work has 
described working memory capacity limits of 3-5 pieces of information under certain 
circumstances (see: Cowan, 2010), however human working memory capacity for spatial 
locations in a radial-arm maze setting, specifically, has been estimated as 7 ± 2 items of 
information (Glassman et al., 1994; 1998). We built the maze with walls that extended 
above human height, and required participants to retrieve rewards from all 11 arms to 
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complete the maze. This provided a fully translational RAM task with actual locomotive 
motor movements, and full realism, as compared to virtual reality versions that can 
produce distortions due to computer lag, and lack a fully realistic array of location and 
depth cues. On the floor at the end of each arm was a 2’ x 3’ (0.6 meters x 0.9 meters) 
solid black floor mat, which served to conceal a reward. Each reward was a single bill of 
fake paper money; denominations varied across rewards. External visual cues on the 
room walls were present, including two basketball hoops on opposite ends of the room, 
solid black posters, and a clock.  
Instructions were given to introduce the participants to the goals of the task and to 
prevent participants from simply sequentially proceeding down successive arms or every 
other arm. This was done to encourage participants to use utilize spatial strategies or to 
utilize more complex strategies than simple chaining to traverse the maze. Each 
participant was read the following instructions prior to maze testing: 
“Money is under the mat at the end of each arm of this maze. Your goal is to find 
all of the money in the shortest amount of time. Once you find the money in an arm, it 
will not be replaced. Therefore, you should avoid going into any arm twice. Do not enter 
arms that are immediately next to each other or go in a pattern entering every other arm. 
Only travel into an arm immediately next to the one you previously entered if you 
absolutely must in order to obtain the remaining money, which means only do it when 
you are almost certain that you are on your last reward. If you do travel into an arm 
immediately next to the previous one you will be asked to stop and return to the center. 
Once you find money, please return it to the researcher located in the center of the maze. 
Then, wait until they tell you to go, and proceed to the rest of the arms to collect the 
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remaining money. During the course of testing please do not ask the researcher how 
many rewards remain or any other questions regarding your performance, as they are not 
permitted to respond.” 
Each participant started at the center of the maze; after receiving the instructions, 
the participant was told to begin collecting the rewards from each arm. For each trial, the 
researcher recorded the exact arm(s) the participant went down and recorded the time it 
took the participant to discover each reward. Upon locating a reward, the participant was 
instructed to return to the center of the maze, hand the reward to the researcher and then 
continue on to the next trial. This process was repeated until all 11 rewards were located, 
resulting in 11 total test trials (testing session A).  
Following successful collection of all 11 rewards, participants were brought 
outside the maze and administered the WRAT-3, which served as a general measure of 
verbal intelligence. During this time (approximately 5 minutes), a second experimenter 
replaced all 11 rewards in the HRAM. After the WRAT-3, participants were tested on the 
HRAM a second time (testing session B), adhering to the same set of directions. 
Participants were scored based upon the number of total incorrect arm entries they made 
(HRAM Errors). Because all of the arms contain rewards at the beginning of each testing 
session, errors solely consist of repeat arm entries within each testing session and all 
errors are considered to be working memory errors. After completion of the HRAM and 
WRAT-3, participants were taken to a separate room and administered a general survey 
and the remaining cognitive tests. 
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Intelligence Measure 
Between HRAM testing sessions, the WRAT-3 Reading subtest was 
administered, serving as a general measure of verbal intelligence. The WRAT-3 relies on 
the participants’ ability to read aloud a list of increasingly less common irregularly 
spelled words, and is useful as an estimate of verbal intelligence (Lezak et al., 2004).  
Episodic Memory 
The Rey Auditory Verbal Learning Task (RAVLT) was used to assess episodic 
memory ability. In this task, participants must listen to and verbally recall words from a 
15-item word list (List A) in 5 consecutive recall trials (Trials A1-A5; Total Words 
Learned). List A is then followed by recall of a distractor list (List B) in a single trial 
(Trial B1), and an immediate recall of List A (Trial A6; Retroactive Interference), which 
is often used as a measure of retroactive interference and short-term memory. After 20 
minutes, delayed memory/long term memory recall is assessed in a single recall trial 
(Trial A7; Delayed Recall). Participants were scored on the number of words recalled 
correctly on each trial. Scores for Trials A1-A5 (Total Words Learned) were the total 
number of correctly recalled words across all five trials. Finally, participants complete a 
recognition trial discriminating words from List A from foils. We did not standardize 
scores by age or sex, but rather acknowledged age and sex as potential demographic 
variables that may influence scores on multiple tasks. Given that the rodent RAM has 
been reliably shown to be sensitive to both age and sex, this best facilitated our goal to 
examine the relationship between variance in our cognitive test scores and variance in our 
HRAM scores. 
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Visuospatial Ability 
Two paper-and pencil measures of visuospatial ability were used in this study. 
The first was a version of the Vandenberg and Kuse Mental Rotation Task (MRT) 
(Vandenberg and Kuse, 1978), redesigned by Peters, et al., 1995. Version A of the MRT 
was used, which consists of 4 practice and 24 test questions. Each question is composed 
of five simple three-dimensional images made up of blocks. For each question, the 
objective is to match the target figure to a rotated version that is presented among a group 
of distractor items, which are either mirror images of the target figure or a different shape 
than the target figure. Participants were given 2 minutes to read the instructions and 
complete the practice items (not scored), 3 minutes to complete the first 12 items, and 
another 3 minutes to complete the remaining 12 items. Answers are considered correct 
only if the participant selects both correct images, with no partial credit for only one 
correct item (Peters et al., 1995). We also used the Judgment of Line Angle and Position-
15 (JLAP) (Collaer, 2001) to measure visuospatial ability. The JLAP-15 consists of 20 
test items and 5 practice items; each test item consists of two target line segments located 
directly above the comparison spectrum of 15 numbered lines in a 180° array. The target 
line segments were each 1 cm in length, whereas the comparison lines were 3 cm in 
length (Cherney & Collaer, 2005). Participants were given 2 minutes to read the 
instructions and complete the practice items (not scored), after which they were given 7 
minutes to complete as many of the 20 test items as possible. Credit for correct answers is 
given only when both of the correct target lines are identified, with no partial credit for 
only one correct line. For the MRT and the JLAP, the score assigned was the total 
number of items answered correctly.  
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Working Memory Capacity 
Working memory was assessed by a set of four computerized complex-span 
working memory tasks. These tests require participants to maintain mental memoranda 
(either verbal or spatial) in the face of completing a distracting task. These tests included 
verbal (Operation Span; OSpan and Reading Span; Rspan) and spatial (Symmetry Span; 
SymSpan and Rotation Span; RotSpan) working memory tasks (see Unsworth et al., 2009 
for full task descriptions). In complex-span tasks, the participant is given verbal or spatial 
memoranda interspersed with distracting activity for a set of lists containing between 3 
and 7 items. The participant’s task is to remember the information in the order it was 
presented while simultaneously completing the distractor task. In all working memory 
tasks the dependent variable was the number of correct items recalled in the correct serial 
position.  
Task Administration Overview 
The HRAM (testing session A) was the first task participants completed as a 
measure of spatial working memory. The WRAT-3 was administered between the two 
HRAM testing sessions as a measure of verbal intelligence. The WRAT-3 was followed 
by a second HRAM testing session (testing session B), to determine whether participants 
improved performance across testing sessions. After completion of the second session of 
HRAM testing, participants completed a survey regarding health and demographic 
factors. Participants were then administered the RAVLT Trials A1-A6, MRT, JLAP, 
RAVLT Trial A7, and computer tasks. The testing battery was given in the same order 
for all participants. Upon completion of all tasks, participants were debriefed. The total 
time from beginning to completion was approximately 2 hours per participant.  
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Statistical Analyses 
HRAM data were analyzed using repeated measures ANOVA, with HRAM 
Errors on Trials 1-11 and Sessions A and B as the repeated measures. Relations between 
performance on the MRT, JLAP-15, RAVLT, WRAT-3, RSpan, OSpan, SymSpan, and 
RotSpan with HRAM performance were examined with correlations and multiple 
regression analysis. In order to determine the extent to which each task predicts 
performance on the HRAM, a real-world, immersive task requiring spatial navigation, 
learning and memory, individual regressions were run with each task serving as the 
predictor and total errors made on both sessions of the HRAM combined (HRAM Total 
Errors) as the dependent (predicted) variable. 
Additionally, hierarchical regression analysis was utilized to determine whether 
tasks measuring different domains of learning and memory offered unique predictive 
value to a regression equation predicting HRAM scores. Tasks that emerged as 
significant predictors of HRAM performance were entered into a regression equation in 
sequence, starting with the tasks that accounted for the largest proportion of variance in 
HRAM scores. Tasks were entered in clusters according to which cognitive domain they 
measure. The dependent variable for all equations was total errors made on both sessions 
of the HRAM combined (HRAM Total Errors). Four measures of working memory 
capacity, OSpan, RSpan, RotSpan, and SymSpan accounted for the largest proportion of 
variance in HRAM Total errors, and were entered as a first block of predictors to yield 
Equation 1: 
HRAM Total Errors = b1OSpan+ b2RSpan+ b3RotSpan+ b4SymSpan+ b0 
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Two measures of visuospatial ability, MRT and JLAP were added to yield 
Equation 2: 
HRAM Total Errors= b1OSpan+ b2RSpan+ b3RotSpan+ b4SymSpan+ b5MRT+ 
b6 JLAP+ b0 
Gain in prediction from Equation 1 to Equation 2 assessed prediction from 
visuospatial ability measures over and above working memory capacity. Analyses were 
performed using SPSS 21 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, 
Version 21.0. Armonk, NY: IBM Corp.).  
Results   
Human Radial Arm Maze Performance 
 There was a main effect of Trial [F(10,1520)= 97.19; p< 0.0001] on HRAM Errors, 
with HRAM Errors increasing as trials progressed and working memory load increased 
(figure 2A). HRAM Errors increased from trial 8 to 9 (Trial 8: M= 0.28, SE= 0.04; Trial 
9: M= 0.53, SE= 0.06; p< 0.05), from trial 9 to trial 10 (Trial 10: M=1.03; p<0.0001) and 
again from trial 10 to trial 11 (Trial 11: M=2.67, SE=0.11; p<0.0001). This increase in 
errors occurred when the number of arms participants needed to avoid exceeded roughly 
8-9 items. HRAM Errors declined significantly across Testing Sessions (Both Sessions: 
M=0.436, SE=0.04, Session 1: M=0.51, SE=0.04, Session 2: M= 0.37, SE= 0.04; 
[F(1,152)= 7.85; p< 0.01]). The pattern of performance across trials was the same across 
Testing Session, (Session x Trial interaction: F(10,1520)= 1.80; p>0.05, NS]. Figure 2B 
shows error patterns observed in different versions of the rodent RAM for comparison. 
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Relationships Between General Intelligence and HRAM Performance 
 WRAT-3 scores did not correlate with HRAM Total Errors. Consistent with the 
lack of correlation, the WRAT-3 was not a significant predictor of HRAM Total Errors 
(figure 3).  
Relationships Between Episodic Memory and HRAM Performance 
 RAVLT Total Words Learned, Retroactive Interference, and Delayed Recall did 
not correlate with HRAM Total Errors (p>0.05, NS). Regression analysis indicated that 
Total Words Learned, Retroactive Interference, and Delayed Recall trials of the RAVLT 
were not significant predictors of HRAM Total Errors (figure 4). Combining all measures 
of the RAVLT also did not predict HRAM Total Errors (Adjusted R2multiple=0.00, F(3, 151)= 
0.88, p>0.05, NS).  
Relationships Between Visuospatial Tasks and HRAM Performance 
 Both visuospatial tasks, the MRT and JLAP, correlated negatively with HRAM 
Total Errors (p<0.01 and p<0.0001, respectively). For every additional question 
participants answered correctly on the MRT, HRAM errors decreased by 0.40 on 
average; errors decreased by 0.66 for each one point increase in JLAP (figure 5). The 
MRT and JLAP together predicted HRAM Total Errors (Adjusted R2multiple=0.11, F(2, 152)= 
10.29, p<0.0001).  
Relationships Between Working Memory Capacity Tasks and HRAM Performance 
 Performance on the working memory capacity tasks, the OSpan, Rspan, RotSpan, 
and SymSpan, correlated negatively with HRAM Total Errors (p<0.001, p<0.0001, 
p<0.05, p<0.05, respectively). For every additional point earned on the Ospan or Rspan, 
HRAM Total Errors decreased by 0.17, on average; HRAM Total Errors decreased by 
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0.19 for each one-point increase in RotSpan or SymSpan scores (figure 6). The Ospan, 
Rspan, RotSpan, and SymSpan together predicted HRAM Total Errors (Adjusted 
R2multiple=0.09, F(4,146)= 4.80, p<0.001).  
Unique Predictive Value of Tasks Measuring Different Domains of Cognition  
 The baseline regression equation (Equation 1), including working memory 
capacity predictor variables, accounted for a significant proportion of variance in HRAM 
Total Errors (Adjusted R2multiple= 0.09, F(4,146)=4.80, p<0.001 ). Only the Rspan predicted 
HRAM Total Errors when all other WM Span test scores were held constant (β=-0.12, 
95% CI: [-0.24, 0.00], t=-1.99, p<0.05); none of the other WM Span tasks offered unique 
predictive value in a regression equation including all four tasks (Ospan: β=-0.10, 95% 
CI: [-0.22, 0.02], t=-1.59, p>0.05; RotSpan β=0.01, 95% CI: [-0.20, 0.23], t=0.13, 
p>0.05; SymSpan: β=0.01, 95% CI: [-0.20, 0.22], t=0.09, p>0.05). 
 The addition of two visuospatial tasks, MRT and JLAP, as predictor variables 
(MRT: b=-0.28; 95% CI [-0.55, -0.02]; t=-2.14; p<0.05; JLAP: b=-0.45; 95% CI [-0.78, -
0.13]; t=-2.75; p<0.01) significantly increased the proportion of variance in HRAM Total 
Errors that was accounted for by our regression equation [Adjusted R2multiple= 0.18; Fchange 
(2,144) =8.58; p<0.0001]. The Adjusted R2multiple for Equation 2 indicated that adding MRT 
and JLAP as predictors roughly doubled the proportion of explained variance in HRAM 
Total Errors. JLAP scores offered predictive value over and above MRT scores (β=-0.55, 
95% CI: [-0.88, -0.21], t=-3.22, p<0.01); however MRT scores were not predictive of 
HRAM Total Errors when JLAP scores were held constant (β=-0.23, 95% CI: [-0.50, 
0.03], t=-1.73, p>0.05). 
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Discussion 
 The current study employed a human-sized, walk-through version of the RAM that 
was modeled after the rodent version used commonly in learning and memory research. 
The RAM has been used for decades to study spatial memory in the rodent. Notable 
landmark work includes that of Tolman in the 1940s utilizing the structurally-similar 
sunburst maze (Tolman, 1948), Olton utilizing the RAM in the 1970s (Olton & Samuelson, 
1976; Olton, 1977; Olton & Feustle, 1981; Olton & Papas, 1979), and more recent work 
many decades later (e.g., Eckerman at al., 1980; Luine & Rodriguez, 1994; Bimonte & 
Denenberg, 1999, 2000; Bimonte et al., 2000; Bimonte-Nelson et al., 2003; Bimonte-
Nelson et al., 2006; Daniel et al., 2006; Eckerman et al., 2008). Despite the many 
advantages of using animal models in research, there remain questions about the extent that 
findings in animals can truly be translated to humans, especially in the context of 
neurobehavioral assays. One approach to addressing this obviously complex issue is to 
create an intermediate testing instrument by adapting experimental paradigms from animals 
to humans. The present study did this through the development of the HRAM. Previous 
research teams have developed human versions of mazes, in particular the RAM, with their 
own unique set of parameters designed to answer their research questions (Astur et al., 
2004; Bohbot et al., 2002; Glassman et al., 1998; Levy et al., 2005; O'Connor & Glassman, 
1993; Scharine & McBeath, 2002). Our version of the HRAM was built with these prior 
studies in mind, and optimized the parameters to be as comparable as possible to the rodent 
version. I expected to see an increase in working memory errors as trials progressed. As 
predicted, participants began to make errors around trial 6, with the highest number of 
errors made on trial 11, when working memory demand was at its highest (figure 2A). The 
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increase in errors across trials in the HRAM is similar to that shown in the RAM with rat 
subjects (Bimonte & Denenberg, 1999, 2000; Bimonte et al., 2000; Bimonte-Nelson et al., 
2003; Camp et al., 2012), as seen in figure 2B. Additionally, performance improved across 
testing sessions, indicating a learning effect, as seen in rodent RAMs (Bimonte & 
Denenberg, 1999, 2000; Bimonte et al., 2000; Bimonte-Nelson et al., 2003; Camp et al., 
2012). 
 One major goal of this study was to explore the translational relationship between 
human performance on the HRAM and commonly used neuropsychological tests that tap 
spatial ability, episodic memory, working memory, and intelligence. Evaluating these 
relationships allowed us to determine which tests commonly used in clinical settings and 
cognitive psychology account for variance in performance on the HRAM, a commonly 
used rodent task adapted to humans. Of the battery of tests we administered in this 
study, the JLAP emerged as the strongest predictor of HRAM performance, accounting for 
10% of HRAM Total Errors. The verbal working memory capacity tasks, the Ospan and 
Rspan, surfaced as the next strongest predictors, predicting 8% and 9% of the total variance 
in HRAM error scores, respectively. The MRT predicted 5% of variance on HRAM Total 
Errors, and the predictive value of the spatial working memory tasks (the RotSpan and 
SymSpan) was similar to the predictive value of the MRT, each predicting 4% of the total 
variance in HRAM error scores (Table 3). Total Words Learned, Retroactive Interference, 
and Delayed Recall measures of the RAVLT did not offer significant predictive value, nor 
did scores on the WRAT-3, an estimate of general intelligence. 
 When evaluating the nature of these tasks, plausible explanations for the observed 
relationships emerge. The predictive ability of the MRT and JLAP-15 may be attributable 
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to the proposed use of a mental visuospatial sketchpad (Baddeley, 2000). The visuospatial 
sketchpad has been theorized to be the temporary storage and manipulation of spatial and 
visual information, such as shapes, locations or speed of objects in space. The visuospatial 
sketchpad is theorized to contribute to performance in tasks that require planning of spatial 
movements, such as planning one's way through a complex environment like the HRAM 
and it is not surprising that better performance on visuospatial tasks predicts enhanced 
performance in a three-dimensional, immersive task that requires navigation through space. 
The working memory tasks used in this study assess the ability to ‘hold on’ to multiple 
pieces of information in the face of interference and an increase in working memory 
demand (e.g., Baddeley, 2003; Unsworth et al, 2009). Similarly, to perform well on the 
HRAM, participants must also maintain multiple pieces of information in the face of an 
increasing working memory load to successfully complete the task.  
 Performance on the HRAM did not correlate with the estimate of general verbal 
intelligence used in this study (reading subtest of the WRAT-3) or with new learning and 
long term delay measures of episodic memory, but did correlate with specific measures of 
visuospatial ability and working memory capacity, suggesting that the HRAM requires 
utilization of specific cognitive abilities of working memory and visuospatial skills rather 
than reliance on episodic memory or general verbal intelligence, as measured by the 
WRAT-3. Thus, our findings indicate that tasks measuring working memory (e.g., 
maintaining performance within the context of increased load or distracting stimuli) and 
visuospatial skills are correlated with performance on the RAM, a task used widely in 
rodent literature that we have fully adapted to human proportions.  
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 Hierarchical regression analysis indicated that the proportion of HRAM error 
variance accounted for by each group of predictor variables (working memory capacity and 
visuospatial ability) was unique to that group of variables. Scores on the MRT and JLAP 
accounted for 9% of variance in HRAM scores, in addition to the 9% of variance accounted 
for by the four working memory capacity variables (Table 4). A regression equation 
including the working memory capacity tests and visuospatial ability tests, accounted for 
18% of the total variance in HRAM error scores. These results suggest that including 
multiple measures in a cognitive battery increases the ability of the battery to predict how a 
participant would perform on tasks similar to the HRAM, which requires complex 
reasoning, such as recall of previous instances of navigating to spatial locations in a real-
world setting. Additionally, these results support the hypothesis that successful 
performance on radial-arm maze tasks requires visuospatial abilities and sufficient working 
memory capacity.  
 In conclusion, our collaborative research group created a three-dimensional, fully 
immersive, walk-through version of the RAM designed specifically for human use, in order 
to create an intermediary translational instrument. The results indicate that human 
performance on the RAM is notably similar to rodent performance on the RAM, in that 
there is an exponential increase in errors as trials progress and task difficulty increases, but 
with the human error pattern revealing a larger processing capacity compared to rodents. 
The total number of errors per trial in humans remains low until the trial number exceeds a 
total similar to the classically defined human working memory capacity of 7 ±2 items 
(Miller 1956). Additionally, HRAM performance in our participants improved with 
repeated exposure to the task, indicating learning. We also demonstrated that performance 
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on the HRAM was related to performance on several tasks used in clinical 
neuropsychology and cognitive psychology, with a strong emphasis on tasks designed to 
measure spatial ability and working memory. The behavioral similarities seen in the rodent 
and human versions of the RAM, paired with the strong observed relationships between the 
HRAM and standard human working memory and visuospatial tasks, offer support to 
spatial working memory being the dominant construct common to rodents and humans that 
is reliably measured using existing testing procedures. Moreover, the HRAM has now been 
validated as a valuable instrument to translate, compare, and confirm models and findings 
in rodent research, cognitive neuroscience, navigational modeling, and neuropsychology. 
We took a collaborative and translational approach to bridge gaps between divergent, but 
closely related, fields of experimental and applied memory research. The successful 
implementation of the HRAM confirms our overarching goal to create a practical and 
useful basic– to applied- translational test instrument that can help us connect diverse 
behavioral domains to better understand learning, memory, and cognitive functioning 
processes.  
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CHAPTER 3: EFFECTS OF SEX, MENSTRUAL PHASE, AND HORMONAL 
CONTRACEPTIVES ON THE HUMAN RADIAL ARM MAZE AND A BATTERY 
OF NEUROPSYCHOLOGICAL AND COGNITIVE TASKS 
Introduction 
 We previously performed a collaborative experiment in human participants with 
the goals to unite human and rodent cognitive research methodology and to validate a 
human analogue of a rodent testing paradigm as a viable measure of spatial working 
memory (Mennenga et al., 2014). Following substantiation of this task as a measure of 
multiple cognitive constructs, including both working memory capacity and visuospatial 
ability, I now wish to utilize the human radial arm maze (HRAM) to begin to directly 
translate preclinical rodent spatial learning and memory research to human participants, 
and vice versa. Numerous studies have reported sex differences in mental rotation and 
spatial perception abilities in humans, favoring men (Linn and Petersen, 1985), yet 
controversy remains concerning the extent that men outperform women in functional 
real-world spatial navigation tasks (Taylor and Tversky, 1996). My proficiency in 
translational cognitive endocrinology (Mennenga and Bimonte-Nelson, 2013), coupled 
with the newly validated HRAM as a human analogue to the rodent radial arm maze 
(Mennenga et al., 2014), now allow me to systematically address this question. 
 In the human literature, men typically excel on tasks that measure spatial ability, 
such as mental rotation of three-dimensional figures, spatial visualization, spatial 
perception, and targeting and intercepting objects (Linn and Petersen, 1985; Rahman and 
Wilson, 2003; Voyer et al., 1995), while women tend to perform better on tasks that 
measure non-spatial memory, such as episodic memory (Ruff et al., 1989; Trahan and 
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Quintana, 1990). There is also evidence in women that changes in estrogen levels across 
the menstrual cycle influence working memory (Hampson and Morley, 2013) and spatial 
ability (Mäntylä, 2013). In the rodent literature, males generally learn the land version of 
the RAM at a faster rate than females (Einon, 1980; Luine and Rodriguez, 1994; Roof, 
1993; Williams et al., 1990), although sex differences are not always reported (Juraska et 
al., 1984; Kolb and Cioe, 1996; van Haaren, 1987), and females have been shown to 
encode more types of spatial information during learning than males (Williams et al., 
1990). 
 Many endogenous ovarian hormone fluctuations as well as exogenous hormone 
exposures occur throughout the female lifespan. Relative levels of several hormones 
naturally change across the reproductive cycle, throughout aging, and with reproductive 
senescence. In addition to these natural changes across the lifespan, many women 
purposefully alter their ovarian hormone levels via regimens such as hormonal 
contraceptives and hormone therapy (HT). Explicating the cognitive effects of both 
endogenously produced and exogenously administered estrogens is necessary to optimize 
brain aging in women. Basic science and clinical research have progressed our 
understanding of how factors related to aging, menopause, and hormonal treatments 
impact cognitive function throughout aging, but a direct test of preclinical rodent research 
findings in human participants is lacking. 
 In the current study, I divided our participants according to hormonal status to 
determine whether sex, menstrual phase, or hormonal contraceptive use were associated 
with differences in performance on several tasks measuring different domains of 
cognitive function. The primary goal of this study was to determine whether differences 
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in visuospatial ability, working memory, and real-world spatial navigation would emerge 
between males and various groups of females with qualitatively different hormone 
profiles. I hypothesized that as working memory demand increases, a difference in spatial 
navigational ability will become apparent in the HRAM, such that males will outperform 
females experiencing high estrogen levels. This difference should manifest as an 
interaction between working memory load (trial) and errors on the HRAM, whereby all 
participants perform equally on the initial trials, but men outperform women with higher 
levels of estrogen on the final trials, when the fewest rewards remain and working 
memory load is highest. Further, I expected this difference in HRAM performance to 
correspond to differences in visuospatial task performance, rather than working memory 
capacity. I divided participants into four categories: men, women in the follicular phase 
of their menstrual cycle, which is characterized by relatively high levels of endogenous 
estrogens, women in the luteal phase of their menstrual cycle, which is characterized by 
relatively high levels of progesterone, and women actively taking hormonal 
contraceptives that include the synthetic estrogen, ethinyl estradiol (EE). These groups 
were chosen to broadly represent different hormone profiles that many women 
experience across their reproductive lifespan. 
Materials and Methods 
Participants 
 Participants were identical to those described in chapter 2 (experiment 1), with the 
exception of 26 participants that were excluded from analyses for one of more of the 
following reasons: no response on survey questions about current menstrual cycle phase 
or phase of hormonal contraceptive, potential pregnancy, contraceptive users in an 
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inactive pill phase, and use of non-EE containing hormonal contraceptives (progestin-
only formulations). 
 Participants were grouped according to their sex and hormone status, and by 
whether they were utilizing EE-containing hormonal contraceptives. Women who were 
not taking hormonal contraceptives were divided according to the phase of their 
menstrual cycle at their time of testing, based on self-report of how many days had 
passed since their previous menses. Women that were on days 7-13 of their menstrual 
cycle were considered to be in the follicular phase and placed into the follicular group, 
and women who were on days 18-35 of the menstrual cycle were considered to be in the 
luteal phase and placed in the luteal group. These designations were chosen because 
women in the follicular phase of the menstrual cycle have high circulating levels of E2, 
whereas women in the luteal phase have high circulating levels of progesterone (Hoffman 
et al., 2012). We also collected information on the formulations of the various 
contraceptives that our participants were using; the oral combined contraceptives that our 
participants were taking contained between 20 and 35µg per day of EE as well as one of 
the following synthetic progestins: Desogestrel (0.15µg/day), Drosperinone (3.0µg/day), 
Ethynodiol Diacetate (1.0µg/day), Norethindrone (0.4µg/day), Norgestimate (0.18 or 
0.25µg/day), Levonorgestrel (0.1µg/day), or Norethindrone Acetate (1.0 or 1.5µg/day). 
Groups were as follows: males (n=54), females tested while using combined oral 
contraceptives (n=23), females not on contraceptives tested during the follicular phase of 
their menstrual cycle (n=15), and females not on contraceptives tested during the luteal 
phase of the menstrual cycle (n=22).  
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Experimental Procedures 
 Experimental procedures were identical to those described in chapter 2 
(experiment 1). 
Statistical Analyses 
 Orthogonal planned comparisons were as follows: Male versus Females 
Follicular, Male versus Female Luteal, and Male versus Female Oral Contraceptives. 
Errors made on the HRAM were analyzed using repeated measures ANOVA, with Group 
(Males, Females Oral Contraceptives, Females Follicular, or Females Luteal) as the 
between variable, and Runs A and B, each containing Trials 1-11 as the repeated 
measure. Data were further broken up into low working memory load conditions (trials 2-
6) and high working memory load conditions (trials 7-11) and analyzed using one-way 
ANOVAs with Group as the independent variable and average errors made under each 
working memory load condition as the dependent variable. Data from the WRAT-3, 
RAVLT, MRT, JLAP, OSpan, RSpan, RotSpan, and SymSpan were analyzed with one-
way ANOVA with Group as the independent variable and total items correct as the 
dependent variable for each task. 
Results 
Human Radial Arm Maze Performance 
 There was a Trial x Hormone Group interaction (F(30,1100)= 1.47, p<0.05) for Total 
Errors on the HRAM, such that as working memory load (trial) increased, group 
differences began to emerge (figure 7). When trials were grouped into low working 
memory demand and high working memory demand, there were no differences between 
the Male and Female Follicular groups (F(1,67)= 0.12, p>0.05, NS; η2<0.01), Male and 
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Female Luteal groups (F(1,74)= 0.44, p>0.05, NS; η2<0.01), or Male and Female Oral 
Contraceptive groups (F(1,75)= 1.74, p>0.05, NS; η2=0.02) for trials 2 through 6, which 
required participants to remember 1-5 previously visited spatial locations. There was a 
difference on Total Errors between the Male and Female Follicular groups (F(1,67)= 4.38, 
p<0.05; η2=0.06), and between the Male and Female Oral Contraceptive groups  (F(1,75)= 
6.17, p<0.05; η2=0.08), but not between the Male and Female Luteal groups (F(1,74)= 0.14, 
p>0.05, NS; η2<0.01), for trials 7 through 11, which corresponded to a demand of 6-10 
previously visited spatial locations (figure 7).  
Reading Proficiency 
 We found a difference in WRAT-3 scores between the Male and Female 
Follicular (F(1,60)= 6.95, p<0.05; η2=0.10), but not between the Male and Female Luteal 
(F(1,67)= 1.54, p>0.05, NS; η2=0.02) groups, or the Male and Female Oral Contraceptive 
groups (F(1,71)= 2.26, p>0.05, NS; η2=0.03). Mean scores on the WRAT-3 for each group 
were as follows: men (M=109.6; SD=7.2), contraceptive users (M=106.7; SD=9.0), 
follicular phase (M=103.3; SD=6.0), and luteal phase (M=103.7; 13.5). Although this 
difference in scores is statistically significant, it is not considered to be a clinically 
relevant difference, as these scores are all well within the range of normal reading ability. 
Episodic Memory 
 There were no differences between Male and Female Follicular (F(1,67)= 1.06, 
p>0.05, NS; η2=0.02), Male and Female Luteal (F(1,74)= 0.71, p>0.05, NS; η2=0.01), or 
Male and Female Oral Contraceptive (F(1,75)= 1.82, p>0.05, NS; η2=0.02) on Total Words 
Learned (trials A1-A5). There were no differences between Male and Female Follicular 
(F(1,66)= 1.08, p>0.05, NS; η2=0.02), Male and Female Luteal (F(1,73)= 0.38, p>0.05, NS; 
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η2=0.01), or Male and Female Oral Contraceptive (F(1,74)= 0.99, p>0.05, NS; η2=0.01) on 
number of words recalled on the retroactive interference trial (trial A6). There were no 
differences between Male and Female Follicular (F(1,67)= 2.29, p>0.05, NS; η2=0.03), 
Male and Female Luteal (F(1,74)= 0.85, p>0.05, NS; η2=0.01), or Male and Female Oral 
Contraceptive (F(1,75)= 2.05, p>0.05, NS; η2=0.03) on number of words recalled following 
a 20-minute delay (trial A7; figure 9).  
Visuospatial Tasks 
 There were differences in MRT scores between the Male and Female Follicular 
groups (F(1,67)= 11.57, p<0.01; η2=0.15), the Male and Female Luteal groups (F(1,74)= 
6.09, p<0.05; η2=0.08), and the Male and Female Oral Contraceptive groups (F(1,75)= 
8.91, p<0.01; η2=0.11). There was also a marginal difference in JLAP scores between the 
Male and Female Follicular groups (F(1,67)= 3.54, p<0.10; η2=0.05), and a significant 
difference between the Male and Female Oral Contraceptive groups (F(1,75)= 5.73, 
p<0.05; η2=0.07), but not between the Male and Female Luteal groups (F(1,74)= 1.67, 
p>0.05, NS; η2=0.02) (figure 10). 
Working Memory Capacity Tasks 
 There were no differences between groups on the OSpan (Male versus Female 
Follicular: F(1,65)= 0.28, p>0.05, NS; η2<0.01; Male versus Female Luteal: F(1,72)= 0.02, 
p>0.05, NS; η2<0.01; Male versus Female Oral Contraceptive: F(1,73)= 0.65, p>0.05, NS; 
η2<0.01), RSpan (Male versus Female Follicular: F(1,65)= 0.10, p>0.05, NS; η2<0.01; Male 
versus Female Luteal: F(1,72)= 2.31, p>0.05, NS; η2=0.03; Male versus Female Oral 
Contraceptive: F(1,73)= 0.06, p>0.05, NS; η2<0.01), RotSpan (Male versus Female 
Follicular: F(1,65)= 0.20, p>0.05, NS; η2<0.01; Male versus Female Luteal: F(1,72)= 0.57, 
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p>0.05, NS; η2<0.01; Male versus Female Oral Contraceptive: F(1,73)= 0.43, p>0.05, NS; 
η2<0.01), or SymSpan (Male versus Female Follicular: F(1,65)= 0.03, p>0.05, NS; η2<0.01; 
Male versus Female Luteal: F(1,72)= 0.57, p>0.05, NS; η2<0.01; Male versus Female Oral 
Contraceptive: F(1,73)= 0.87, p>0.05, NS; η2=0.01) tasks (figure 11).  
Discussion 
 A large sex difference in mental rotation and spatial perception abilities, favoring 
men, is typically found in humans (Linn and Petersen, 1985), yet there is controversy 
concerning the extent that men perform better in functional real-world spatial 
navigational tasks (Taylor and Tversky, 1996). Here, I evaluated the impact of hormone 
status on a battery of tasks measuring visuospatial ability, working memory, and episodic 
memory. I classified our female participants into three groups according to their hormone 
status: women in the estrogen-dominant follicular phase of the menstrual cycle, women 
in the progesterone-dominant luteal phase of the menstrual cycle, and women taking EE-
containing hormonal contraceptives. I chose to evaluate performance separately in each 
of these groups in order to appraise how fluctuations in endogenously produced and 
exogenously administered estrogens impact several individual cognitive domains, as well 
as a real-world spatial navigational working memory task. 
 Utilizing the newly validated HRAM as a measure of spatial working memory 
(Mennenga et al., 2014), I found that sex differences were limited to comparisons 
between men and women experiencing high levels of endogenous or exogenous 
estrogens. Here, males outperformed women in the estrogen-dominant follicular phase of 
the menstrual cycle, and women on EE-containing hormonal contraceptives, but not 
women in the progesterone-dominant luteal phase of the menstrual cycle. Sex differences 
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have not been seen on other two-dimensional versions of HRAM tasks, including virtual 
reality versions (Astur et al., 2004; Levy et al., 2005), paper-pencil versions (O'Connor 
and Glassman, 1993), and a large outdoor version with arms painted on the grass 
(Glassman et al., 1998). The current results may be due to utilization of hormone status, 
rather than sex, as a variable of interest, or to the specific set of parameters utilized here 
that differed from prior versions of the maze. It appears that the implementation of an 11-
arm paradigm was sufficient to tax the working memory capabilities of our participants 
(Mennenga et al., 2014). Because there was an interaction between Hormone Status and 
Trial, it is probable that sex differences would not be detectable in tasks that do not 
sufficiently tax the working memory system. It is also possible that the three-dimensional 
real-world nature of our maze is key to measuring spatial memory in humans.  
 I also investigated differences in visuospatial ability between groups, and found 
that men outperformed women on the MRT, a result in line with an abundance of prior 
research using this task (Astur et al., 2004; Cherney and Collaer, 2005; Linn and 
Petersen, 1985; Vandenberg and Kuse, 1978). Previous reports that have not accounted 
for female hormone status have reported sex differences on the JLAP, also favoring men 
(Cherney and Collaer, 2005). I now report that when women are characterized according 
to their hormone profile, sex differences on the JLAP are limited to women in the 
estrogen-dominant follicular phase of the menstrual cycle and women actively taking 
hormonal contraceptives. No difference was observed in JLAP performance between 
women in the progesterone-dominant luteal phase of the menstrual cycle and men, 
similar to our observations on HRAM performance. Following a meta-analysis, Linn and 
Petersen (1985) concluded that large sex differences in visuospatial ability were limited 
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to mental rotation tasks, and that other spatial perception tasks produced smaller male 
benefits. The findings support and expand on this notion; while males outperform 
females in the follicular and luteal phase of the menstrual cycle, as well as women taking 
EE-containing contraceptives on the MRT, the female disadvantage previously reported 
on the JLAP task only becomes apparent in women experiencing high levels of either 
endogenous or exogenous estrogens. Campbell and Collaer (2009) reported that sex 
differences on the JLAP are sensitive to the stereotype threat that men typically 
outperform women on this task. Participants in the current study were not told anything 
about expected performance on any of the tasks, and it is unknown how fluctuations in 
hormone levels might interact with environmental factors such as stereotype threat.  
 There were no differences in performance across groups on the OSpan, RSpan, 
RotSpan, or SymSpan, which are each measures of human working memory capacity. 
Thus, current findings signify that hormone status impacts visuospatial ability and 
HRAM performance, but not working memory capacity. In chapter 2, I reported that the 
working memory tasks (OSpan, RSpan, RotSpan, and SymSpan) and the visuospatial 
tasks (MRT and JLAP) utilized here each predict unique variance in performance on the 
HRAM. I now report that it is likely that successful navigation of the HRAM relies on 
working memory capacity as well as visuospatial ability, and that fluctuations in estrogen 
levels impact performance on the HRAM through disrupting visuospatial aptitude. 
 The HRAM task was created in order to allow direct translation between basic 
science and clinical research findings. Here, the HRAM, along with a battery of standard 
neuropsychology and cognitive psychology tasks tapping several domains of cognitive 
function, were utilized to probe the cognitive effects of fluctuations in female hormone 
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levels. The three groups of females utilized in this study (follicular phase, luteal phase, 
and hormonal contraceptive users) were chosen to broadly represent the various 
hormonal states that women experience across their reproductive lifespan. The current 
classifications were utilized only as a starting point; much heterogeneity remains within 
each of the three groups of women studied here. Variations in endogenous hormone 
production and in hormonal contraceptive formulations, including route of 
administration, dose of EE, and dose and type of progestin, are likely to produce unique 
cognitive effects. Additional hormonal states such as those seen during pregnancy, or 
following surgically induced or natural menopause are not represented in the current 
study, and are also likely to coincide with unique cognitive profiles. Further, a within-
subjects study of the cognitive impact of hormonal fluctuations is necessary to determine 
whether the group differences observed here are reflective of permanent or transient 
changes in cognition. I hope that these findings will spur additional research into the 
contributions of ovarian hormones to individual cognitive profiles, and help to inform 
clinicians and researchers on the impact that various lifetime hormone exposures have on 
brain health and function across the entire lifespan. 
 46 
CHAPTER 4: UNDERSTANDING THE COGNITIVE IMPACT OF THE 
CONTRACEPTIVE ESTROGEN ETHINYL ESTRADIOL: TONIC AND CYCLIC 
ADMINISTRATION IMPAIRS MEMORY, AND PERFORMANCE CORRELATES 
WITH BASAL FOREBRAIN CHOLINERGIC SYSTEM INTEGRITY 
Introduction 
 Ethinyl estradiol (EE), a synthetic form of 17β-estradiol (E2), is the most common 
estrogen in hormonal contraceptives (Shively, 1998), and is the only estrogen used in the 
contraceptive pill. National surveys estimate that, from 2006-2010, 10.6 million women 
between 2006-2010 (Jones et al., 2012), and 17.3% of all women between 2006-2008 
(Mosher and Jones, 2010), used oral contraceptives. Over 30 contraceptive formulations 
contain EE (Curtis et al., 2005), including both oral regimens and non-oral, tonic delivery 
regimens, such as the transdermal patch and vaginal ring. EE is also found in hormone 
therapies (HT) for menopausal women, such as Estinyl™ and Femhrt™ (Curtis et al., 
2005). Understanding the cognitive impact of estrogens is critical, as exogenous exposure 
to estrogens occurs throughout the lifespan through contraceptives and HT. Of note, EE is a 
synthetic analogue to E2; however, these estrogens have different pharmacokinetic profiles 
(Coelingh Bennink et al., 2004). EE is more biologically active than E2 (Dickson and 
Eisenfeld, 1981) and cannot be converted to estrone or other weaker estrogens (Fotherby, 
1996), whereas E2 can (Prokai-Tatrai, et al., 2005). These estrogens also have different 
binding profiles, which vary across species (Paradiso et al., 2001).  
 Although EE is among the most commonly prescribed estrogens for contraception, 
and is prescribed to women from puberty to post-menopause, most preclinical research on 
the cognitive impact of estrogens has focused on 17β-estradiol and other endogenous 
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estrogens, and does not include EE (for reviews see: Bimonte-Nelson et al., 2010; Acosta et 
al., 2013). Methodically evaluating EE in a rodent model allows the opportunity to 
systematically control for many variables that could impact cognitive scores, including 
mode of administration, dosing, endogenous hormone variations, age, and diet.  
There have been a few studies investigating the cognitive effects of EE as a contraceptive 
or HT, with effects that vary across memory domains. In human contraceptive users, no 
impact of EE-containing contraceptives was found on several tests measuring memory and 
concentration (Silber et al., 1987). Another study found enhanced verbal memory during 
the active compared to the inactive phase of oral contraceptives, although benefits were not 
seen on visuospatial measures (Mordecai et al., 2008). Importantly, although each of the 
contraceptive formulations used in these studies contained EE, other aspects of the 
formulations differed, including dose and the progestin component. Thus, it is difficult to 
decipher whether or to what extent EE was responsible for these effects. In studies 
investigating EE as a HT, cognitive effects depend on the domain as well. In aged, 
ovariectomized (Ovx) rhesus monkeys, EE improved spatial working memory (Lacreuse et 
al., 2002), but impaired face recognition (Lacreuse and Herndon, 2003), and had no impact 
on executive function (Lacreuse et al., 2004). An fMRI study of menopausal women found 
EE-containing HTs increased frontal cortex activation during a working memory task 
(Smith, et al., 2006).  
 Estrogen Receptors (ERs) are highly expressed in several cognitive brain regions, 
including the basal forebrain (BF) (Shughrue et al., 1999), which contains cholinergic cell 
bodies that project to the hippocampus (McEwen, 2001; Gibbs, 2010). These projections 
are known to be intimately involved in spatial learning and memory (Luine et al., 1986) 
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and are required for E2 to benefit rodent performance on a spatial delay-match-to-position 
(Gibbs, 2002, 2007). E2 and EE may differentially affect the basal forebrain cholinergic 
system due to differing receptor binding abilities in the hippocampus (Paradiso et al., 
2001); however, no studies have evaluated the impact of EE on these projections, or how 
this impact relates to spatial learning and memory.  
 The current study was performed to test the cognitive and neurobiological effects of 
cyclically administered EE, given via a daily injection, to model oral contraceptive use. In 
order to encompass the entire range of clinically used doses, an additional medium dose of 
EE was assessed, equivalent to the highest dose of EE currently available in contraceptives, 
(Curtis et al., 2005). Following behavioral evaluations, cholinergic cells in the BF were 
quantified using unbiased stereology and relations between cell populations and 
performance on cognitive tasks were evaluated. The current studies aim to isolate the 
cognitive and neurobiological effects of several clinically relevant administration regimens 
of EE, using the Ovx rodent model.  
Materials and Methods 
Subjects 
 Subjects were 36 female Fischer-344 rats raised at Harlan Laboratories 
(Indianapolis, IN). Animals were three months old at the beginning of the study, four 
months old at maze testing initiation, and five months old at euthanasia. After arrival, 
animals were pair-housed, had food and water ad-lib, and were maintained on a 12-h 
light/dark cycle. All procedures were approved by the Institutional Animal Care and Use 
Committee and adhered to National Institutes of Health standards.  
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Experimental Design and Hormone Treatments 
 At three months old, all animals received Ovx surgery. Rats were anesthetized via 
isoflurane inhalation, received bilateral dorsolateral incisions in the skin and peritoneum, 
and ovaries and tips of the uterine horn were ligatured and removed. Muscle and skin 
were then sutured closed. During surgery, rats received an injection of Rimadyl™ 
(5mg/ml/kg) for pain, and saline (2ml) to prevent dehydration.  
 Eighteen days after Ovx, animals started receiving daily, subcutaneous injections 
at a volume of 0.1ml, continuing until euthanasia. Rats were randomly assigned to one of 
four treatment groups (n=9 per group): vehicle (sesame oil), low EE (0.125µg per day), 
medium EE (0.18µg per day), or high EE (0.3µg per day). EE (Sigma, St. Louis, MO) 
was dissolved in sesame oil at the appropriate dose at the beginning of the study, then 
aliquoted into daily quantities and stored in the refrigerator (2-4°C) until needed. The 
medium EE dose was based on a 45-50µg per day regimen that an average woman 
weighing 60-70kg would be prescribed in an oral contraceptive (Curtis et al., 2005; 
Hoffman et al., 2012), adjusted to the weight of a rat (about 0.25kg).  
Water Radial Arm Maze 
 Eighteen days later, subjects were tested for 13 days on the eight-arm, win-shift 
Water Radial-Arm Maze (WRAM) to evaluate spatial working and reference memory, as 
previously described (Bimonte and Denenberg, 1999; Bimonte et al., 2000, 2002, 2003; 
Bimonte-Nelson et al., 2003; Bimonte-Nelson et al., 2004). The maze was an eight-arm 
apparatus (each arm 38.1 x 12.7cm) filled with opaque, room temperature water. Water 
temperature was measured at the beginning of each day of testing, and was between 18-
20°C for testing. Four of the eight maze arms contained hidden platforms (10cm 
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diameter) just beneath the surface of the water and spatial cues were present to aid the 
animals in spatial navigation. Each subject was assigned different platform locations that 
remained fixed across all days of testing. A subject was released from the start arm and 
given 3 minutes (min) to locate a platform. Once a platform was found, the animal 
remained on it for 15 seconds (s), then was returned to its heated testing cage for a 30s 
inter-trial interval (ITI). During the ITI, the just-found platform was removed from the 
maze and the water was cleaned to remove any debris and obscure olfactory cues. The 
animal was then placed back into the start arm and given another 3min to locate a 
platform. Each animal received four trials per day for 13 days, with the number of 
remaining platforms reduced by one on each subsequent trial. Thus, the working memory 
system was increasingly taxed as trials progressed within a day, allowing working 
memory load to be assessed. On the 13th day of testing, a six-hour delay was given 
between trials 2 and 3 to test delayed memory retention. 
Morris Water Maze 
 One day after the WRAM, spatial reference memory was evaluated using the 
Morris water maze (MM). The apparatus was a round tub (188cm diameter) filled with 
opaque, room temperature water (18-20°C) containing a submerged platform (10cm 
diameter) in the northeast quadrant. The platform location remained fixed across all days 
and trials, with spatial cues available to aid the animals in spatial navigation, testing 
spatial reference memory (Morris et al., 1982). Animals received six trials per day for 
three days. At the beginning of each trial, animals were dropped off from one of four 
starting points (north, south, east or west), varying semi-randomly. Animals had 60s to 
locate the platform, where they remained for 15s before being placed back into a heated 
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cage for an ITI of 5-8min. To evaluate whether animals utilized a spatial strategy, a 
seventh probe trial was given on the third day of testing, during which the platform was 
removed and animals were given 60s to swim freely in the maze. A video camera and 
tracking system tracked and measured each rat’s swim path (Ethovision; Noldus 
Instruments, Wageningen, The Netherlands).  
Visible Platform Task 
 After completion of behavioral testing, motor and visual competences were 
evaluated using the visible platform task. This was a non-spatial adaptation of the spatial 
MM task, previously used to dissociate visual and motor acuity from place memory 
(Morris et al., 1982). This task is ideal for this purpose due to its similarity to other 
spatial water-maze tasks with respect to motor and visual requirements, differing only in 
that animals are not required to associate the location of the platform with distal cues. 
The apparatus was a rectangular tub (100 x 60cm) filled with clear room temperature 
water (18-20°C). A black platform (10cm wide) was positioned 4cm above the surface of 
the water, following previously published methods (Hunter et al., 2003). A ring of 
opaque curtains surrounded the maze, blocking all obvious spatial cues to prevent spatial 
navigation. Animals received six trials in one day. The drop off location remained the 
same across trials; however the platform location varied semi-randomly across three 
locations. Each rat had 90s to locate the platform, where it remained for 15s before being 
placed back into a heated cage for an ITI of 5-8min.  
Markers of Peripheral Stimulation 
 To verify Ovx and subsequent hormone treatment, vaginal smears were taken at 
four months old for four days, after animals were given hormone treatment. Smears were 
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classified as proestrus, estrus, metestrus, or diestrus (Goldman et al., 2007; Engler-
Chiurazzi et al., 2012). At euthanasia, uteri of all subjects were removed and trimmed of 
visible fat, and wet uterine weight (grams) was measured, as done previously (Westerlind 
et al., 1998; Engler-Chiurazzi et al., 2012). Osmotic pumps were visually inspected at 
euthanasia for visible cracks or tops that had come off of the pumps. 
Euthanasia 
 Animals were euthanized one day after completion of the visible platform task by 
researchers blinded to treatment group. Animals were decapitated under isoflurane 
anesthesia; brains were rapidly removed and blocked just posterior to the BF. The 
anterior portion of each brain was fixed in 4% paraformaldehyde for 48 hours following 
removal, then transferred to 0.1 M phosphate-buffered solution (PB, pH 7.4). Brains were 
then soaked in 30% sucrose solution in PB for 72 hours, frozen, and sectioned at 40µm 
through the BF (plates 1–28 Paxinos and Watson, 2005) using a Microtome Cryostat 
(Microm HM 500 OM). 
Serum Analyses 
 Serum levels of E2, E1 and EE were obtained from a subset of the vehicle and 
EE-medium groups to verify Ovx status and to determine whether experimental 
treatments resulted in circulating serum EE levels similar to those found in women taking 
EE-containing hormonal contraceptives. Blood was obtained via cardiocentesis at the 
time of euthanasia, and estrogen levels were determined using mass spectrometry with a 
lower detection limit of 10pg/ml.  
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Immunohistochemistry 
 ChAT-immunoreactive (ChAT-IR) cells in the BF were labeled using 
immunohistochemistry, following similar previously published protocols from our 
laboratory following treatment with estrogens (Acosta et al., 2009). Briefly, four animals 
from each group were selected, and a series of every third section through the BF was 
selected from each brain for immunohistochemistry processing, yielding six sections per 
animal 120µm apart, corresponding to plates 23-28 (roughly 1.2mm- 0.6mm Bregma) 
from Paxinos and Watson (2005), similar to prior publications (Gibbs, 2002). See 
supplemental materials for more detailed methods. 
Stereology 
 Unbiased stereology was used to quantify ChAT-IR cells within the medial 
septum (MS) and vertical/diagonal bands (VDB), regions that contain neurons known to 
innervate the hippocampus (Lewis and Shute, 1967; Dutar et al., 1995; Banuelos et al., 
2013). One researcher blind to treatment groups used the optical fractionator method, 
where the number of cells counted in a known, uniformly random sample of a region of 
interest is used to estimate the total cell population in that region (Gundersen, 1986; 
West, 1999; Banuelos et al., 2013).  
Statistical Analyses 
 We planned a priori to assess the differences in maze performance between each 
EE group and the Vehicle group to compare effects of each dose to a “blank” ovarian 
hormone background. After completion of the study, we performed additional post-hoc 
comparisons between the EE-low and EE-high groups.  
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 For WRAM analyses, orthogonal measures of working memory and reference 
memory errors were quantified as done previously in WRAM studies (Bimonte et al., 
2000). Working memory correct (WMC) errors were the number of first and repeat 
entries into an arm that previously contained a platform within each session. Reference 
memory (RM) errors were the number of first entries into an arm that never contained a 
platform within each session. Working memory incorrect (WMI) errors were repeat 
entries into reference memory arms within each session.  
 WRAM testing was blocked into learning (days 2-7) and asymptotic (days 8-12) 
phases, based on prior studies (e.g., Bimonte and Denenberg, 1999; Bimonte et al., 2000; 
Hyde et al., 2000; Bimonte et al., 2003). Data were analyzed separately for each type of 
error using repeated measures ANOVA, with treatment as the between-groups variable 
and number of errors on each trial as the dependent variable. Steroid treatment induced 
differences on the lattermost portion of WRAM testing have been observed previously, 
with most pronounced effects on trial 4, the highest working memory load trial (Bimonte 
and Denenberg, 1999; Bimonte-Nelson et al., 2003, 2004; Braden et al., 2010); therefore, 
interactions between treatment and working memory load (trials) were analyzed. Fisher 
PLSD post-hoc tests were used, alpha level was set at 0.05. 
 MM data were analyzed using repeated measures ANOVA, with treatment as the 
between-groups variable and distance to the platform across days and trials as the 
dependent variable. Probe trial data were analyzed identically, except with percent 
distance in the northeast (platformed) and southwest (diagonally opposite of the platform) 
quadrants as the dependent variable. 
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 Visible platform data were analyzed using repeated measures ANOVA, with 
treatment as the between-groups variable and latency to reach the platform on each trial 
as the dependent variable.  
  One-way ANOVA was used to analyze treatment group differences in the 
number weighted mean section thickness population estimate (ChAT-IR cell counts) in 
each region, and correlations between region population estimates and behavioral 
measures were examined. Accuracy of stereological estimates was evaluated using 
Gundersen’s smoothness classification m=1 coefficients of error (CEs).  
Results 
Water Radial Arm Maze 
 When delivered via daily subcutaneous injection, there were no effects of EE 
treatment on WMC, WMI, or RM during the learning portion of testing. During the 
asymptotic phase of testing, similar to effects seen previously in our lab with tonic EE 
treatment (Mennenga et al., 2015), there was a Trial x Treatment interaction for WMC 
errors [F(6,64)= 2.82; p<0.05] with a planned comparison showing that the high EE treated 
animals made more errors than vehicle treated animals as working memory load 
increased [F(2,32)= 5.78; p<0.01] (figure 12). Post-hoc analyses also showed that the high 
EE group committed more WMC errors than the low EE (Fisher, p<0.05) and medium 
EE (Fisher, p<0.05) animals at the highest working memory load (figure 12). There were 
no differences in WMC errors between the vehicle group and the low EE or medium EE 
group, and there were no group differences for WMI or RM errors during the asymptotic 
phase of testing (figure 12). There were no group differences on the post-delay trials on 
day 13. 
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Morris Water Maze 
 There was a marginal Treatment x Day interaction for MM testing [F(6,64)=2.21; 
p=0.05]. Further analyses revealed a main effect of Treatment [F(3,32)= 3.22; p<0.05] for 
Day 1 of MM, whereby the vehicle group performed better than the low EE [F(1,16)= 6.84; 
p<0.05], medium EE [F(1,16)= 8.51; p<0.05], and high EE [F(1,16)= 9.47; p<0.01] groups. 
There was no Treatment x Trial interaction for Day 1, indicating that this effect was 
present across all trials and was not carried by the initial exposure to the task on trial 1. 
There were no effects of Treatment for Days 2 or 3 of MM testing (Figure 13a). A higher 
percent distance was spent in the previously platformed quadrant versus the opposite 
quadrant [F(1,32) =374.33; p<0.0001] for the probe trial, with no quadrant by Treatment 
interaction, indicating that all groups spatially localized the platform quadrant by the end 
of testing (Figure 13b). Treatment did not impact number of crossings through the 
platform area during the probe trial (data not shown). 
Visible Platform Task 
 The average escape time across all 6 trials was a rapid 7.71 seconds with a 
standard deviation of 7.47 seconds. There were no treatment effects for latency (data not 
shown), indicating that all animals possessed similar procedural capabilities to solve a 
water maze task (p>0.05).  
Markers of Peripheral Stimulation 
 Fourteen days after the start of injections, all vehicle-treated rats exhibited 
diestrus smears indicating a lack of uterine stimulation, while animals treated with any 
dose of EE alternated between estrus and metestrus smears, with each smear showing 
numerous cornified cells, indicating uterine stimulation (Goldman et al., 2007). One 
 57 
uterine weight score was lost due to experimental error and was not included in these 
analyses. For wet uterine weight, there was a significant effect of Treatment 
[F(3,31)=29.88; p<0.0001], with uteri of vehicle-treated rats weighing less than low EE- 
[F(1,15)= 62.17; p <0.0001], medium EE- [F(1,16)= 117.36; p <0.0001], and high EE- 
[F(1,16)= 109.10; p <0.0001] treated rats (figure 14). 
Serum Analyses 
 Circulating serum E1 and E2 levels were below the lower limit for detection 
(10pg/ml) in all animals, verifying Ovx status. The mean circulating serum EE 
concentration in the medium EE treatment group was 23.17 pg/ml with a standard 
deviation of 12.50 pg/ml, which is remarkably similar to the range of serum levels found 
in women taking an oral contraceptive containing 35ug of EE near the beginning of their 
monthly cycle (Devineni et al., 2007). 
ChAT Cell Counts 
 Mean measured tissue thickness was 27µm, CEs ranged from 0.05 to 0.10 and 
were less than half of the observed variation across subjects (coefficients of variation 
ranging from 0.21 to 0.34), indicating that the sampling and counting parameters utilized 
here were adequate to detect differences in cell populations among treatment groups 
(Gundersen and Osterby, 1981; Gundersen and Jensen, 1987; West, 1999; Dorph-
Petersen et al., 2001).  
 There was a main effect of Treatment [F(3,12)=3.66; p<0.05] in the VDB, whereby 
ChAT-IR cell counts were lower in the medium EE group (Fisher, p<0.05), and lower in 
the high EE group (Fisher, p=0.05), than those in the vehicle group (figure 15a). ChAT-
IR cell counts in the low EE group did not differ from the vehicle group. Post-hoc tests 
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indicate that the ChAT-IR cell counts were lower in the medium EE group (Fisher, 
p<0.05) and marginally lower in the high EE group (Fisher, p=0.09), than the low EE 
group (figure 15a). There were no effects of Treatment on ChAT-IR cell counts in the 
MS (figure 15b). 
 The MS had a lower ChAT-IR cell count than the VDB (F(1,12)=96.49, p<0.001) 
(figure 15c). There was also a positive correlation between ChAT-IR cell counts in the 
VDB and MS of the basal forebrain (r=0.56, p<0.05), indicating that animals with higher 
ChAT-IR cell counts in the MS tended to also have higher cell counts in the VDB (figure 
15d). 
Relationship Between Cholinergic Cell Population Estimates and Maze Performance 
 Correlations between behavioral data and BF cell counts were assessed to 
determine whether group differences in behavior data relate to changes in BF cholinergic 
cell populations. There was a negative correlation between ChAT-IR cell counts in the 
VDB and number of WMC errors on the highest load trial (trial 4) during the asymptotic 
portion of WRAM testing [r= -0.55; p<0.05], such that animals with lower ChAT-IR cell 
counts committed more WMC errors (figure 15e). Both intra- and inter- class correlations 
were assessed to ensure that the directionality of intra-class correlations agreed with that 
of the overall correlation across groups; all intra-class correlations were also negative, 
and thus in accordance with the overall correlation, but not significant (data not shown). 
VDB ChAT-IR cell counts did not correlate with any other types of errors and there were 
no correlations between MS ChAT-IR cell counts and behavior data. 
 
 
 59 
Discussion 
 The present study was the first to investigate the effects of several doses of EE on 
cognition and the cholinergic system, in rodents. Overall, I found that: 1) EE impacted 
cognition in a dose- dependent manner, with high EE treatment impairing high demand 
spatial working memory, and low and medium EE treatment producing only modest 
transient impairments in a different memory domain, spatial reference memory, and 2) EE 
decreased the number of ChAT-positive neurons in the BF at medium and high doses. 
Analysis of brain and behavior measures revealed a relationship between ChAT-IR cell 
counts in the VDB and working memory performance on the WRAM. Specifically, animals 
with higher VDB ChAT-IR cell counts tended to make fewer working memory errors.  
Collectively, these results suggest that dose modifies the cognitive impact of EE; the high 
dose of EE produced working memory impairments, but low and medium doses of EE 
produced a transient impairment on only one task. These findings are clinically important, 
as the low EE treatment corresponds to the low end of available doses currently prescribed 
to women in contraceptive formulations. These doses were chosen to model the exact 
formulations currently prescribed to women, adjusted to the weight of a rat (Curtis et al., 
2005).  
 While the cognitive profiles of the low and medium EE doses did not differ, the 
medium EE dose decreased the number of ChAT-positive cells in the VDB of the BF, 
while treatment with low EE did not alter this cell population, relative to vehicle treatment. 
Of note, while the present study did not detect overt maze learning or memory differences 
following treatment with the medium dose of EE, this dose was sufficient to alter our brain 
measure of cholinergic cell counts. Additionally, cell populations in the VDB of the BF 
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negatively correlated with maze errors. This effect size is large, and it can be alternately 
stated that as cell populations decreased, number of working memory errors in the maze 
increased. This information can be used to design and implement future studies 
investigating the mechanisms responsible for the cognitive impact of EE. 
 These findings, combined with results showing that our rat serum hormone levels 
correspond with serum levels in women using hormonal contraceptives, raise concerns 
about the impact EE has on the brain and its function, as clinically prescribed for women. It 
is still unknown how extended exposure to these hormones may modulate their impact or 
whether cessation of hormone treatment would attenuate these effects. It also remains to be 
determined whether exposure to EE early in life, such as for contraception, may impact the 
cognitive impact of hormone loss or estrogen-containing HT later in life.  
 The mechanisms by which EE modulates the BF cholinergic system are still 
unknown, although there are multiple points at which estrogens can influence this system. 
E2 is well known to interact with this system, however it has been reliably shown to 
produce an increase in BF cholinergic cell counts and there is strong evidence that E2 
produces cognitive benefit through the BF cholinergic system (For review see Gibbs and 
Aggarwal, 1998, and Gibbs, 2010), the opposite of the impact of EE seen here. There is 
ample evidence that dose and duration of E2 administration alter its impact on the 
cholinergic system and, in fact, E2 delivered for a comparable duration, and at an 
equivalent dose, to the regimen used here has been shown to decrease cell populations in 
the MS (Gibbs, 2010). Although we do not see treatment group differences in the MS, the 
medium EE and high EE groups tended to have fewer ChAT-IR cells in the MS, relative to 
the vehicle group. This evidence, in conjunction with the clear behavioral deficits produced 
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by EE treatment here, seems to indicate that EE and E2 are working on similar targets, but 
in different manners.  
 Differences in the structure and function of EE and E2 may account for these 
opposing effects. For example, Paradiso et al., 2001 found that a small structural difference 
between human and rat α4β2 Nicotinic Acetylcholine Receptors (NAchRs) in the binding 
domain results in an inability of E2, but not EE, to potentiate this receptor in rats. 
Interestingly, the human α4β2 NAchR can be stimulated by both E2 and EE. These 
receptors, along with the α7 subtype, are the primary type of NAchRs present in the rodent 
brain (Flores et al., 1992), and are closely related to many cognitive processes, including 
hippocampal-dependent learning and memory (for review, see Hogg et al., 2002). Direct 
potentiation of hippocampal α4β2 NAchRs from exogenous EE may contribute to a 
downregulation in the production of endogenous acetylcholine. While this distinction has 
the potential to contribute to the opposing cognitive impacts of EE and E2, the cholinergic 
system is extensively complex and there are many factors yet to be investigated that will 
likely modulate the impact of different estrogens.  
 It is crucial to mention that clinically used EE-containing contraceptives and HTs 
require a progestin component to prevent the increased risk of endometrial cancer 
associated with unopposed estrogen. There are currently several clinically available 
progestins, each of which has a distinct pharmacological profile (Curtis et al., 2005). One 
commonly prescribed progestin, medroxyprogesterone acetate (MPA) (Curtis et al., 2005), 
when delivered alone, has been shown to impair spatial memory during treatment as well as 
several months later, when MPA levels are no longer detectable in serum (Braden et al., 
2010, 2011). EE has yet to be methodically tested for cognition along with specific 
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progestins, and it is unknown how the inclusion of a progestin may influence the behavioral 
or brain impact of EE. 
 Results from the present study suggest that the contraceptive regimen that may 
produce the most favorable cognitive impact includes a low dose of EE (30-35µg EE/day or 
less). These findings also offer insight into how small differences in hormone structure and 
function can produce large differences in behavioral and brain profiles. Further studies are 
necessary to outline the many mechanisms by which estrogens can alter cognitive brain 
regions and how changes produced by exogenously delivered and endogenously circulating 
estrogens relate to cognitive function. The popularity that contraceptives have gained since 
their introduction in the 1960’s has effectively changed the lifetime hormone profile of the 
average woman. The current aging generation is the first to have had long-term exposure to 
synthetic hormones and it is now crucial to understand how a lifetime of different 
endogenous and exogenous hormone exposures can influence cognitive aging. The broad 
goal of this research is to elucidate the impact that clinically prescribed hormones have on 
cognitive function and, ultimately, to optimize contraceptive and HT use for healthy 
cognitive aging, beginning in young adulthood. I hope the results of the current studies will 
set the stage for a series of future methodical investigations into the effects these clinically-
prescribed hormones have on the brain and related memory processes. 
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CHAPTER 5: COGNITIVE IMPACT OF ETHINYL ESTRADIOL IN OVARY-
INTACT YOUNG ADULT RATS 
Introduction 
 Ethinyl estradiol (EE) is a synthetic analogue of the natural estrogen, 17β-estradiol 
(E2), and is the primary estrogen utilized in hormonal contraceptives (Shively, 1998). 
Numerous contraceptive formulations contain EE (Curtis et al., 2005), and EE is also found 
in hormone therapies (HTs) for menopausal women, such as EstinylTM and FemhrtTM 
(Curtis et al., 2005). It has been estimated that 10.6 million women between 2006-2010 
(Jones et al., 2012), and 17.3% of all women between 2006-2008 (Mosher and Jones, 
2010), used EE-containing contraceptives. Elucidating the cognitive impact of EE is 
critical, as exogenous exposure to EE can occur during young adulthood and during the 
transition to menopause through contraceptives and HT. Of note, EE is a synthetic 
analogue to E2; however, these estrogens have different pharmacokinetic profiles 
(Bennink, 2004). EE is more biologically active than E2 (Dickson and Eisenfeld, 1981) and 
cannot be converted to estrone (E1) or other weaker estrogens (Fotherby, 1996), whereas 
E2 can (Prokai-Tatrai, et al., 2005). Each of these estrogens also exhibits a distinct binding 
profile, which varies across species (Paradiso et al., 2001).  
 Although EE is widely used by women, and many women take EE-containing 
hormonal formulations for a large portion of their lives, most preclinical research on the 
cognitive impact of estrogens has excluded EE (for review see: Acosta et al., 2013; 
Bimonte-Nelson et al., 2010). There have been a few studies investigating the cognitive 
effects of EE as both a contraceptive and HT, with effects that vary across memory 
domains (Silber et al., 1987; Mordecai et al., 2008). Although these studies each utilized 
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hormonal contraceptive formulations containing EE, the specific dose of EE and the 
included progestin differed. Because of these differences, it is unknown whether or to what 
extent EE produced these effects.  
 In chapter 4, I tested the cognitive and neurobiological effects of cyclically 
administered EE, given via a daily injection, to model oral contraceptive use. By 
methodically evaluating EE in the ovariectomized (Ovx) rodent model, I was able to 
investigate the effects of EE alone, without the effects of any other ovarian hormones. I 
found that EE in the Ovx model impacted cognition in a dose- dependent manner, with 
high EE treatments impairing high demand spatial working memory, and low treatment 
producing only modest transient impairments in a different memory domain, spatial 
reference memory. I also found that cyclic EE decreased the number of Choline 
Acetyltransferase (ChAT)-positive neurons in the basal forebrain at medium and high 
doses. Analysis of brain and behavior measures revealed a relationship between ChAT-
positive cell counts in the VDB and working memory performance on the WRAM. 
Specifically, animals with higher VDB ChAT-positive cells tended to make fewer working 
memory errors. An animal model using ovary intact female rats is necessary, given that 
most women are ovary intact for the majority of their lives. In fact, only a small percentage 
of women have their ovaries removed via oopherectomy. The aim of the current study is to 
evaluate the effects of EE administration in ovary	intact	animals, to determine how the 
administration of EE affects cognition in ovary intact rats, as a model of hormonal 
contraceptive use. 
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Materials and Methods 
Subjects 
 Thirty three-month old virgin F-344 female rats were raised at Harlan Laboratories 
(Indianapolis, IN). Similar to Study I, animals were three months old at the beginning of 
the study, four months old at maze testing initiation, and five months old at euthanasia. 
After arrival, animals were pair-housed, had food and water ad-lib, and were maintained on 
a 12-h light/dark cycle. All procedures were approved by the Institutional Animal Care and 
Use Committee and adhered to National Institutes of Health standards.  
Experimental Design and Hormone Treatments 
 Rats were vaginally smeared and catalogued for 35 days to ensure that each 
animal’s estrous cycle was regular, meaning that they consistently progressed through each 
phase of the estrous cycle within four or five days. Animals were then randomly assigned 
to one of three groups (n=10/group) and given either empty silastic tubing, or one of two 
lengths of silastic tubing containing EE (Dow Corning; 0.062in I.D. x 0.125in O.D.). Rats 
were anesthetized via isoflurane inhalation, a small incision was made, and a subcutaneous 
pocket was created in the dorsal scruff of the neck. A length of silastic tubing that was 
either empty (4mm long), or one of two lengths containing EE ((Sigma, St. Louis, MO; 
2mm or 4mm long) was inserted below the skin, and the skin was closed with surgical 
staples. The 2mm length of silastic tubing was selected to produce circulating serum levels 
of EE similar to those that we have seen with our low EE dose, which is based on the 30-
35µg daily regimen that an average 60-70kg woman would be prescribed in an oral 
contraceptive (Curtis et al., 2005; Hoffman et al., 2012), adjusted to the weight of a rat 
(about 0.25kg). The 4mm length of silastic tubing was chosen to produce circulating serum 
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levels similar to our previously used high dose of EE, which is one-tenth of a similar dose 
of E2 previously shown to enhance performance on spatial tasks (Talboom et al., 2008) and 
corresponds to a 75-80µg/day dose of EE (in a 60-70kg woman), within the range of 
previously available contraceptives for women in the 1960’s, before the benefits of lower-
dose formulations were known (Chadwick et al., 2012).  
 Eighteen plus or minus two days after silastic insertion surgeries, behavioral testing 
ensued. Behavioral testing consisted of: water radial arm maze, Morris water maze, open 
field, and object recognition. Figure 16 shows a timeline depicting the temporal relations 
among the various treatments.  
Water Radial Arm Maze 
 Water radial arm maze testing was identical to the testing procedures described in 
chapter 4. 
Morris Water Maze 
 Morris water maze testing was identical to the procedures described in chapter 4, 
with the exception that animals were tested for four trials per day across five days of 
testing, with an additional fifth probe trial on the final day of testing. 
Markers of Peripheral Stimulation 
 To verify hormone treatment, vaginal smears were taken throughout the study. 
Smears were classified as proestrus, estrus, metestrus, or diestrus (Goldman et al., 2007; 
Engler-Chiurazzi et al., 2012; Mennenga and Bimonte-Nelson, 2013). At sacrifice, uteri of 
all subjects were removed and trimmed of visible fat, and wet uterine weight (grams) was 
measured, as done previously to confirm hormone status (Westerlind et al., 1998; Engler-
Chiurazzi et al., 2012; Mennenga and Bimonte-Nelson, 2013). Serum was collected at 
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sacrifice via cardiocentesis and processed for levels of androstenedione, E2, E1, leutenizing 
hormone (LH), and follicle stimulating hormone (FSH). Levels were obtained using an 
iodinated radioimmunoassay (RIA) by the CORE Endocrine Laboratory at Pennsylvania 
State University, exactly as reported elsewhere (Acosta et al., 2009, 2010). 
Statistical Analyses 
 WRAM testing was blocked into learning (days 2-7) and asymptotic (days 8-12) 
phases, based on prior studies (e.g., Bimonte and Denenberg, 1999; Bimonte et al., 2000; 
Hyde et al., 2000; Bimonte et al., 2003). Data were analyzed separately for each type of 
error using repeated measures ANOVA, with treatment as the between-groups variable and 
number of errors on each trial as the dependent variable. Steroid treatment induced 
differences on the lattermost portion of WRAM testing have been observed previously, 
with most pronounced effects on trial 4, the highest working memory load trial (Bimonte 
and Denenberg, 1999; Bimonte-Nelson et al., 2003, 2004; Braden et al., 2010); therefore, 
interactions between treatment and working memory load (trials) were analyzed. Fisher 
PLSD post-hoc tests were used, alpha level was set at 0.05. 
 MM data were analyzed using repeated measures ANOVA, with treatment as the 
between-groups variable and distance to the platform across days and trials as the 
dependent variable. Probe trial data were analyzed identically, except with percent distance 
in the northeast (platformed) and southwest (diagonally opposite of the platform) quadrants 
as the dependent variable. 
 Results 
 The high EE group was removed from the behavioral analyses due to extensive 
health issues that arose from the high EE treatment. By sacrifice, 5 out of the 10 animals in 
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this group had developed extremely enlarged uterine horns that appeared to be cancerous. 
The remaining 5 animals all also had very enlarged uterine horns, which are likely the 
result of this high dose of synthetic estrogen being given to animals with intact ovaries. 
Uterine stimulation was apparent in the low EE group as well, but it was not as extensive as 
seen in the high dose group. Behavioral data from the vehicle and low EE groups are 
presented. 
Water Radial Arm Maze 
 There was a main effect of Treatment on Total Errors made on days 2-7 of WRAM 
testing, which is considered the learning phase of testing (F(1,16)= 4.80, p<0.05), with the 
EE-treated group committing more errors across all trials than the vehicle-treated animals 
(figure 17). There was no interaction between Treatment and Trial (F(3,48)= 1.59, p=0.20, 
NS), indicating that this difference was not specific to any trial. This difference was no 
longer apparent during the asymptotic portion of testing, days 8-12 (F(1,16)= 1.94, p=0.18, 
NS) and there was no interaction between Treatment and Trial for this portion of testing 
(F(3,48)= 0.70, p=0.56, NS) (figure 17).  
Morris Water Maze 
 There were no main effects of Treatment on Total Swim Distance (cm) for the MM 
(F(1,16)= 1.08, p=0.31, NS), but there was a Day x Treatment interaction (F(4,64)= 3.32, 
p<0.05) (figure 18). Further analyses revealed that there was an effect of Treatment on 
Total Swim Distance on Day 1 of testing (F(1,16)= 5.25, p<0.05), with the EE-treated 
animals swimming a shorter distance than the vehicle-treated animals across all four trials, 
suggesting that they covered a shorter distance during the allotted trial time (figure 18). 
Given that the majority of the animals did not locate the platform successfully during the 
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allotted trial time on the first day of testing with this testing protocol that only includes four 
trials per day, I analyzed only successful trials, in which the animal found the platform 
within the allotted trial time; there was no difference on any trial of Day 1 when only 
successful trials were included (Trial 1: no animals found the platform; Trial 2: F(1,5)=0.05, 
p>0.05, NS; Trial 3: F(1,7)=1.61, p>0.05, NS; Trial 4: F(1,8)=0.47, p>0.05, NS; figure 19). 
Further, mean swim velocity (cm/s) was marginally decreased in the EE group (F(1,16)=3.93, 
p<0.10; figure 19). By the end of the second day of testing, animals were able to locate the 
platform on their own on the majority of the trials given, and this difference was no longer 
apparent. For the probe trial, there was a main effect of Quadrant (F(1,16)= 173.00, 
p<0.0001; figure 18), indicating that all animals preferred the previously-platformed 
quadrant over the diagonally opposite quadrant and were therefore likely employing a 
spatial strategy. 
Markers of Peripheral Stimulation 
 There was a main effect of Treatment on androstenedione levels (F(1,14)= 11.99, 
p<0.01), E2 levels (F(1,16)= 5.54, p<0.05), and FSH levels (F(1,17)= 8.32, p<0.05), such that 
EE treatment increases androstenedione levels, decreases E2 levels, and increased FSH 
levels, relative to vehicle treatment (figure 20). There was no effect of EE treatment on E1 
levels (F(1,17)= 0.05, p=0.83, NS) or LH levels (F(1,17)= 0.92, p= 0.36, NS). There was an 
effect of Treatment on wet uterine weight (F(1,17)= 14.85, p<0.01), such that EE treatment 
increased uterine weights (figure 20).  
Discussion 
 I previously reported cognitive-impairing effects of high-dose EE in Ovx animals 
(Mennenga et al., 2015; chapter 4), and the current study now extends those findings to 
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ovary-intact animals. Here, EE treatment given to ovary-intact young adult rats produced 
impairments on the WRAM, and marginally decreased swim velocity on the MM. EE did 
not impact non-spatial object recognition. Silber et al. (1987) found no impact of EE-
containing contraceptives on several tests measuring memory and concentration in 
women, and Mordecai et al. (2008) found enhanced verbal memory during the active 
compared to the inactive phase of oral contraceptives in women, although benefits were 
not seen on visuospatial measures. Thus, the results here are in keeping with the general 
finding that estrogenic effects are specific to memory domain. In chapter 3, I reported 
memory-domain-specific differences between males and females experiencing different 
hormonal states. It seems that visuospatial ability is particularly impacted by changes in 
estrogen status. Thus, the spatial memory tasks utilized in the current set of experiments 
may be ideal to detect the cognitive impact of EE and other estrogens.  
 EE also increased serum follicle stimulating hormone and androstenedione, 
decreased serum E2, and did not impact serum estrone or LH in these ovary-intact young 
adult rats. Our lab has shown in several studies that elevated androstenedione levels are 
associated with impaired performance on several maze tasks (Acosta et al., 2009, 2010; 
Camp et al., 2012; Mennenga et al., 2014), implicating this hormone in the cognitive 
impairments seen here. This study serves only as the starting point from which future 
investigations into the cognitive effects of natural and synthetic hormones can be derived; 
investigations into the many administration parameters that vary by formulation are 
needed. Follow-up studies utilizing popular available synthetic progestins will be 
necessary to determine how the inclusion of another hormone might offset or interact 
with the effects of EE alone. Also, the doses investigated in this dissertation cover a wide 
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range, and more refined studies of dose-response relationships will be valuable towards 
understanding how contraceptive formulations impact the brain and its function. 
Additionally, administration route is an important factor to consider when studying the 
behavioral pharmacology of any drug. Contraceptives are delivered via several different 
mechanisms, including tonic regimens that release a steady rate of hormone across time, 
such as transdermal patches or the vaginal ring, and cyclic regimens that are delivered in 
a daily pill, resulting in a steady rise and fall of hormone levels across time. Phasic 
formulations that deliver EE and progestins in a pattern more closely representative of the 
natural fluctuations in hormone levels that happen across the menstrual cycle are also 
available; these formulations are as-of-yet unexplored for effects on cognition.  
 There is an abundance of hormone formulations available to women, and these 
treatments are prescribed for many purposes, including for contraception, endometrial 
and ovarian regulation, and for relief from symptoms associated with menopause. This 
wide array of available formulations means that there is ample potential for cognitively 
detrimental treatments to unknowingly be given to women; however, this also means that 
we, as scientists, have a long list of potentially cognitively neutral, or even beneficial 
formulations to study. Since each of these formulations achieve similar clinical purposes, 
future women may have the opportunity to choose hormone treatments based on 
scientifically informed information on the whole-body impact of each available option.  
 72 
CHAPTER 6: OPTIMIZING HORMONE THERAPY ACROSS THE MENOPAUSE 
TRANSITION I: WINDOW OF OPPORTUNITY 
Introduction 
 Around the fifth decade of women’s lives, their eggs stop maturing, ovulation and 
menstruation become irregular, and eventually menstruation stops; this natural cessation of 
the menses is known as menopause (NAMS; Curtis et al., 2005). With halting of ovulation, 
ovarian production of estrogens and progesterone drastically decrease, resulting in several 
undesirable health consequences. Common menopause-related issues include hot flashes, 
bone density loss, cardiovascular changes, vaginal atrophy, and cognitive decline (Curtis et 
al., 2005). Increasing life expectancy and stable age of natural menopause onset mean that 
women are now spending up to 40% of their lives post-menopause (ACOG, 2011). Many 
women utilize estrogen-containing hormone therapy (HT), which can alleviate several 
symptoms of menopause. Conjugated equine estrogens (CEE, tradename Premarin®, 
Prempro with the synthetic progestin Medroxyprogesterone acetate; MPA) were the most 
commonly prescribed estrogen component of HT in the US (Hersh et al., 2004); fourteen 
million women in the US were estimated to use CEE in 2005, and CEE has been prescribed 
as HT since 1942 (Stefanick, 2005). CEE contains several estrogens, including many that 
are not naturally produced by women, trace amounts of 17β-estradiol (E2), the most potent 
naturally circulating estrogen in women, and over 50% estrone sulfate (E1S; Gleason et al., 
2005), which is desulfated in the liver, converting it to estrone (E1). In many women, CEE 
HT is effective at attenuating or preventing symptoms of menopause, including hot flashes, 
vaginal atrophy, and decreased bone density (Curtis et al., 2005); however, whether CEE 
reduces the cognitive decline associated with menopause remains unclear. The large 
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Women’s Health Initiative Memory Study (WHIMS) reported that CEE alone produced no 
change in risk of developing mild cognitive impairment (MCI) and a trend for an increase 
in probable dementia incidence; CEE plus progestin treatment produced no change in MCI 
risk and increased the risk of probable dementia in menopausal women (Espeland et al., 
2004; Shumaker et al., 2004), findings which prompted many women to discontinue their 
HT use altogether (ACOG, 2011). 
 There is accumulating evidence that a ‘window of opportunity’ for HT initiation 
following hormone loss exists (Singh et al., 2013). Clinical studies demonstrating a limited 
window of time during which HT can exert positive effects have given rise to the critical 
period, or window of opportunity, hypothesis (Resnick & Henderson, 2002; Zandi et al., 
2002; MacLennan et al., 2006; Maki, 2006; Maki & Sundermann, 2009; Khoo et al., 2010). 
For example, recent reports have found that HT initiated prior to natural menopause was 
beneficial to cognitive performance; however, HT initiated post-menopause was 
detrimental (Greendale et al., 2009), and use of HT during the menopause transition has 
been shown to enhance memory and hippocampal function, as detected by fMRI, in women 
(Maki et al., 2011). Several preclinical rodent studies also support the window of 
opportunity hypothesis for beneficial effects of HT on cognition (Gibbs, 2000; Daniel et 
al., 2006; McLaughlin et al., 2008; Bohacek & Daniel, 2010) and brain health (Bohacek et 
al., 2008; Bohacek & Daniel, 2009), but this research has been limited to the Ovx model of 
hormone loss and to E2 as HT. In middle-aged Ovx rats, E2 given immediately, but not 
five months after Ovx, enhances spatial working memory (Daniel et al., 2006) and 
attentional processes on the five-choice serial reaction time task (Bohacek & Daniel, 2010). 
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Additionally, E2 given immediately or three months after Ovx, but not 10 months after 
Ovx, enhances delayed-match-to-position performance (Gibbs, 2000).  
 Using the ovariectomized (Ovx) rodent as an ovarian hormone ‘blank slate’, we 
showed that CEE HT exerted beneficial effects on spatial working and reference memory 
(Acosta et al., 2009; Engler-Chiurazzi et al., 2011). Importantly, reproductive senescence in 
women differs from reproductive senescence in female rats. The aging rat does not 
experience menopause; it experiences estropause, which includes several hormonal states 
indicative of irregular ovulation. Estropause can manifest as a persistent estrus state, 
associated with low to medium circulating levels of E2, E1, and the androgens testosterone 
and androstenedione, along with low levels of progesterone, or it can produce a persistent 
diestrus state with intermediate levels of E2, E1, and androstenedione, low testosterone, 
and high progesterone (Lu, 1979). Although these processes differ from menopause, there 
are notable similarities in the physiological triggers of these events. In both women and 
rodents, patterns of FSH and LH release from the pituitary gland change before changes in 
ovulation occur (Wise et al., 1999; Downs and Wise, 2009), and there is indication that 
changes in pituitary gonadotropin release, coupled with changes in ovarian function, lead to 
both estropause and menopause (Wise, 1999; Wise et al., 1999). These parallels are 
important, and lend support to the rodent as a reliable model of the human reproductive 
system; nonetheless, estropause is not the ideal model of human menopause. Likewise, the 
Ovx model is an excellent tool to study the estimated 600,000 women per year who have 
undergone surgically induced menopause (ACOG, 2008; Rocca et al., 2009), and it is the 
gold standard for isolating the effects of exogenously administered hormones (Mennenga & 
Bimonte-Nelson, 2013); however, the Ovx model has limited generalizability to the 
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majority of women who have undergone natural, transitional menopause and retained their 
follicle-deplete ovaries.  
  Natural menopause can be more closely modeled in the rodent via the industrial 
chemical 4-vinylcyclohexene diepoxide (VCD). Treatment with VCD accelerates the 
natural process of atresia in the finite primary and primordial follicle pool, producing a 
gradual loss of follicles (Flaws et al., 1994; Springer, McAsey, et al., 1996; Springer, Tilly, 
et al., 1996; Borman, et al., 1999; Kao et al., 1999; Hu et al., 2002; Mayer, et al., 2002, 
2004, 2005), leading to ovarian failure, and a drastic decrease in ovarian-derived E2 and 
progesterone (Hirshfield, 1991; Springer et al., 1996: Mayer, et al., 2004, 2005). Thus, 
treatment with VCD results in an ovary-intact, follicle-deplete rat with a hormone profile 
similar to that of a naturally menopausal woman. Using the VCD model, our laboratory has 
previously shown that CEE administration can improve performance on a spatial working 
and reference memory task following surgical menopause, but can impair performance 
when administered following a VCD-induced transitional hormone loss (Acosta et al., 
2010). We have repeatedly shown a positive relationship between circulating levels of 
androstenedione, the primary hormone released following follicular depletion, and maze 
errors (Acosta et al., 2009b, 2010; Camp et al., 2012), and we have also shown that 
exogenous androstenedione impairs spatial memory in Ovx rats (Camp et al., 2012), as 
does its estrogenic metabolite E1 (Engler-Chiurazzi et al., 2012). Moreover, 
pharmacological blockade of exogenous androstenedione’s conversion to E1 prevented its 
negative cognitive impact (Mennenga et al., 2015). These results indicate that ovarian-
produced androstenedione-derived E1 is contributing to the cognitive deficits associated 
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with transitional menopause. CEE is primarily composed of E1S that is converted to E1, 
making it unlikely to be beneficial for memory once follicular depletion has ensued.  
 Thus, clinical and preclinical findings concur that beneficial effects of estrogen HT 
may be dependent on early initiation; however, there have been no preclinical rodent 
studies on the window of opportunity utilizing a model of transitional menopause, or the 
popular HT CEE. In our previous study demonstrating detrimental effects of CEE in 
transitionally menopausal, ovary-intact rats (Acosta et al. 2010), CEE treatment initiation 
took place after follicular depletion had ensued, when androstenedione is the primary 
hormone released by the ovaries. I hypothesized that timing of treatment initiation relative 
to follicular depletion or duration of treatment alter the cognitive effects of CEE HT. I 
investigate whether giving CEE at the onset of accelerated follicular depletion changes its 
cognitive effects. The goals of the present study were to determine whether the cognitive 
impact of CEE HT is influenced by: the timing of treatment initiation relative to the onset 
of accelerated follicular depletion, or the duration of treatment. I evaluated cognition using 
tasks tapping spatial working and reference memory.  
Materials and Methods 
Subjects 
 Thirty-four eight month-old Fischer-344 female rats raised at the aging colony of 
the National Institute on Aging at Harlan Laboratories (Indianapolis, IN) were used. After 
arrival, rats were pair-housed, had food and water ad-lib, and a 12-h light/dark cycle. 
Animals were 12 months old at the initiation of behavioral testing. All procedures were 
approved by the local Institutional Animal Care and Use Committee (IACUC) and adhered 
to National Institutes of Health (NIH) standards. 
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Experimental Design and Hormone Treatments 
 To make behavioral testing feasible, animals were run in two experimental waves, 
six weeks apart, with each treatment group represented in each wave. Rats were randomly 
divided into 4 groups (n in parentheses): Control (8), Post (9), Peri Long-Term (Peri-LT) 
(10), and Peri Short-Term (Peri-ST) (7). Figure 21 provides a comprehensive overview of 
the experimental design. 
VCD Treatment 
 One week after arrival, animals in the Control, Post and Peri-LT groups received 
VCD treatment (160 mg/kg diluted in 50% DMSO/Saline at a volume of 2.5µl/g body 
weight; IP; Sigma-Aldrich, St. Louis, MO) while animals in the Peri-ST group received 
vehicle injections (50% DMSO/Saline at a volume of 2.5µl/g body weight; IP), for 15 days. 
VCD follicular depletion procedures were adapted from prior studies (Acosta et al., 2009, 
2010; Mayer et al., 2002). Sixty-four days after the first VCD injection, a second set of 
VCD/Vehicle injections were administered. Peri-ST animals received VCD injection for 15 
days (160 mg/kg diluted in 50% DMSO/Saline at a volume of 2.5µl/g body weight; IP; 
Sigma-Aldrich, St. Louis, MO), while Control, Post, and Peri-LT animals received vehicle 
injections (50% DMSO/Saline at a volume of 2.5µl/g body weight; IP).   
CEE Treatment 
 Twenty-eight ±1 days after the beginning of VCD treatment for the Control, Post, 
and Peri-LT groups, CEE treatment was initiated for the Peri-LT group. CEE, in its 
unconstituted powder form, as prescribed to women (manufactured by Wyeth 
Pharmaceuticals Inc., Philadelphia, PA, obtained from a commercial pharmacy via 
veterinary prescription) was dissolved in sesame oil at a dose of 30µg/injection (injection 
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volume=0.1ml). One subcutaneous injection was given for two consecutive days followed 
by two days off, a pattern repeated throughout the study (exactly as done in Acosta et al., 
2009). Using this injection regimen, we have previously shown CEE to alter cognition in 
middle-aged Ovx rats (Acosta et al., 2009), and we, and others, have shown E2 to impact 
hippocampal plasticity and memory (Korol and Kolo, 2002; McLaughlin et al., 2008; 
Woolley and McEwen, 1993). All other groups received sesame oil injections following the 
same administration regimen at a volume of 0.1ml. 
 Next, 90±1 days after the Control and Post groups’ VCD treatment was initiated, 
CEE treatment began for the Post and Peri-ST groups. CEE administration for the Post and 
Peri-ST groups was identical to that of the Peri-LT group, with the exception of the 
treatment initiation time-point. The Control group continued to receive sesame oil 
injections following the same administration regimen at a volume of 0.1ml. These injection 
regimens were continued until sacrifice. 
 To confirm follicular depletion following VCD as well as CEE treatment, vaginal 
smears were performed during the 10 days prior to behavioral testing. Smears were 
classified as proestrus, estrous, metestrus or diestrus (Goldman et al., 2007). Behavioral 
testing began 107±1 days after the first VCD injection, 79±2 days after initiation of CEE 
treatment for the Peri-LT group, and 17 days after initiation of CEE treatment for the Post 
and Peri-ST groups Hormone/vehicle treatment was continued throughout behavioral 
testing, and animals received the last CEE/Sesame oil injection one day before sacrifice. 
Water Radial Arm Maze 
 Water radial arm maze (WRAM) procedures were identical to those in chapter 4, 
except that on the 13th day of testing, a 6-hour delay was given between trials 2 and 3, and 
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on the 14th day of testing, an 8-hour delay was given between trials 2 and 3, to test delayed 
memory retention. 
Morris Water Maze 
 Morris water maze (MM) procedures were identical to those in chapter 4. 
Delay Match-to-Sample Asymmetrical Three-Choice Task 
 One day after MM testing concluded, spatial working memory and short-term 
memory retention were evaluated using a win-stay water-escape DMS asymmetrical place-
learning task. The maze was an asymmetrical, four-arm apparatus (each arm 38.1 x 
12.7cm) filled with opaque, room temperature water containing a submerged platform 
(10cm diameter) in one of the four arms. This task was identical to the win-stay DMS plus 
maze (Engler-Chiurazzi et al., 2011; Frick et al., 1995), with the exception of the 
asymmetrical arm configuration. Animals were released into a different start arm at the 
beginning of each trial, varying semi-randomly such that the animals were released from 
each of the three non-platformed arms twice within a day of testing. The platform remained 
in the same location within a day, but changed location across days. Animals received six 
trials/day for 8 days with 90 seconds to locate the platform, 15 seconds on the platform and 
a 30 second inter-trial-interval in a heated cage. On the 7th day of testing, a 6-hour delay 
was given between trials 1 and 2, and on the 8th day of DMS testing, an 8-hour delay was 
given between trials 1 and 2, to test delayed memory retention. 
Visible Platform Task  
 Visible platform procedures were identical to those described in chapter 4. 
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Peripheral Markers of Treatment 
 To verify VCD and subsequent hormone treatment, vaginal smears were taken for 
ten days just prior to behavioral testing. Smears were classified as proestrus, estrus, 
metestrus, or diestrus, exactly as reported elsewhere (Goldman et al., 2007; Engler-
Chiurazzi et al., 2012; Acosta et al., 2009, 2010). At sacrifice, uteri of all subjects were 
removed and trimmed of visible fat, ovaries were removed for histological processing, and 
wet uterine weight (grams) was measured, exactly as reported elsewhere (Westerlind et al., 
1998; Engler-Chiurazzi et al., 2012; Acosta et al., 2009, 2010). Ovaries were removed, 
trimmed of fat, and preserved in 10% formalin. Sections were then processed for paraffin 
embedding and sectioned at 5µm, then stained using hematoxylin and eosin. Corpora lutea 
and follicle populations were counted.  
Hormone Assays 
 Serum was collected at sacrifice via cardiocentesis and processed for levels of 
Androstenedione. Levels were obtained using an iodinated radioimmunoassay (RIA) by the 
CORE Endocrine Laboratory at Pennsylvania State University, exactly as reported 
elsewhere (Acosta et al., 2009, 2010). 
Statistical Analyses 
 Orthogonal planned comparisons were set a priori. We first compared animals 
treated with CEE post-depletion (Post group), to animals given vehicle treatment (Control 
group). Next, we compared animals treated with CEE post-depletion (Post group) to each 
group of animals whose CEE treatment administration began during depletion (Peri-LT and 
Peri-ST groups). These comparisons were chosen 1) to replicate prior findings that CEE 
initiated post-depletion impairs memory relative to vehicle treatment and 2) to determine 
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whether previously observed CEE-induced cognitive impairments following transitional 
menopause could be reversed with early CEE initiation. We predicted that the animals 
treated with CEE post depletion (Post group) would make more WRAM errors than the 
animals that received vehicle treatment (Control group); this would be a direct replication 
of our prior findings using the VCD model (Acosta et al., 2010). Thus, alpha level was set 
at 0.05 (1-tail) for Post versus Control group WRAM and MM comparisons. We also 
anticipated that the Post group would make more errors than the Peri-ST and Peri-LT 
groups, based on prior findings from others evaluating a window of opportunity for 
cognitive benefits of E2 in the Ovx model (Gibbs, 2000; Daniel et al., 2006; Bohacek & 
Daniel, 2010). However, since early initiation of HT has never been evaluated in rodents 
using CEE or a transitional model of menopause, and the DMS 3-choice task has not been 
used to evaluate cognitive effects of CEE in the VCD model, alpha level for all remaining 
comparisons was set at 0.05 (2-tail). 
 WRAM errors were counted when the tip of a rat’s snout crossed a mark on the 
outside of the arm (not visible from inside the maze; 11cm into the arm). Errors were 
initially quantified using previously established orthogonal measures of working and 
reference memory (Jarrard et al., 1984; Bimonte et al., 2000, 2002; Hyde et al., 2000; 
Braden et al., 2010, 2011). Working Memory Correct (WMC) errors included all entries 
into arms that previously contained a platform, Reference Memory (RM) errors included 
first entries into arms that never contained a platform and Working Memory Incorrect 
(WMI) errors included all subsequent entries into arms that never contained a platform. An 
initial analysis indicated that there was no interaction between Treatment and WRAM 
Error Type (F(6,58)= 0.701; p>0.05, NS); therefore, total errors are presented. WRAM 
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testing was divided into 3 testing blocks of 4 days each (Block 1: Days 1-4, Block 2: Days 
5-8, Block 3: Days 9-12). Data were analyzed using repeated measures ANOVA, with 
treatment as the between-groups variable and number of errors on each trial as the 
dependent variable. Estrogen-induced differences on the lattermost portion of WRAM 
testing have been observed previously, and the largest differences are typically seen on trial 
4, the highest working memory load trial (Bimonte and Denenberg, 1999; Bimonte-Nelson 
et al., 2003, 2004; Braden et al., 2010; Acosta et al., 2010); therefore, data were analyzed 
separately within each testing block, and interactions between Treatment and working 
memory load (Trial) were investigated.  
 MM data were analyzed using repeated measures ANOVA, with treatment as the 
between-groups variable and distance to the platform as the dependent variable. Probe trial 
data were analyzed using repeated measures ANOVA with quadrant (Northeast vs. 
Southwest) as the between-groups variable and percent distance as the dependent variable, 
to determine the percent of each animal’s swim distance spent in the previously platformed, 
versus the diagonally opposite quadrant.  
 For DMS testing, trial 1 was considered to be the information trial and was not 
included in analyses, trial 2 was the working memory trial and trials 3-6 were considered 
recent memory trials. Entry into any non-platformed arm was counted as an error. An arm 
entry was counted when the tip of a rat’s snout reached a mark on the outside of the arm 
(not visible from the inside of the maze; 11 cm into the arm). DMS testing was divided into 
learning (days 1-3) and asymptotic (days 4-6) phases and analyzed separately for each 
phase of testing using repeated measures ANOVA, with Treatment at the between-groups 
variable and number of errors across days and trials as the repeated dependent measure.  
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 Visible platform data were analyzed using repeated measures ANOVA, with 
treatment as the between-groups variable and latency to reach the platform on each trial as 
the dependent variable. 
 Wet uterine weights, serum hormone levels, ovarian follicles, and corpora lutea 
were all analyzed with one-way ANOVAs, with Treatment as the between-groups variable 
and wet uterine weights (g), circulating levels of Androstenedione (pg/ml), estimated 
number of follicles, and number of corpora lutea as the respective dependent variables. 
Subjects with serum hormone levels below the lower detectable limit of the assay were 
excluded from serum analyses.  
Results 
Water Radial Arm Maze 
 We did not observe an effect of Wave (F(1,25)= 2.53; p>0.05, NS, ηG2<0.01), nor a 
Wave x Treatment interaction (F(3,25)= 1.19; p>0.05, NS, ηG2<0.01) for WRAM errors, 
therefore analyses were collapsed across wave. An initial analysis indicated that there was 
no interaction between Treatment and WRAM Error Type (WMC, WMI, RM) for WRAM 
testing (days 1-12; F(6,58)= 0.70; p>0.05, NS); therefore, total errors are presented. There 
were no effects of Treatment or Trial x Treatment interactions for Blocks 1 or 2. For Block 
3, there was a main effect of Treatment, such that the Post group made more errors than the 
Control group (F(1,15)=3.22, p≤0.05, ηG2=0.01), as expected (Acosta et al., 2010) 
(F(1,15)=3.22, p≤0.05, ηG2=0.01). The Post group also made more error than the Peri-ST 
group (F(1,14)=6.20, p≤0.05, ηG2=0.03) across all trials, indicating a benefit of early 
treatment, but did not differ from the Peri-LT group (F(1,17)=1.20, p>0.05, NS, ηG2=0.01), 
indicating that the benefit of early initiation is restricted to short-term treatment (figure 22).  
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Morris Water Maze 
 We did not observe an effect of Wave (F(1,26)= 1.22; p>0.05, NS, ηG2=0.02), nor a 
Wave x Treatment interaction (F(3,26)= 1.42; p>0.05, NS, ηG2=0.04) for MM swim distance, 
therefore analyses were collapsed across wave. There were no differences in swim distance 
on Days 1-3 between the Post and Control groups (F(1,15)=0.36, p>0.05, ηG2=0.01; NS), the 
Post and Peri-LT groups (F(1,17)=2.29, p>0.05, ηG2=0.02; NS), nor the Post and Peri-ST 
groups (F(1,14)=1.21, p>0.05, ηG2=0.03; NS; Figure 23a). For the probe trial, there was a 
main effect of Quadrant (F(1,30)=353.88, p≤0.0001, ηG2=0.90; Figure 23b) in the absence of 
a Quadrant x Treatment interaction (F(3,30)=1.38, p>0.05, ηG2=0.10; NS). All treatment 
groups covered a higher percent distance in the previously platformed vs. the opposite 
quadrant, indicating that all groups spatially localized the platform by the end of testing. 
Delay Match-to-Sample Asymmetrical Three-Choice Task 
 We did not observe an effect of Wave (F(1,26)= 0.47; p>0.05, NS, ηG2<0.01), nor a 
Wave x Treatment interaction (F(3,26)= 2.35; p>0.05, NS, ηG2=0.01) for DMS errors, 
therefore both waves are presented together. There was a Trial x Treatment interaction for 
the Control versus the Post group (F(4, 60)=6.22; p≤0.001, ηG2=0.08; Figure 24a), whereby 
the Post group made fewer errors on Trial 2, the working memory trial (F(1,15)=16.26, 
p≤0.01, ηG2=0.14; Figure 24a), during the learning phase of testing (Days 1-3). There were 
no differences between the Post and Peri-LT groups (F(1,17)=0.66, p>0.05, ηG2=0.01; NS) or 
Post and Peri-ST groups (F(1,14)=0.03, p>0.05, ηG2=0.04; NS) for the learning portion of 
testing (Figure 24a). There were no effects of Treatment for the asymptotic portion of DMS 
testing (Days 4-6; Figure 24b), and there were no effects of Treatment on errors following 
a 6- or 8-hour delay between trials 1 and 2. 
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 We analyzed the number of perseverations into the previously-platformed arm (PPP 
Errors) on Days 2-3 of DMS testing to examine the animals’ ability to switch from win-
stay (return to the same locations) to win-shift (do not return to the same location) behavior 
across days (there is no previously platformed arm on Day 1). On trial 2, the working 
memory trial, the Post group made fewer PPP Errors than the Control group (F(1,15)= 7.09, 
p≤0.05, ηG2=0.14), indicating that the Control group continued to exhibit win-stay behavior 
on days 2 and 3 of DMS testing, while the Post animals were able to adapt to the new task 
rules more quickly. The Post group did not differ from the Peri-LT (F(1,17)= 0.16, p>0.05, 
ηG2=0.01, NS) or Peri-ST (F(1,14)= 2.85, p>0.05, ηG2=0.10, NS) groups on PPP Errors.  
Peripheral Markers of Treatment 
 Animals in the Control group did not cycle through the four phases of the estrous 
cycle, but rather exhibited intermittent elongated estrus and diestrus phases, as expected in 
middle-aged female rats (Mennenga & Bimonte-Nelson, 2015). Animals treated with CEE 
exhibited consistent estrus smears containing primarily cornified cells, with some 
leukocytes, as expected (Acosta et al., 2009a, 2009b). We did not observe an effect of 
Wave, nor a Wave x Treatment interaction, for uterine weights (Wave: F(1,26)= 1.90, 
p>0.05, η2<0.07, NS; Wave x Treatment: F(3,26)= 2.82, p>0.05, NS; η2=0.24), corpora lutea 
(Wave: F(1,26)= 0.001, p>0.05, η2<0.01, NS; Wave x Treatment: F(3,26)= 0.82, p>0.05, NS; 
η2=0.08), or follicles (Wave: F(1,26)= 0.57, p>0.05, η2=0.18, NS; Wave x Treatment: F(3,26)= 
0.43, p>0.05, NS; η2=0.05), therefore analyses were collapsed across wave. There was a 
main effect of Treatment on uterine weights (F(3, 30)=4.44; p≤0.05, η2=0.31; Figure 25a), 
such that the Control group had lower uterine weights than all CEE-treated groups (Post: 
Fisher, p≤0.05; Peri-LT: Fisher p≤0.05; Peri-ST: Fisher, p≤0.01). There was also a main 
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effect of Treatment on corpora lutea counts (F(3, 30)=8.91; p≤0.001, η2=0.47; Figure 25c), 
such that animals in the Peri-ST group had more corpora lutea than the Control (Fisher, 
p≤0.01), Post (Fisher, p≤0.001), and Peri-LT (Fisher, p≤0.0001) animals, indicating that 
animals in this group have recently ovulated (Haas et al., 2007), as expected, since this 
group had not completed follicular depletion at the time of sacrifice. There were no effects 
of Treatment on number of follicles in the ovaries (F(3, 30)=1.59; p>0.05, η2=0.14, NS; 
Figure 25b), and all treatment groups had fewer than 30 follicles remaining in their ovaries 
on average, indicating that the VCD treatment effectively depleted follicles in each 
treatment group. 
Hormone Assays 
  We did not observe an effect of Wave (F(1,25)= 0.14; p>0.05, NS, η2<0.01), nor a 
Wave x Treatment interaction (F(3,25)= 0.39; p>0.05, NS, η2=0.05) for DMS errors, 
therefore analyses were collapsed across wave. There were no group differences in serum 
levels of androstenedione (F(3,29)=0.13; p>0.05, η2=0.02 NS; Figure 26). In all treatment 
groups, androstenedione levels positively correlated with total WRAM errors on Trials 1-4 
across all days of testing (r=0.51, p≤0.05; figure 27), as well as on Trial 4 alone, the trial 
with the highest working memory load, (r=0.58, p≤0.01; figure 27), a replication of 
previous findings from our lab (Acosta et al., 2009, 2010; Camp et al., 2012).  
Discussion 
 Here I evaluated whether the timing of treatment initiation relative to follicular 
depletion, or duration of treatment, alters the cognitive impact of CEE HT in the VCD rat 
model of transitional menopause. I replicated previous findings (Acosta et al., 2010), that 
CEE HT initiated after follicular depletion impairs spatial working memory. Relative to 
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vehicle treatment, CEE administered after follicular depletion produced impairments 
during the lattermost phase of WRAM testing, did not affect performance on the MM, and 
improved behavioral flexibility, allowing animals to more quickly adjust to the rules of 
DMS asymmetrical 3-choice task. Short-term CEE administration initiated at the beginning 
of follicular depletion improved performance relative to short-term CEE administration 
initiated after follicular depletion on the lattermost portion of WRAM testing (Peri ST 
versus Post groups). Short-term CEE administration initiated at the beginning of follicular 
depletion (Peri ST group) did not impact performance on the MM or the DMS 
asymmetrical 3-choice task, relative to CEE given after follicular depletion had ensued 
(Post group). CEE is known to confer several health benefits apart from its potential 
cognitive impact; therefore, while CEE does not appear to offer benefits for learning and 
memory outside of very specific treatment parameters, finding a delivery method that is 
cognitively neutral is nonetheless clinically promising. Our results indicate that current 
recommendations for HT during menopause, which include individualized decision-
making, early initiation, and the shortest possible duration of treatment (NAMS, 2012), are 
optimal for CEE’s cognitive impact.  
 A benefit of post-depletion CEE treatment did emerge; animals in the Post group 
made fewer errors than the control animals and the Peri ST group on the first three days of 
the DMS asymmetrical 3-choice task, as measured by Total Errors. Thus, the Post animals 
appear to be outperforming the Control group, so long as we operationally define 
performance as making the fewest number of Total Errors. However, if we pause to 
consider that this was the third maze in a cognitive battery, and it followed a fully win-stay 
version of the MM, we may wish to revise our operational definition of ‘good’ performance 
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on this new task; at least for the first few exposures, in which animals are not yet aware of 
the change in task rules. In fact, one may actually consider better performance on the 
second day of DMS testing, following MM learning, to be returning to the previously 
rewarded platform location. Prior to the MM, animals learned the WRAM, which also 
involved a win-stay across days rule; even though animals must not return to platforms 
within a day, the task starts with the same subset of baited arms at the beginning of each 
day. Additionally, the win-stay-within-a-day feature of the DMS task likely acts to further 
reinforce the behavior of returning to the previously rewarded location during the initial 
exposures to the task. Indeed, when we carefully examined the animals’ performance 
during the first exposures to this task, we made an interesting discovery: the control 
animals made more errors into the arm of the maze that had contained the platform on the 
previous day. 
 The behavioral assessments utilized in this study bring to light the complexity that 
exists when measuring constructs in non-verbal animals. As behaviorists, we are forced to 
rely on operational definitions that we can be reluctant to deviate from for various reasons 
including consistency, replication and ease of interpretation. Because evaluation depends 
on the task at hand, these operational definitions are typically tied to particular tasks that 
are used to evaluate specific domains of learning and memory. However, consideration 
must be given to the greater structure into which each of these individual tasks is 
implemented. When utilizing multiple tasks in sequence, the way that performance should 
be defined may be different on the first exposure, depending on what set of rules the 
animals have previously learned and consistently been rewarded for following. It may 
seem, at first consideration, that three days of failure to update to this new rule is a 
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substantial amount of time. However, because the DMS platform location is constant 
across six trials within each day, it is not until the first trial of the second day of testing that 
the animals experience the first event contrary to the win-stay rule previously learned. 
Then, it is not until the first trial of the third day of testing that the second reinforcement 
opportunity for this new rule is presented. When viewed in this context, it seems reasonable 
for an animal to return to the previously rewarded location on each of these instances. 
Thus, we can conclude that the Control animals exhibited a deficit in adapting to the 
demands of a different spatial learning task, relative to Post animals. However, we do not 
believe that this is a deficit in spatial memory, as the Control animals exhibited more 
entries into the arm that they were rewarded for entering repeatedly on the previous day. 
Rather, this behavior is indicative of an intact spatial memory coupled with difficulty 
updating to the rules of a new task. Whether this effect is beneficial or detrimental depends 
on the situation and the way that a ‘good’ outcome is defined. If we are concerned with an 
organism’s ability to quickly adjust to new situations with changing demands, then Post 
treatment appears to produce a benefit relative to the Control group. Likewise, if we are 
concerned with an organism’s ability to recall a previously rewarded spatial location, the 
Post group no longer outperforms the Control group.  
 As the Peri-ST group had a delayed onset of VCD treatment, their VCD-induced 
ovarian depletion was not complete at the onset of testing or at sacrifice. While all other 
groups had completed their depletion process by the beginning of behavioral testing (107±1 
days after the first VCD injection), animals in the Peri-ST group began behavioral testing 
43±1 days after their first VCD injection, and were sacrificed 72±1 days after their first 
VCD injection, inside of the 90 days that VCD treatment requires to fully deplete ovarian 
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follicles. It is likely that the Peri-ST group continued ovulating intermittently throughout 
testing. Although I did not include a non-VCD control group, all groups exhibited very low 
follicle counts, relative to what would be expected in a normally cycling animal (Mayer et 
al., 2002). Elevated follicle and corpora lutea counts observed in the Peri-ST group lend 
further support to the likelihood that follicular depletion in this group was underway, but 
not complete. 
 Of interest, the only indication of a cognitive benefit of CEE HT was seen in the 
group of animals that was midway through the follicular depletion process. Moreover, the 
cognitive protection seen with CEE HT administered early during follicular depletion is not 
seen when the treatment is continued long-term. This is in line with recent findings from 
the Study of Women’s Health Across the Nation (SWAN), indicating that the cognitive 
impairments seen with menopause, and the cognitive benefits of estrogen-containing HT, 
are limited to the menopausal transition. In fact, post-menopausal HT use impairs 
cognition, even when HT was initiated before the final menstrual period (Greendale et al., 
2010). Further, the cognitive impairments seen during late perimenopause do not appear to 
be due to depressive, anxiety, sleep, or vasomotor symptoms (Greendale et al., 2009), 
implicating a direct effect of perimenopause on learning and memory. The effect sizes of 
the behavioral differences we report here are small, indicating that group membership 
explains only a small proportion of variability on these tasks; many other, as of yet 
undefined, factors are likely to contribute to the cognitive effects of CEE-containing HT 
during and after menopause. Animal models provide a promising avenue for the 
exploration of these questions, as they allow systematic manipulation of menopause 
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variants independently of aging, permitting experimental control not possible in human 
research.  
 Several studies offer insight into the putative mechanisms by which the transition to 
menopause impacts cognition. Degradation of functionality in the septo-hippocampal 
cholinergic system has been previously proposed as an underlying cause of the window of 
opportunity for HT following Ovx (Gibbs 2000; Gibbs, 2002; Gibbs 2010). Emerging work 
also indicates a widespread deregulation of brain metabolic function associated with loss of 
estrogen stimulation that likely underlies the cognitive impact of menopause and 
subsequent HT (Yin et al., 2015; Brinton et al., 2015). Our findings indicate that similar 
mechanisms likely exist in the VCD model of natural menopause, creating a window of 
opportunity for cognitively safe HT administration. We have previously reported that 
elevated circulating levels of androstenedione are associated with poorer memory (Acosta 
et al., 2009, 2010, Camp et al., 2012), and that exogenous androstenedione impairs memory 
(Camp et al., 2012), an effect that is blocked by preventing its conversion to E1 (Mennenga 
et al., 2015). Further, we have shown that exogenous E1 administration produces cognitive 
impairments (Engler-Chiurazzi et al., 2011), and higher circulating levels of E1 are related 
to poorer memory (Mennenga et al., 2015). These reports, coupled with the current results, 
lead us to propose that elevated levels of ovarian-produced androstenedione-derived E1, 
relative to other estrogens, serve to exacerbate the cognitive effects of hormone loss with 
menopause.  
 Collectively, these results suggest that there is a limited window of opportunity 
around the onset of natural menopause, during which benefits can be seen with CEE 
treatment, and outside of which cognitive detriments are seen with CEE administration, 
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even if initiation is early. Additionally, I conclude that the ovaries remain active following 
follicular depletion, and androstenedione-derived E1 from these follicle-deplete ovaries 
negatively impacts spatial memory. Accumulating research evaluating multiple systems 
collectively indicates that CEE is not the optimal solution to alleviate the hormonal 
imbalance brought on by menopause, likely due to its high E1S content. It is possible that 
an alternative estrogen, such as E2, may act to help restore the hormonal balance that 
changes with menopause, providing cognitive benefit where CEE produces impairments. 
These findings draw attention to the need for investigation into the cognitive effects of the 
transition to menopause, as well as of alternative HTs.  
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CHAPTER 7: OPTIMIZING HORMONE THERAPY ACROSS THE MENOPAUSE 
TRANSITION II: BIOIDENTICAL ESTROGEN 
Introduction 
 Around the fifth decade of life, women will experience menstrual irregularity and 
eventual cessation of the menses known as menopause (NAMS; Curtis et al., 2005; 
Hoffman et al., 2012). With menopause comes a halting of ovulation, and thus a drastic 
decline in ovarian production of the hormones estrogen and progesterone. Loss of these 
hormones results in several undesirable health consequences, including hot flashes, bone 
density loss, cardiovascular changes, atrophy of vaginal tissue, and cognitive decline 
(Curtis et al., 2005; Hoffman et al., 2012). Although advances in health and medicine have 
resulted in an increasing average life expectancy, menopause onset has remained stable and 
typically begins in a woman’s 40’s. This means that women are living increasingly larger 
proportions of their lives (up to 40% of the expected lifespan in the United States) in a 
hypo-estrogenic menopausal state (NAMS; ACOG Women’s Health 2011). Many women 
choose to utilize estrogen-containing hormone therapy (HT), to alleviate the health 
consequences of menopause. Conjugated Equine Estrogens (CEE) have been prescribed to 
menopausal women as HT since 1942, and CEE became the most commonly prescribed 
HT in the US in the early 2000’s; approximately fourteen million women in the US were 
estimated to use CEE at this time (Hersh et al., 2004; Stefanick, 2005). CEE contains 
minute amounts of 17β- estradiol (E2), the most potent naturally circulating estrogen in 
women and rats, and is over 50% estrone sulfate (E1s; Gleason et al., 2005), which is 
converted to estrone (E1), another estrogen, by the liver. 
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 CEE HT is effective at alleviating many of the non-cognitive symptoms of 
menopause in women; however, whether CEE prevents the cognitive decline associated 
with menopause remains uncertain. Several studies have examined the impact of CEE on 
health and cognition, including the large Women’s Health Initiative (WHI). However, in 
2002, the WHI announced that the estrogen plus progestin vs placebo trial would be halted 
due to an increased risk of breast cancer and cardiovascular disease associated with 
estrogen plus progestin treatment (Writing Group for the Women's Health Initiative 
Investigators, 2002). Two years later, the WHI memory study (WHIMS), an ancillary study 
to the WHI, reported that in menopausal women, CEE alone did not affect risk of 
developing mild cognitive impairment (MCI), and non-significantly increased the risk of 
probable dementia, while CEE plus progestin treatment did not impact MCI risk and 
increased the risk of probable dementia in (Espeland et al., 2004; Shumaker et al., 2004). 
Following the publication and heavy media coverage of the WHI and WHIMS results, 
many women halted their HT regimens altogether. In fact, according to the American 
Congress of Obstetricians and Gynecologists (ACOG), roughly 65% of women using HT 
stopped in response to the 2002 WHI study results. This negative public reaction led to just 
over 76 million HT prescriptions being dispensed in 2003, compared to almost 129 million 
prescriptions dispensed three years earlier, in 2000 (ACOG Women’s Health, 2011). 
However, by 2004, the year the WHIMS study results were released, the ACOG reports 
that one in four of the women who previously discontinued HT re-initiated it (ACOG 
Women’s Health, 2011). Since then, a demand for alternative, safer HTs has led to a huge 
shift in prescription rates. A 2015 report from the Endocrine Society states that almost half 
of the prescriptions filled for HT are now custom-compounded bioidentical hormones 
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(Endocrine Society, 2015). Bioidentical hormones have the exact same chemical and 
molecular structure as hormones found naturally circulating in the human body prior to 
menopause; these hormones have gained popularity and have also created a great deal of 
confusion among the general public about HT options (Sood et al., 2011). 
 Our lab has previously investigated the cognitive impact of both CEE and so-called 
‘bioidentical’ E2 HT following surgical removal of the ovaries (ovariectomy; Ovx). We 
have previously shown that CEE HT benefits spatial working memory, a form of short term 
memory for information that is updated, and spatial reference memory, a form of long term 
memory for information that stays constant, and protects against scopolamine-induced 
amnesia (Acosta et al., 2009a). Our and others’ laboratories have shown that E2 HT 
following Ovx can also benefit performance in multiple cognitive domains, including 
spatial working memory (Daniel et al., 1997; Fader et al., 1999; Bimonte & Denenberg, 
1999; Bohacek & Daniel, 2007; Gibbs and Johnson, 2008; Rodgers et al., 2010), and 
spatial reference memory (Bimonte and Denenberg 1999; Gibbs, 2000; Bimonte-Nelson et 
al., 2006; Talboom et al., 2008).  
 Notably, the aging female rat experiences reproductive senescence known as 
estropause, which includes several hormonal states indicative of irregular ovulation, and 
differs from human menopause. Estropause involves either a persistent estrus state, or a 
persistent diestrus state, with hormone profiles dissimilar to those of naturally menopausal 
women (Lu, 1979). Although the aging rat does not experience menopause, both rodent 
estropause and human menopause appear to result from simultaneous changes in pituitary 
gonadotropin release and changes in ovarian function (Wise, 1999; Wise et al., 1999), 
rendering the rodent a reliable model of the human reproductive system and, to some 
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extent, of human reproductive aging. Nonetheless, estropause does not produce hormone 
profiles similar to those seen in natural human menopause. The Ovx model is a valuable 
model that affords the opportunity to isolate effects of individual ovarian hormones, and it 
is an appropriate model for the many hundreds of thousands of women who undergo 
surgically induced menopause (ACOG, 2008; Rocca et al., 2009). However, it has limited 
generalizability to the population of women who have undergone natural, transitional 
menopause. Treatment with the industrial chemical 4-vinylcyclohexene diepoxide (VCD) 
can be used as a rodent model of transitional human menopause. Treatment with VCD 
accelerates the natural process of atresia in the finite primary and primordial follicle pools, 
producing a gradual loss of follicles (Flaws et al., 1994; Springer et al., 1996; Springer, 
McAsey, et al., 1996; Springer, Tilly, et al., 1996; Borman, et al., 1999; Kao et al., 1999; 
Hu, et al., 2001; Hu et al., 2002; Mayer, et al., 2002; Mayer et al., 2004; Mayer et al., 
2005), leading to halting of ovulation and a drastic decrease in ovarian production of 
estrogens and progesterone (Springer et al., 1996: Mayer, et al., 2004; Mayer et al., 2005), 
creating a rodent with a hormone profile more similar to that of a naturally menopausal 
woman than following estropause or Ovx.  
 Using this VCD model, our lab has demonstrated that transitional hormone loss 
impairs spatial working memory if the follicle-deplete ovaries are retained, but improves 
spatial working memory if the residual ovary is removed following follicular depletion, 
indicating that the follicle-deplete ovary itself is negatively impacting cognition (Acosta et 
al., 2009). Acosta et al., 2010 reported another important distinction, whereby CEE 
improves cognition following surgical menopause, but impairs cognition following VCD-
induced menopause, showing that follicle-deplete ovaries alter the cognitive impact of HT. 
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As a whole, these studies imply that the ovaries remain active following follicular 
depletion, and the hormones produced by these follicle-deplete ovaries may be responsible 
for memory impairments associated with menopause. This series of results led us to 
investigate the cognitive impact of the androgen androstenedione. Androstenedione is the 
primary hormone produced by follicle-deplete ovaries, and it can be converted to E1 via the 
aromatase enzyme. In several studies, we have reported that high serum levels of 
androstenedione are associated with worse performance on the WRAM (Acosta et al., 
2009b; 2010; Camp et al. 2012), and we have also shown that exogenous administration of 
androstenedione to Ovx rats impairs spatial memory (Camp et al., 2012). Our lab also 
demonstrated that exogenous delivery of E1, a metabolite of androstenedione, to Ovx 
animals produces memory impairment (Engler-Chiurazzi et al., 2012), and that a 
pharmacological blockade of androstenedione’s conversion to E1 prevents its negative 
cognitive impact (Mennenga et al., 2015). Collectively, these data suggest that 
androstenedione, the primary hormone released following ovarian follicular depletion, 
impairs memory in the VCD model of menopause through its conversion to E1.  
 These experiments led to the development of the hypothesis that high levels of 
ovarian androstenedione-derived E1 relative to E2 are responsible for impaired memory 
following follicular depletion. Given this assumption, administration of CEE, composed 
primarily of E1 sulfate, is unlikely to benefit cognition following follicular depletion. I now 
suspect that bioidentical E2 may be capable of producing a more favorable cognitive 
outcome than CEE following ovarian follicular depletion. I predicted that E2 will benefit 
cognition in follicle-delete rats by bringing hormone ratios closer to those found prior to 
menopause. The current experiment was conducted to determine how E2 administration to 
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VCD-treated follicle-deplete rats would impact cognition. I also wished to compare E2 
treatment to Ovx, which is the only treatment that has thus far been shown to improve 
memory following VCD-induced follicular depletion in rodents (Acosta et al., 2009b).  
Materials and Methods 
Subjects 
 Subjects were 33 eight month-old Fischer-344 female rats raised at the aging colony 
of the National Institute on Aging at Harlan Laboratories (Indianapolis, IN) were used. 
After arrival, rats were pair-housed, had food and water ad-lib, and a 12-h light/dark cycle. 
Animals were 11 months old at the initiation of behavioral testing. All procedures were 
approved by the local Institutional Animal Care and Use Committee (IACUC) and adhered 
to National Institutes of Health (NIH) standards. Animals were randomly assigned to one 
of three treatments groups, as follows (n per group): VCD (11), VCD-E2 (11), VCD-Ovx 
(11). 
VCD, Ovx, and E2 Treatments 
 One week after arrival, animals received VCD treatment (160 mg/kg diluted in 50% 
DMSO/Saline at a volume of 2.5µl/g body weight; IP; Sigma-Aldrich, St. Louis, MO) 
exactly as reported previously (Acosta et al., 2009b, 2010). Seventy-four days into the 
follicular depletion process, Ovx or sham surgeries were conducted. Rats were anesthetized 
via isoflurane inhalation, received bilateral dorsolateral incisions in the skin and 
peritoneum, and ovaries and tips of the uterine horn were ligatured and removed. Muscle 
and skin were then sutured closed. During surgery, rats received an injection of RimadylTM 
(5 mg/ml/kg) for pain, and saline (2 ml) to prevent dehydration. Sham surgeries consisted 
of skin and muscle incisions and sutures only. Ninety days after VCD treatment began, 
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animals underwent a second surgery to have a subcutaneous osmotic Alzet pump placed 
into the scruff of their neck. The Alzet 2006 model was used, which held a total of 200µl of 
solution, released for 6 weeks, at a rate of 0.15µl per hour. Rats were anesthetized via 
isoflurane inhalation, a small incision was made, and a subcutaneous pocket was created in 
the dorsal scruff of the neck. A pump filled with vehicle (polyethylyene glycol) or E2 
(3µg/day, released at a steady rate across time) dissolved in polyethylyene glycol was 
inserted below the skin, and the skin was closed with surgical staples.  
 One hundred seven days after the beginning of VCD treatment, water radial arm 
maze testing began, followed by Morris water maze testing. These animals were a subset of 
a larger group of animals, which also received an additional treatment; therefore, they also 
received daily subcutaneous injections of 0.5ml PEG, starting on the day of E2 or vehicle 
pump insertion and continuing to sacrifice. Figure 28 shows the treatment groups and a 
timeline for the study. 
Water Radial Arm Maze 
 Water radial arm maze (WRAM) procedures were identical to those in chapter 4, 
except that on the 13th day of testing, a 8-hour delay was given between trials 2 and 3 to 
test delayed memory retention.  
Morris Water Maze 
 Morris water maze (MM) procedures were identical to those in chapter 5. 
Visible Platform Task 
 Visible platform procedures were identical to those in chapter 4. 
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Peripheral Markers of Treatment 
 At sacrifice, uteri of all subjects were removed and trimmed of visible fat, ovaries 
were removed for histological processing, and wet uterine weight (grams) was measured, 
exactly as reported elsewhere (Westerlind et al., 1998; Engler-Chiurazzi et al., 2012; 
Acosta et al., 2009, 2010). Ovaries were removed, trimmed of fat, and preserved in 10% 
formalin. Sections were then processed for paraffin embedding and sectioned at 5µm, then 
stained using hematoxylin and eosin. Corpora lutea and follicle populations were counted.  
Hormone Assays 
  Serum was collected at sacrifice via cardiocentesis and processed for levels of 
androstenedione and Progesterone. An iodinated radioimmunoassay (RIA) was used by the 
CORE Endocrine Laboratory at Pennsylvania State University, exactly as reported 
elsewhere (Acosta et al., 2009, 2010) to determine serum hormone levels. 
Statistical Analyses 
 Orthogonal planned comparisons were set a priori; we compared the group that 
underwent follicular depletion followed by sham surgery and vehicle treatment (VCD 
group) to the E2-treated animals (VCD-E2 group) and the Ovx animals (VCD-Ovx group). 
We predicted that the VCD-Ovx group would outperform the VCD group on the WRAM; 
this would be a replication of our prior findings using the VCD model (Acosta et al., 
2009b). We predicted that E2 treatment would also improve performance on the WRAM 
task, however the cognitive impact of E2 has never been investigated following VCD 
treatment. Thus, alpha level was set at 0.05 (1-tail) for VCD vs VCD-Ovx comparisons, 
and alpha level for comparisons of VCD versus VCD-E2 was set at 0.05 (2-tail).  
 101 
 WRAM errors were divided into 3 testing blocks of 4 days each, except the first 
testing block, which only included three days because we excluded the first day of maze 
testing (Block 1: Days 2-4, Block 2: Days 5-8, Block 3: Days 9-12). Data were analyzed 
with repeated measures ANOVA. Treatment was used as the between-groups variable and 
number of errors on each trial was the dependent variable.  
 MM data were also analyzed with repeated measures ANOVA. Again, treatment 
served as the between-groups variable, however distance to the platform was the dependent 
variable for MM analyses. Probe trial data were analyzed with repeated measures ANOVA 
with quadrant (Northeast vs. Southwest) as the between-groups variable and percent swim 
distance as the dependent variable. MM probe analysis was necessary to determine whether 
any of the treatments impacted animals’ use of a spatial navigation strategy.  
 Wet uterine weights, serum hormone levels, ovarian follicles, and corpora lutea 
were each analyzed using one-way ANOVA with Treatment as the between-groups 
variable in each analysis and wet uterine weights (g), circulating hormone levels, estimated 
number of follicles, and number of corpora lutea as the respective dependent variables for 
each analysis. Fisher’s post-hoc tests were used following significant omnibus tests. ). 
 Generalized eta squared (ηG2) is reported for mixed designs that utilize both 
between- and within- subjects variables (WRAM, MM, DMS behavior data), and eta 
squared (η2) is reported for analyses that include only a single between-subjects 
independent variable (Wet uterine weights, serum hormone levels, ovarian follicles, and 
corpora lutea), to allow comparability of effect sizes across variables (Olejnik & Algina, 
2003; Bakeman, 2005). Effect sizes are interpreted by Cohen’s guidelines for η2 
(0.02=small, 0.13=medium, 0.26=large; Cohen, 1988; Bakeman, 2005). 
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Results 
Water Radial Arm Maze 
 On the first block of WRAM testing, days 2-4, there was a Trial x Treatment 
interaction for the VCD and VCD-Ovx groups (F(3,60)= 2.52, p<0.05; ηG2=0.04; figure 29), 
such that on trial 4, the trial with the highest working memory load, the VCD animals made 
more errors than the Ovx animals (F(1,20)= 2.96, p<0.05; ηG2=0.06; figure 29). There was 
also a marginal Trial x Treatment interaction for the VCD and VCD-E2 groups (F(3,60)= 
2.48, p<0.10; ηG2=0.04; figure 29), such that on trial 4, the trial with the highest working 
memory load, the VCD animals made marginally more errors than the VCD-E2 animals 
(F(1,20)= 2.94, p<0.10; ηG2=0.06; figure 29). On the second testing block, days 5-8, there 
was a Trial x Treatment interaction for the VCD and VCD-E2 groups (F(3,60)= 3.70, p<0.05; 
ηG2<0.01; figure 29). On Trial 4, the trial with the highest working memory load, E2 
treatment enhanced performance; the E2 animals made fewer errors than the VCD group 
(F(1,20)= 4.68, p<0.05; ηG2=0.04; figure 29). There were no effects of Treatment on Days 9-
12 of testing (figure 29).  
Morris Water Maze 
 There were no effects of Treatment on MM performance for the VCD versus Ovx 
(F(1,20)= 0.86, p=0.37, NS; ηG2=0.01) or for the VCD versus E2 (F(1,20)= 0.46, p=0.51, NS; 
ηG2=0.01) groups. On the probe trial, there was a main effect of Quadrant (F(1,30)= 150.65, 
p<0.0001; ηG2=0.80), with no effect of Treatment (F(2,30)= 0.68, p= 0.52; ηG2=0.01; NS), or 
Quadrant x Treatment interaction (F(2,30)= 0.67, p= 0.52; ηG2=0.03; NS).  
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Peripheral Markers of Treatment 
 There were no differences in total number of follicles present in the ovaries of the 
E2 and Vehicle groups at sacrifice (F(1,20)= 0.93, p= 0.35; η2=0.04; NS; figure 30), or the 
number of corpora lutea (F(1,20)= 0.46, p= 0.51; η2=0.02; NS; figure 30). There was a main 
effect of Treatment on wet uterine weights (F(2,30)= 14.93, p<0.0001; η2=0.50; figure 30), 
with E2-treated animals having heavier uterine horns than vehicle-treated or Ovx animals 
(Fisher, p<0.0001). There was no difference between the Vehicle and Ovx groups in 
uterine weight, indicating a lack of uterine stimulation in the Vehicle-treated VCD animals.  
Serum Hormone Levels 
 There was a main effect of treatment on serum E2 levels (F(2,30)= 17.85, p<0.0001; 
η2=0.54; figure 31), with the E2-treated group showing higher circulating levels of E2 than 
both the Ovx and Vehicle groups (Fisher, p<0.0001). There was no difference in serum E2 
levels between the Ovx and Vehicle groups at sacrifice (Fisher, p=0.76; NS; Vehicle 
M=5.42pg/ml, Ovx M=1.45pg/ml), suggesting there is a negligible amount of ovarian-
derived circulating E2 in animals treated with the VCD regimen utilized here.  
 There was also a main effect of treatment on serum E1 levels (F(2,27)= 21.55, 
p<0.0001; η2=0.62; figure 31), with the E2-treated group showing higher circulating levels 
of E1 than both the Ovx and Vehicle groups (Fisher, p<0.0001). There was no difference in 
serum E1 levels between the Ovx and Vehicle groups (Fisher, p=0.64, NS; Vehicle 
M=39.42pg/ml, Ovx M=36.76pg/ml), again suggesting a very minor amount of ovarian-
derived estrogen in our Vehicle group following VCD-induced follicular depletion. 
 Finally, there was a main effect of treatment on serum androstenedione levels 
(F(2,27)= 8.86, p<0.01; η2=0.40; figure 31), with the E2-treated group and the Ovx group 
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showing lower circulating levels of androstenedione than the Vehicle group (Fisher, 
p<0.01). There was no difference in serum androstenedione between the Ovx and E2 
groups (Fisher= 0.22, NS; Ovx M= 0.09ng/ml, E2 M=0.21ng/ml), indicating that treatment 
with E2 reduces circulating androstenedione levels to the same extent as surgical removal 
of the follicle-deplete ovaries. 
Discussion  
 Through a series of studies, I have investigated how various HT parameters, 
including timing of administration, length of exposure, and type of estrogen, modify the 
cognitive effects of HT following VCD-induced follicular depletion in rodents. Our lab has 
shown previously that CEE treatment initiated post-depletion produces memory detriments 
(Acosta et al., 2010), and that surgical removal of follicle-deplete ovaries produces a 
cognitive benefit (Acosta et al., 2009b). I now demonstrate that bioidentical E2 has a 
favorable impact on cognition following follicular depletion, possibly because of E2’s 
ability to correct the hormonal imbalances created by disruption of ovulation. In the current 
study, E2 treatment produced marginal benefits on the earliest block of WRAM testing, and 
improved performance on the second testing block of WRAM. Benefits of E2 on radial arm 
maze performance have been previously reported numerous times in Ovx animals (Daniel 
et al., 1997; Fader et al., 1999; Bimonte & Denenberg, 1999; Bohacek & Daniel, 2007; 
Gibbs and Johnson, 2008; Rodgers et al., 2010), but the cognitive impact of E2 had 
previously never been investigated following VCD-induced follicular depletion. E2 is now 
the fist clinically-utilized HT to be shown to improve cognition in the VCD rodent model 
of menopause.  
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 Ovx during follicular depletion also improved performance on the initial learning 
phase of WRAM testing. Acosta et al. (2009b) reported a benefit of Ovx treatment 
following a 4-hour delay between trials 2 and 3 of the WRAM in 14 month-old VCD-
treated rats. Acosta et al., 2010 utilized slightly younger rats that were 11 months old at the 
initiation of maze testing, and did not find differences between vehicle- and CEE-treated 
groups following a 4-hour delay. In the present study, animals were 11 months old at the 
initiation of maze testing, identical to the age in Acosta et al., 2010, which prompted us to 
instill a more challenging, 8-hour delay at the end of WRAM testing. Our groups did not 
differ in performance following the delay, and all groups performed very well in spite of 
the challenge, making fewer than 3 total errors on average across the post-delay trials. The 
younger age of these animals likely produced a steeper learning curve than what a 14-
month-old rodent would exhibit, resulting in Ovx benefits manifesting earlier during 
WRAM testing than what was observed in Acosta et al., 2009b.  
 Serum hormone levels of E1, E2 and androstenedione were measured to gain 
insight into the potential mechanism by which each of these treatments may be impacting 
brain function. Here, E2 treatment increased circulating E1 and E2, and decreased 
circulating androstenedione levels, compared to vehicle treatment. These effects were large 
and, together, amount to a substantial multi-hormone shift towards a hormone profile 
similar to pre-follicular-depletion (increased E1 and E2, decreased androstenedione), 
possibly resulting in the observed cognitive benefit of E2 treatment. Ovx during follicular 
depletion resulted in decreased androstenedione levels, but did not alter E1 or E2 levels 
relative to sham surgery with vehicle treatment. Interestingly, this set of hormonal changes 
represents only a partial shift towards the pre-follicular-depletion hormone profile, slightly 
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less than what is produced by E2 treatment. This partial shift is in line with the less robust 
cognitive benefits observed with Ovx, relative to E2. Exactly how these hormone levels 
impact brain function and spatial memory remains to be determined. Recent work indicates 
loss of estrogen signaling as a trigger for extensive metabolic dysfunction in brain cells 
(Yin et al., 2015; Brinton et al., 2015); this metabolic deregulation is a potential 
downstream result of ovarian follicular depletion that would likely be offset by exogenous 
E2 treatment. 
 Importantly, the timing of the E2 administration regimen here, where we show that 
post-depletion administration of E2 improves memory, was identical to that of the CEE 
administration in Acosta et al. (2010), where we showed that post-depletion administration 
of CEE impairs memory in the VCD model of menopause. It remains to be determined 
whether the same cognitive benefits would be seen with E2 administered during follicular 
depletion. Of note, the E2 administration regimen utilized here, as well in as clinical E2-
containing HTs, is insufficient to prevent pregnancy. Gynecologists now recommend that 
sexually active women utilize some form of contraception during perimenopause, due to 
the risks that unintended pregnancies during this time pose to the mother and fetus (Ikhena 
and Johnson, 2012). Notably, the hormones utilized in contraceptive formulations are 
different than those marketed as HTs. Ethinyl estradiol (EE), a synthetic form of natural 
E2, is the primary estrogen utilized in contraceptive formulations (Curtis et al., 2004; 
Hoffman et al., 2012). Many women choose to take EE-containing contraceptives over E2-
containing HT in order to prevent unintended pregnancy during the transition to 
menopause. Future studies investigating the cognitive and whole-body impact of each of 
these estrogens during perimenopause are necessary.  
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 The results presented here lend support to the hypothesis that androstenedione-
derived E1 produces cognitive impairments in follicle-deplete rodents. It follows that, 
although both E1 and E2 are bioidentical hormones, administration of E1-containing 
compounds is unlikely to benefit cognition following follicular depletion, whereas 
administration of E2 should provide cognitive protection. The findings reported here have 
considerable clinical implications; beginning with the broad message that HT will likely 
produce optimal benefits with minimal risks only if it is tailored to each woman’s personal 
hormonal makeup. Further, as a woman’s hormone profile changes across time, different 
HT regimens may offer cognitive benefit or detriment. A recent publication from the Study 
of Women’s Health Across the Nation (SWAN) identifies four distinct clusters of E2 
change patterns across the menopausal transition, as well as 3 distinct patterns of follicle-
stimulating hormone change (Tepper et al., 2012). Understanding and predicting these 
hormone change trajectories at an individualized level may prove to be crucial for 
optimization of HT during the menopausal transition. Further individualization along with 
modeling of the natural hormone cycle will likely result in a more comprehensive HT that 
confers even greater cognitive and general health benefits.  
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CHAPTER 8: PHARMACOLOGICAL BLOCKADE OF THE AROMATASE 
ENZYME, BUT NOT THE ANDROGEN RECEPTOR, REVERSES 
ANDROSTENEDIONE-INDUCED COGNITIVE IMPAIRMENTS IN YOUNG 
SURGICALLY MENOPAUSAL RATS 
Introduction 
 By the year 2050, the population over the age of 65 in the U.S. is projected to reach 
88.5 million people, more than double what it was in the year 2010, and more than half of 
the population will be female (US Census, 2010). Around the fifth decade of life, most 
females experience menopause, whereby eggs stop maturing, and eventually ovulation and 
menstruation cease. With this reproductive senescence, there is a drastic loss of ovarian-
derived estrogen and progesterone, and the androgen androstenedione becomes the 
principal hormone released by the ovaries (Timaras et al., 1995). This androgen-rich 
hormone milieu is also seen in a rodent model of natural menopause via treatment with 4-
vinylcyclohexene diepoxide (VCD), an industrial chemical that induces gradual depletion 
of primary and primordial follicles in the female rat (Mayer at al., 2002, 2004; Acosta et 
al., 2009b, 2010).  
 Accumulating evidence in the female rat suggests that androstenedione has a 
negative impact on cognition. Our laboratory previously demonstrated that VCD-induced, 
transitional menopause in middle-aged, female rats elicits inferior cognitive performance 
across multiple domains, compared to rats that had undergone surgical menopause via 
ovariectomy (Ovx). Of note, this finding is not apparent in animals that have undergone 
Ovx following their VCD treatment; such that the follicle-deplete ovaries were removed 
after follicular depletion had ensued (Acosta et al., 2009b). An unexpected finding from 
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this study was that higher serum levels of androstenedione, which is released from the 
follicle-deplete menopausal ovary (Timaras et al., 1995), correlated with poorer memory 
scores in follicle-deplete, VCD treated rats (Acosta et al., 2009b). In a follow-up study, we 
again found that higher androstenedione levels correlated with impaired performance in 
transitionally menopausal rats demonstrating an androgen-rich serum profile (Acosta et al., 
2010). This correlation was evident for multiple types of errors representing several 
domains of memory, including reference memory, a form of long-term memory that 
remains constant across all days and trials, as well as two orthogonal measures of working 
memory, a form of short-term memory that requires updating of information (Acosta et al., 
2010). If androstenedione is truly related to poorer memory, impairments should be 
revealed after administration of androstenedione to a “blank” ovarian hormone template. 
To test this hypothesis, I performed a study in which middle-aged (14 month old) Ovx rats 
were administered either vehicle or one of two doses of androstenedione, and then tested 
with a battery of mazes that assess learning and memory. Relative to vehicle treatment, 
androstenedione administration impaired spatial reference memory on the Morris water 
maze, was detrimental to performance on the water radial-arm maze (WRAM) when the 
working memory load was most demanding, and impaired memory retention on a win-stay 
delay match to sample (DMS) task (Camp et al., 2012). Thus, in several different studies 
we have shown that androstenedione, released from the follicle-deplete ovary in both 
women and rats, markedly impairs memory. 
 Understanding the effects of androstenedione on the brain and its function is 
critically important to understanding the cognitive impact of natural menopause; ovarian-
derived androstenedione is present in menopausal women who maintain their ovaries, an 
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effect observed for at least ten years after menopause ensues (Fogle et al., 2007). Drugs 
that block the activity of the aromatase enzyme (Santen et al., 2009), which catalyzes the 
conversion of androstenedione to the estrogen estrone, are some of the tools used to treat 
metastatic breast cancer prevalent in menopausal women (Glück et al., 2013), as well as 
manage estrogen-dependent endometrial carcinoma (Gao et al., 2014). Here, we seek to 
decipher the hormone mechanism(s) underlying the negative cognitive impact of 
androstenedione using a rat model. Androstenedione could be exerting cognitive effects 
through a multitude of mechanistic pathways; it is a direct precursor to testosterone via the 
17β-hydroxysteroid dehydrogenase (17β-HSD) enzyme, and to estrone via the aromatase 
enzyme, and, further, it binds to androgen receptors (Horton & Tait, 1966; Jasuja et al., 
2005). In the rodent model, testosterone administration has been shown to enhance spatial 
working memory (Bimonte-Nelson et al., 2003b), spatial reference memory (Benice & 
Raber, 2009), and performance on avoidance tasks (Flood et al., 1995; Edinger et al., 
2004). There is also evidence that higher relative levels of testosterone are associated with 
better spatial ability performance in women, while lower relative levels of salivary 
testosterone were related to better spatial ability performance in men (Gouchie & Kimura, 
1991). We have previously shown that estrone administration in Ovx rats produces 
cognitive impairments (Engler-Chiurazzi et al., 2012). Given these results, we now 
hypothesize that androstenedione’s conversion to estrone underlies its negative cognitive 
impact, rather than its actions on the androgen receptor.  
 The primary purpose of the current study was to systematically evaluate whether 
androstenedione’s conversion to estrone, or its effects on the androgen receptor, are 
responsible for the negative cognitive effects of androstenedione administration in the 
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surgically menopausal young adult rat. Herein, I tested the hormonal mechanism 
underlying the previously observed androstenedione-induced cognitive impairments using 
pharmacological manipulations that either block androstenedione’s conversion to estrone, 
or block androstenedione’s androgenic effects by blocking activation of the androgen 
receptor. Anastrozole, a non-steroidal aromatase inhibitor, or flutamide, a non-steroidal 
anti-androgen, were co-administered with androstenedione to determine whether 
androstenedione impairs memory via its conversion to estrone, or via its action on the 
androgen receptor, respectively. A secondary purpose of this study was to test the effects of 
anastrozole given alone. Indeed, aromatase inhibitors such as anastrozole are currently used 
to treat breast cancer and prevent breast cancer recurrence (Santen et al., 2009). Elucidating 
the impact of aromatase and estrogen metabolism on the brain and its function is critical to 
our understanding of the systems-level alterations that occur with changes in both 
endogenous and exogenous steroid hormones. 
Materials and Methods 
Subjects 
 Forty-eight four-month-old Fischer-344 virgin female rats born and raised at the 
National Institute on Aging colony at Harlan Laboratories (Indianapolis, IN) were used. 
Upon arrival, rats were pair housed, had access to food and water ad-lib, and were 
maintained on a 12-hour light/dark cycle at the Arizona State University animal facility. 
All procedures were approved by the local IACUC committee and adhered to NIH 
standards. Rats arrived two weeks before experiment initiation. 
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Experimental Design and Hormone Treatments 
 All rats received Ovx 13-14 days before the start of behavioral testing. Animals 
received bilateral dorsolateral incisions in the skin and peritoneum, the ovaries and tips of 
the uterine horns were ligatured and removed, and the muscle and skin were then sutured 
closed. During surgery, rats received an injection of Rimadyl (5mg/ml/kg) for pain and 
saline (2ml) to prevent dehydration. Hormone or vehicle treatment began 2-3 days after 
surgery (11 days before behavioral testing ensued) and continued until sacrifice. All 
assigned treatments were administered daily via subcutaneous injection into the scruff of 
the neck at an injection volume of 0.5ml. Rats were randomly assigned to one of five 
treatment groups: Vehicle (n=10), Androstenedione (n=10), Androstenedione+Anastrozole 
(n=10), Androstenedione+Flutamide (n=10), and Anastrozole (n=10). Vehicle-treated 
animals received 0.5ml of polyethylene glycol (PEG) (Sigma-Aldrich, St. Louis, MO, 
USA) only. All rats receiving androstenedione (Steraloids, Newport, RI, USA) were given 
2mg daily dissolved in PEG; this dose of androstenedione was based on previous literature 
(Lea & Flanagan, 1998; Sprando et al., 2004; Camp et al., 2012) and has been shown to 
produce working memory impairments in middle-aged Ovx rats (Camp et al., 2012). 
Animals in the Androstenedione+Anastrozole group received 0.025mg/day anastrozole 
(Tocris, Minneapolis, MN, USA) co-administered with 2mg androstenedione treatment, in 
order to block activity of the aromatase enzyme, preventing the conversion of 
androstenedione to estrone. Animals in the Androstenedione+Flutamide treatment group 
received 27.5mg of flutamide (Sigma-Aldrich, St. Louis, MO, USA) co-administered with 
2mg androstenedione treatment, to block the action of testosterone on androgen receptors. 
The Anastrozole treatment group received 0.025mg/day anastrozole dissolved in PEG. 
 113 
  Twelve days after the initiation of hormone treatment administration, behavioral 
testing began. Behavioral testing commenced approximately one hour after injections each 
day, and all treatment groups were counterbalanced across testing squads. All rats were 
subjected to the complete battery of behavioral evaluations. The order of behavior tests is 
concordant with our prior studies showing correlations between serum androstenedione 
levels and memory (Acosta et al., 2009b; Acosta et al., 2010; Camp et al., 2012). Figure 32 
contains a timeline with depictions of each behavioral task used. 
Water Radial Arm Maze 
 WRAM procedures were identical to those in chapter 4. 
Delay Match-to-Sample Asymmetrical Three-Choice Task 
 Delay-match-to-sample (DMS) procedures were identical to those described in 
chapter 6, except that animals were given 7 days to learn the task. 
Morris Water Maze 
 Morris water maze procedures were identical to those in chapter 4. 
Visible Platform Task 
 Visible platform procedures were identical to those in chapter 4. 
Uterine Weights 
 Prior studies have shown that androgens can stimulate the uterus and lead to 
increased uterine weight (Ruizeveld de Winter et al., 1991; Horie et al., 1992). To further 
validate androstenedione’s effects on uterine tissues, at sacrifice the uteri of all subjects 
were removed, trimmed of visible fat, and immediately weighed (wet weight; g). 
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Serum Hormone Levels 
 At the time of sacrifice, blood was collected via cardiocentesis. Blood was allowed 
to clot at 4°C (Vacutainer 367986, Becton Dickinson and Company, Franklin Lakes, NJ, 
USA), serum was collected after centrifugation for 20min at 4°C, and serum was stored at -
20°C until assays were performed. Serum hormone levels were determined by 
radioimmunoassay using previously described methods (Acosta et al., 2010; Camp et al., 
2012). Androstenedione was measured in serum using a solid-phase radioimmunoassay 
(Beckman-Coulter, Webster, TX), based on androstenedione-specific antibodies 
immobilized to the wall of polypropylene tubes and a 125I-labeled androstenedione tracer. 
Interassay Precision: CV of 7% at mean of 1.1ng/ml (3.8nmol/L), CV of 5% at mean of 3.8 
ng/ml (13.3nmol/L). Functional Sensitivity: 1ng/ml.  
 Testosterone was determined in serum using a competitive solid-phase 
radioimmunoassay (Beckman-Coulter, Webster, TX) that relies on testosterone-specific 
antibodies that are immobilized to the wall of polypropylene tubes and compete for 
testosterone in the sample or purified testosterone standards with 125I-labeled testosterone 
added to the tube as the tracer. Interassay Precision for the assay averages 7% at a mean 
value of 84ng/dl  (2.9nmol/L) and less than 5 % at a mean value of 403ng/dl (13.9nmol/L). 
Functional sensitivity of the assay is 15ng/dl (0.5nmol/L).  
 Estrone was determined in serum using a competitive radioimmunoassay 
(Beckman-Coulter, Webster, TX) with 125I-labeled estrone and a highly specific primary 
antibody. Separation of bound and free antigen was achieved using a double antibody 
system. Interassay Precision for the assay averages 11% at a mean value of 35pg/ml. 
Functional sensitivity of the assay is 5pg/ml.  
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Statistical Analyses 
 Statistical analyses were identical to those in chapter 4, with the exceptions that 
WRAM testing was divided into three four-day blocks (Block 1=Days 1-4, Block 2=Days 
5-8, Block 3=Days 9-12), and we did not choose comparisons a priori. For DMS testing, 
data were analyzed using repeated measures ANOVA with Treatment as the independent 
variable and number of total errors across Days and Trials as the repeated measure. Morris 
water maze testing was blocked into six three-trial blocks (two Blocks per Day) and 
analyzed using repeated measures ANOVA with Treatment as the independent variable and 
swim distance across Blocks and Trials as the repeated measure. Probe trial data were 
analyzed identically to the analysis in chapter 4. Visible platform data were analyzed 
identically to the analysis in chapter 4. 
 Two-tailed tests were used throughout, and alpha was set at 0.05. Uterine weights 
(g), serum androstenedione levels (ng/ml), serum testosterone levels (ng/dl), and serum 
estrone levels (pg/ml) were analyzed separately using one-way ANOVA, with each 
respective measure as the dependent variable and Treatment as the independent variable. 
Results 
Water Radial Arm Maze 
 Errors decreased across block for all three memory measures on the WRAM, 
indicating learning (main effect of Block for WMC [F(2,88) =52.13, p<0.0001], WMI [F(2,88) 
=55.39, p<0.0001], and RM [F(2,88) =69.25, p<0.0001] errors. There were no Treatment 
effects for WMC, WMI, and RM for Block 1 (Days 1-4) or Block 2 (Days 5-8) of WRAM 
testing. We have previously observed effects of exogenous treatment with both androgens 
and estrogens during the latter portion of testing, so we were particularly interested at 
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effects at the latter testing block (Acosta et al., 2010; Bimonte & Denenberg, 1999; 
Bimonte-Nelson et al., 2003b; Camp et al., 2012). On Block 3, as predicted, a general 
pattern emerged, revealing that androstenedione-induced impairments were negated by the 
addition of the aromatase inhibitor anastrozole, but not by blockade of the androgen 
receptor through the addition of flutamide. This pattern was observed for all three types of 
errors evaluated on the WRAM. 
 For Block 3 of WRAM testing, there was a Treatment x Trial interaction for WMC 
errors [F(8,88) =3.05, p<0.01; figure 33a]. For Trial 4, the trial with the highest working 
memory load, there was a main effect of Treatment for WMC errors [F(4,44) =4.31, p<0.01; 
figure 33a]; post hoc analysis revealed that, on Trial 4, the Androstenedione group 
committed more WMC errors compared to the Vehicle group (Fisher, p<0.001); the 
addition of aromatase inhibition via anastrozole treatment reversed this androstenedione-
induced impairment [Androstenedione vs.  Androstenedione+Anastrozole, Fisher, p<0.01]. 
At the highest memory load for WMC, the Androstenedione group also made more errors 
than the Anastrozole group (Fisher, p<0.01) group, and the Androstenedione+Flutamide 
group committed more errors than the Vehicle group (Fisher, p<0.05).  
 Similar to the effect on Block 3 for WMC, there was also an effect on Block 3 for 
WMI, with a Treatment x Trial interaction for WMI errors [F(12,132) =5.36, p<0.0001; figure 
33b]. For Trial 4, there was a main effect of Treatment for WMI errors [F(4,44) =5.90, 
p<0.001; figure 33b]; post hoc analysis revealed that, on this trial requiring the highest 
working memory demand, the Androstenedione group committed more WMI errors 
compared to Vehicle (Fisher, p<0.01). Again, the addition of anastrozole reversed the 
impairing effect of andostenedione at the highest working memory load [Androstenedione 
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vs Androstenedione+Anastrozole (Fisher, p<0.01)], and the Androstenedione group made 
more errors than the Anastrozole group (Fisher, p<0.01). Post hoc analysis also 
demonstrated that the Androstenedione+Flutamide group committed more WMI errors on 
Trial 4 than the Vehicle (Fisher, p<0.01), Androstenedione+Anastrozole (Fisher, p<0.01), 
and Anastrozole (Fisher, p<0.01) groups.  
 A main effect of Treatment for RM errors was also revealed [F(4,44) =6.30, p<0.001; 
figure 33c] for Block 3 of WRAM testing. Post hoc analysis demonstrated that the 
Androstenedione group committed more RM errors than the Vehicle group (Fisher, 
p<0.001), and, in accordance with effects for both orthogonal working memory error types 
for the WRAM, the addition of anastrozole reversed reference memory impairments 
induced by androstenedione [Androstenedione vs. Androstenedione+Anastrozole, Fisher, 
p<0.05]. The Androstenedione group also made more RM errors than the Anastrozole 
group (Fisher, p<0.05), and the Androstenedione+Flutamide group committed more RM 
errors compared to Vehicle (Fisher, p<0.001), Androstenedione+Anastrozole (Fisher, 
p<0.01), and Anastrozole (Fisher, p<0.05) groups. 
 Hormone treatment did not impact performance on the delayed memory retention of 
multiple platform locations, as there were no treatment effects on the post-delay trials on 
Day 13 for WMC, WMI, or RM errors on the WRAM.  
Delay Match-to-Sample Asymmetrical Three-Choice Task 
 There was a main effect of Day [F(6,264) =17.17, p<0.0001] with Total Errors 
decreasing as days progressed. There were no Treatment effects for Total Errors (Days 1-7; 
figure 34), nor was there a Treatment x Day interaction.  
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Morris Water Maze 
 Analyses revealed a main effect of Block [F(5,220) =150.06, p<0.0001], with swim 
distance decreasing across blocks showing learning. There was a Treatment x Block 
interaction for Morris water maze testing [F(20,220)=1.84; p<0.05; figure 35a]. For Block 1, 
there was a main effect of Treatment [F(4,44)=2.96; p<0.05; figure 35b]; post hoc analyses 
revealed that the Androstenedione+Anastrozole group swam a shorter distance to the 
platform than the Vehicle (Fisher, p<0.05), Androstenedione (Fisher, p<0.05), and the 
Androstenedione+Flutamide group (Fisher, p<0.01). For the probe trial, there was a main 
effect of Quadrant [F(1,44)=982.20; p<0.0001; figure 35c] in the absence of a Quadrant x 
Treatment interaction [F(4,44)=2.30; p>0.05, NS; figure 35c], indicating that all groups 
equally localized the platform using spatial navigation by the end of Morris water maze 
testing.  
Visible Platform Task 
 Figure 36 shows the mean+SEM latency to escape value for each group across all 
trials for the one day of visible platform testing. There was a main effect of Trial [F(5,220) 
=9.32, p<0.0001], with latency decreasing as trials progressed within the day of visible 
platform testing (figure 36). There were no Treatment main effects [F(4,44)=1.49, p<0.05, 
NS] on latency to escape for the visible platform task. However, there was a Treatment x 
Trial interaction [F(20,220) =2.35, p<0.01], such that there was a main effect of Treatment on 
Trial 1 [F(4,44) =3.65, p<0.05]. Further analyses indicated that the Vehicle group took a 
longer time to reach the platform than the Androstenedione (Fisher, p<0.05), 
Androstenedione+Anastrozole (Fisher, p<0.01), and Anastrozole (Fisher, p<0.001) groups; 
no hormone treated group differed from any other hormone treated group. Most 
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importantly, there were no effects of Treatment on any of the remaining trials (Trials 2-6), 
each animal successfully located the platform on every trial, and by the last trial, all groups 
found the platform within 16s, thereby allowing interpretation that animals demonstrated 
the procedural skills necessary to complete a water maze task.  
Uterine Weights 
 There was a main effect of Treatment for uterine weights [F(4,43)=13.03; p<0.0001; 
figure 37]. The Androstenedione group had higher uterine weights than the Vehicle (Fisher, 
p<0.0001), Androstenedione+Anastrozole (Fisher, p<0.001), Androstenedione+Flutamide 
(Fisher, p<0.0001), and Anastrozole (Fisher, p<0.0001) groups. The 
Androstenedione+Anastrozole group also had higher uterine weights than the Anastrozole 
group (Fisher, p<0.05).  
Serum Hormone Levels 
 There was a main effect of Treatment for serum androstenedione [F(4,31)=6.04; 
p<0.01; figure 38a]. Androstenedione treatment increased serum androstenedione levels in 
all groups receiving this androgen, relative to vehicle treatment [Vehicle vs. 
Androstenedione (Fisher, p<0.01), Vehicle vs. Androstenedione+Flutamide (Fisher, 
p<0.05), Vehicle vs. Androstenedione+Anastrozole (Fisher, p<0.01)], and relative to 
treatment with anastrozole alone [Anastrozole group vs. Androstenedione group (Fisher, 
p<0.001), Anastrozole vs. Androstenedione+Flutamide group (Fisher, p<0.05), Anastrozole 
vs. Androstenedione+Anastrozole group (Fisher, p<0.01)]. 
 A main effect of Treatment for serum testosterone was also demonstrated 
[F(4,28)=4.60; p<0.01; figure 38b]. The Androstenedione group had higher testosterone 
serum levels than the Vehicle (Fisher, p<0.01) and Anastrozole (Fisher, p<0.01) groups, 
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and the Androstenedione+Anastrozole group also had higher serum testosterone levels than 
the Vehicle (Fisher, p<0.05) and Anastrozole (Fisher, p<0.05) groups.  
 The analysis of serum estrone revealed a main effect of Treatment as well 
[F(4,26)=96.67; p<0.0001; figure 38c]. The Androstenedione group had higher serum estrone 
levels than the Vehicle group (Fisher, p<0.001), and the addition of anastrozole decreased 
estrone levels (Androstenedione vs. Androstenedione+Anastrozole Fisher, p<0.05), 
confirming that the anastrozole treatment used herein effectively reduced 
androstenedione’s conversion to estrone. The Androstenedione group also had higher 
serum levels than the Anastrozole group (Fisher, p<0.001), and the 
Androstenedione+Flutamide group had higher serum estrone levels than the Vehicle 
(Fisher, p<0.0001), Anastrozole (Fisher, p<0.0001), Androstenedione (Fisher, p<0.0001), 
and Androstenedione+Anastrozole groups (Fisher, p<0.0001). Additionally, the 
Androstenedione+Anastrozole group tended to have higher serum estrone levels than both 
the Vehicle (p=0.05), and Anastrozole (p=0.05) groups, suggesting that the addition of 
anastrozole did not completely block aromatase activity in this model. 
Correlations Between Serum Hormone Levels and Behavioral Tests 
 Serum estrone levels correlated with average Total Errors on Block 3 of WRAM 
testing across all four trials (r=0.39; p<0.05; figure 39a), as well as on Trial 4, the trial with 
the highest working memory load (r=0.36; p<0.05; figure 39b). Because we found a clear 
bimodal distribution in estrone levels, whereby the Androstenedione+Flutamide group had 
higher estrone levels than all other groups and therefore held the potential to exert a large 
amount of influence over these analyses, we also assessed each of these correlations 
excluding the Androstenedione+Flutamide group. With the Androstenedione+Flutamide 
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group excluded, we found that serum estrone levels still correlated with average Total 
Errors on Block 3 of WRAM testing across all four trials (r=0.58; p<0.01; figure 39a), as 
well as on Trial 4, the trial with the highest working memory load (r=0.62; p<0.01; figure 
39b).  
Discussion 
 Our laboratory has recently reported that androstenedione produces spatial memory 
impairments in the female rat. Specifically, we have found positive correlations between 
endogenous androstenedione levels and maze error scores, and subsequently confirmed 
these relationships by methodically manipulating androstenedione levels in older Ovx rats 
and showing that exogenous androstenedione treatment impairs memory across multiple 
domains (Acosta et al., 2009b, 2010; Camp et al., 2012). The present goals were to extend 
our previous findings and demonstrate that exogenous androstenedione administration 
produces memory impairment in young adult animals, and to evaluate the hormonal 
mechanism(s) underlying these androstenedione-induced cognitive impairments. Because 
we have previously observed spatial memory impairments following tonic administration 
of estrone (Engler-Chiurazzi et al., 2012), I hypothesized that the conversion of 
androstenedione to estrone was, at least in part, responsible for the memory impairments 
observed when androstenedione is administered to otherwise ovarian-hormone blank (Ovx) 
animals.  
 Replicating our previous findings in middle-aged animals, in the current study 
androstenedione impaired several dimensions of cognition including spatial reference and 
working memory in young adult Ovx rats. Offering support to our hypothesis regarding the 
mechanism underlying these effects, androstenedione administration did not induce 
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memory impairments on any measure evaluated here when it was paired with an aromatase 
inhibitor, anastrozole. Anastrozole blocks the activity of the aromatase enzyme, which is 
responsible for the conversion of androstenedione to estrone. This treatment still allows the 
exogenously delivered androstenedione to act both directly as well as indirectly, through its 
conversion to testosterone, on the androgen receptor. Pharmacological blockade of 
androgen receptor activation did not block the cognitive impairing effects of 
androstenedione. Together, these findings offer support to the tenet that androstenedione 
produces robust memory impairments due to its conversion to estrone, rather than due to its 
androgenic effects. 
 Androgens are typically thought of as masculine hormones and are rarely associated 
with menopause. However, increasing evidence indicates that studying the impact of 
androgens on cognition is crucial to our understanding of natural transitional menopause 
and associated cognitive changes. Female rats have been shown to express high 
concentrations of androgen receptors in cognitive brain areas such as the hippocampus and 
cerebral cortex (Simerly et al., 1990), which have been shown to be sensitive to both Ovx 
and androgen administration (Lu et al., 1998), and activation of which could impact 
cognitive function through gene transcription (McPhaul & Young, 2001). There has been a 
paucity of research evaluating the learning and memory effects of endogenous or 
exogenously administered androstenedione. In fact, as far as we are aware, the current 
experiment and our prior research findings (Camp et al., 2012) are the only studies testing 
the effects of androstenedione administration on learning and memory in the rat.  
Much of the prior research testing the effects of androgens on rodent cognition has focused 
on dihydrotestosterone, testosterone, and dehydroepiandrosterone. Interestingly, while 
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reports indicate that dihydrotestosterone has no impact on spatial working or reference 
memory (Raber et al., 2002; Bimonte-Nelson et al., 2003b; Benice & Raber, 2009), we and 
others have shown that testosterone administration enhances working memory (Bimonte-
Nelson et al., 2003b), spatial reference memory (Benice & Raber, 2009), and performance 
on avoidance tasks (Flood et al., 1995; Edinger et al., 2004).  
 The metabolism of androstenedione versus testosterone is likely related to the 
divergence in their respective cognitive impacts; testosterone is directly aromatized to 17β-
estradiol, whereas androstenedione is directly aromatized to estrone. Many studies have 
demonstrated that estradiol can enhance cognition in female rats (e.g. Bimonte & 
Denenberg 1999; Gibbs, 1999, 2005; Gibbs et al., 2004; Daniel et al., 2006; Talboom, 
2008; Rodgers et al., 2010; for review see Acosta et al., 2013). Thus far, the only two 
studies investigating the cognitive impact of estrone have found that estrone treatment was 
detrimental to contextual fear conditioning in young adult female rats (Barha et al., 2010), 
as well as working memory in middle-aged female rats (Engler-Chiurazzi et al., 2012). 
 The potential clinical implications of the current findings are far-reaching. Indeed, 
this work could generate new insight into the already immensely complex relationship 
between the loss of ovarian hormones in menopause and memory changes (Weber & 
Mapstone, 2009; Weber et al., 2013; Fischer et al., 2014). Cognitive effects likely depend 
on an individual’s menopause status, including whether they have intact ovaries (Nappi et 
al., 1999), what phase of the menopause transition they are in (Weber et al., 2013), 
circulating levels of androstenedione, as well as other steroid hormones and gonadotropins 
(Acosta et al., 2009b), and prior hormone exposure history (Bimonte-Nelson et al., 2010). 
Knowledge of how these factors interact is particularly salient towards our goal of 
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optimizing hormone therapy for relief of menopausal symptoms. For example, we have 
demonstrated that conjugated equine estrogen (CEE) hormone therapy benefits cognition 
following surgical hormone loss, but impairs cognition following transitional menopause in 
which the residual, androstenedione-producing ovaries remain intact (Acosta et al., 2010). 
The current results underscore the tenet that CEE is not the optimal hormone therapy for 
menopausal women. Support for this assertion comes from several intersecting lines of 
evidence, including the current data indicating that this may be especially relevant for 
women who retain their ovaries; indeed, CEE is over 50% estrone sulfate (Kuhl, 2005; 
Gleason et al., 2005). Estrone sulfate is converted to estrone by the liver, further adding to 
the estrone load derived from ovarian-produced androstenedione. It is possible that a 
bioidentical estradiol hormone therapy approach may produce more favorable cognitive 
outcomes, as it would act to bring the hormonal milieu closer to ratios seen in pre-
menopausal women (Kuhl, 2005; Gleason et al., 2005).  
 The study of aromatase and estrogen metabolism is critical to moving the endocrine 
field forward, and to our understanding of systems-level changes occurring with hormone 
loss and replacement during menopause. Highlighting the need for a non-estrogenic 
compound that could safely relieve some of the symptoms of menopause, many women are 
unable to utilize estrogen-inclusive hormone therapy due to an increased risk of, or history 
of, breast cancer. The aromatase enzyme is found in breast tissue, and aromatase inhibitors 
are currently used to treat breast cancer and prevent breast cancer recurrence (Santen et al., 
2009). Furthermore, there is a greater degree of androstenedione aromatization to estrogen 
as the body mass index and obesity increase in postmenopausal women, suggesting that 
conversion of androstenedione to estrogens can vary across the menopausal population 
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(Santen et al., 2009). Should aromatase inhibitors prove to offset some of the negative 
cognitive consequences of menopause, this would further add to their value. In fact, it is 
noteworthy that, in the current study, anastrozole alone did not impair any of our many 
measures of cognition; indeed, anastrozole is one of the currently prescribed aromatase 
inhibitors used for breast cancer. Important future directions include developing a better 
understanding of the downstream hormone and brain mechanism(s) through which 
androstenedione and estrone produce cognitive impairments. A primary goal of this 
research is to evaluate alternative hormone therapy options that produce favorable 
outcomes for improved cognition in the menopausal female, utilizing a systematic 
approach that acknowledges and accounts for contributions of the many interacting 
variables that produce cognitive changes throughout aging.  
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CHAPTER 9: EVALUATION OF THE COGNITIVE IMPACT OF HORMONAL 
CONTRACEPTIVES DURING THE MENOPAUSAL TRANSITION 
Introduction 
 Through the set of experiments performed for this dissertation, I have shown that 
several endogenous and exogenous hormone exposures across the lifespan have the 
potential to impact cognition. Chapter 3 demonstrated that use of EE-containing 
contraceptives is associated with worse performance in women tested on the human 
analogue of the rat radial-arm maze task (the HRAM), as well as poorer performance on 
tasks that measure visuospatial ability, compared to men. Chapter 4 reported similar 
impairments in spatial working memory following administration of EE in young adult 
Ovx rats, and chapter 5 extended those findings to ovary-intact rats. Chapter 6 showed that 
there is a narrow window of opportunity around VCD-induced follicular depletion during 
which CEE does not produce cognitive impairments, and chapter 7 demonstrated that 
exogenous administration of E2 following VCD-induced follicular depletion produces 
spatial memory enhancements. Finally, in chapter 8, I collected data to support our 
hypothesis, that follicle-deplete ovarian-derived androstenedione’s conversion to E1 via the 
aromatase enzyme underlies the working memory impairments associated with elevated 
androstenedione levels. Generally, the work so far in this dissertation suggests that 
alterations in estrogen levels impact working memory, while leaving reference memory 
comparatively unaffected, and that background hormone profile is important to consider 
when designing or choosing hormone treatments. This work also indicates that animals that 
have undergone follicular depletion and retained their follicle-deplete ovaries respond more 
strongly to exogenous E2 treatment behaviorally than to CEE treatment, or removal of the 
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ovaries (Ovx), perhaps because E2 produces a comprehensive hormonal shift towards 
higher E1 and E2 levels, and lower androstenedione levels than what is seen with CEE or 
Ovx.  
 Through the last decade, there has been a massive shift in HT prescription trends; 
the heavily publicized WHI and WHIMS results showing no cognitive benefits of CEE HT, 
coupled with increased cognitive and health risks in some cases, spurred a high demand for 
alternative, safer prescription HT regimens (ACOG, 2011; Endocrine Society, 2015). 
Several FDA-approved bioidentical E2-containing HTs are now available in the United 
States, including numerous transdermal, systemic, tonic-E2-releasing patches (Alora, 
Climara, Estraderm, Minivelle®, Vivelle-Dot, and other generic versions), gels (Divigel®, 
EstroGel, Elestrin), and a spray (Evamist®; NAMS). The Estrace vaginal cream, Estring® 
vaginal ring, and Vagifem® vaginal mist are also available for local vaginal, non-systemic 
use. The majority of these products have counterparts that also contain progestogens, for 
use by women that have not undergone hysterectomy (surgical removal of the uterus). 
Activella is an oral formulation that includes the progestin Norethindrone Acetate (NETA), 
Prefest® is another oral formulation that utilizes Norgestimate, another synthetic progestin, 
CombiPatch is a transdermal patch with NETA, and Climara Pro is a transdermal patch that 
releases yet another synthetic progestin, levonorgestrel (levo; NAMS).  
 In addition to this long list of bioidentical FDA-approved HT formulations, a host 
of new, non-FDA-approved, custom compounded estrogen/estrogen+progestogen 
formulations have gained massive popularity in the clinic. This year, the Endocrine Society 
and the North American Menopause Society (NAMS) have published several reports 
expressing concern about rampant off-label prescribing of these new custom compounded 
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estrogen formulations as HT. These formulations are marketed as bioidentical customized 
estrogen cocktails, and now may be the dominant HT prescribed by physicians, accounting 
for 28% to 68% of currently used HTs (NAMS, 2015a, 2015b). Because these formulations 
are not FDA-approved, and therefore not governmentally regulated, it is difficult to track 
their use, and their safety is not guaranteed. Indeed, there are now major concerns that 
these formulations do not contain hormones in the proper ratios to render them safe; in 
many cases the amount of included progestogen was insufficient to protect the uterus from 
estrogenic stimulation, an oversight that can be deadly (Endocrine Society, 2015; NAMS, 
2015a, 2015b).  
 In lieu of the above-described HT options, many physicians now also recommend 
an FDA-approved contraceptive regimen to women in the menopause transition to prevent 
unwanted pregnancies and to regulate the menstrual cycle, which would otherwise become 
increasingly irregular and unpredictable across the transition to menopause (Curtis et al., 
2005; Hoffman et al., 2012; Ikhena & Johnson, 2012). These contraceptive formulations, 
while not FDA-approved for use as HT, are FDA-approved and regulated for contraceptive 
use, providing a general safety guarantee over that of custom-compounded HTs. The 
cognitive effects of the synthetic estrogen EE utilized in hormonal contraceptives, and the 
many available synthetic progestins, have never been evaluated in a rodent model of 
transitional menopause. Other work from our laboratory has shown that treatment with 
medroxyprogesterone acetate (MPA), a synthetic progestin, induces cognitive impairments 
in ovary-intact, as well as Ovx rats (Braden et al., 2010; 2011), and ongoing work in our 
laboratory suggests that a clinically relevant dose of levo, a structurally and functionally 
different progestin, may have a favorable cognitive impact in young Ovx rats.  
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 Findings from this dissertation suggest that EE-containing hormonal contraceptives 
may serve as a more optimal HT during the menopause transition than the current FDA-
approved regimens containing E2 or CEE, and the now-popular non-FDA-approved custom 
estrogen formulations. Although I saw a clear negative impact of low-dose EE in young-
adult ovary-intact rodents in chapter 5, as well as in young adult women in chapter 3, I did 
not see any impact of low-dose EE in Ovx animals in chapter 4, and collectively, the results 
from this dissertation suggest that the cognitive effects of estrogens depend heavily on the 
hormonal profile they are delivered to. EE’s lack of conversion to E1 makes it an especially 
promising candidate to supplement the hormonal profile of naturally menopausal women. 
The addition of a synthetic progestin may further serve to replace the progestogenic 
stimulation lost with menopause. It is also important to consider that the current FDA-
approved E2 and CEE-containing HT regimens are not sufficient to halt ovulation, and 
therefore are not useful as contraceptives. FDA-approved hormonal contraceptives may 
serve the additional function of disguising the irregular hormone fluctuations that occur 
during the transition to menopause, which current FDA-approved HT prescriptions are not 
capable of. Moreover, hormonal contraceptives also provide the added benefit of 
preventing unwanted pregnancies during the transition to menopause, and do not incur the 
same cancer risks as traditional HTs. In fact, combined contraceptive use is associated with 
a reduced risk of ovarian and endometrial cancer (Hoffman et al., 2012). 
 For my final experiment, I tested the cognitive impact of the estrogens E2 and EE, 
as well as the synthetic progestin levo, and the combinations of each estrogen with levo 
during follicular depletion. These hormone regimens were specifically chosen to model 
clinically prescribed formulations of combined contraceptives and FDA-approved HTs that 
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are currently prescribed as closely as possible (Curtis et al., 2005; Hoffman et al., 2012). I 
predicted that E2- and EE-containing treatments would improve performance on a spatial 
working memory task, and that EE+levo would produce the most robust cognitive benefits, 
relative to no hormone treatment during the transition to menopause. 
Materials and Methods 
Subjects 
 Subjects were 59 eight-month-old Fisher-344 rats raised at the National Institute on 
Aging colony at Harlan Laboratories (Indianapolis, IN). After arrival at the ASU Tempe 
campus facilities, rats were pair-housed, had access to food and water ad-lib, and were 
housed on a 12-h light/dark cycle. All procedures were approved by the local Institutional 
Animal Care and Use Committee (IACUC) and adhered to National Institutes of Health 
(NIH) standards.  
Experimental Design and Hormone Treatments 
 Animals received VCD treatment exactly as described in chapters 7 and 8. Thirty 
days after VCD treatment was initiated, administration of Vehicle (n=10), E2 (n=10), EE 
(n=10), levo (n=10), E2+levo (n=9), or EE+levo (n=10) began. Treatment was given via 
subcutaneous Alzet osmotic pump, releasing a tonic dose of hormone treatment for the 
remainder of the study.  
 EE in combination with levo exists in over twenty different contraceptive 
formulations, including Alesse, Aviane, Lutera, Nordette, Altavera, and several other 
generic variations. Doses of EE in these formulations range from 10-30µg/day, while EE as 
a HT is given at a lower dose (2.5 or 5.0µg/day), and clinically used doses of levo range 
from 0.05-0.15mg/day. Here, we utilized the low EE dose from chapter 4 (0.125µg/day), 
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which is equivalent to a roughly 30-35µg/day dose of EE in women, when corrected for 
differences in body weight, and the dose of E2 that was used in chapter 7 (0.3µg/day). We 
chose a dose of 0.6µg/day of levo because ongoing work in our laboratory suggests this 
regimen may have a favorable impact on cognition. This dose in a rat is equivalent to 
roughly 1.4-1.7mg/day dose in women, when corrected for body weight. Figure 40 shows a 
detailed experimental timeline.  
Water Radial Arm Maze 
 Water radial arm maze (WRAM) procedures were identical to those in chapter 4. 
Morris Water Maze 
 Morris water maze (MM) procedures were identical to those in chapter 5. 
Visible Platform Maze 
 Visible platform procedures were identical to those described in chapter 4. 
Peripheral Markers of Treatment 
 Wet uterine weights (g) were measured at sacrifice to verify hormone treatment. 
Ovaries were collected and preserved in 10% formalin for future evaluation of follicle and 
corpora lutea counts.  
Serum Hormone Levels 
 Animals were given two days off from behavioral testing before sacrifice, at which 
time serum was collected for hormone assays, exactly as described in chapter 4. 
Statistical Analyses 
 WRAM, MM, and visible platform data were analyzed exactly as described in 
chapters 7 and 8, with the exception that two independent between-subjects variables will 
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be used: Estrogen (three levels: Vehicle, E2, EE) and Progestin (two levels: Vehicle, Levo), 
rather than one between subjects treatment variable. 
Results 
Water Radial Arm Maze 
 For Block 1 (days 2-3) of WRAM testing, there was a Trial x Estrogen x Progestin 
interaction (F(6,159)=2.33, p<0.05; ηG2=0.04; figure 41a), with group differences appearing 
on Trial 4, the trial with the highest working memory load. On Trial 4, there was a 
Estrogen x Progestin interaction (F(2,53)=3.39, p<0.05; ηG2=0.05; figure 41b), whereby levo 
treatment produced impairments relative to no levo treatment in animals treated with no 
estrogen (Fisher, p<0.05), and in animals treated with E2 (Fisher, p<0.05), but not in 
animals treated with EE (Fisher, p>0.05). 
 On Block 2 of WRAM testing (days 4-6), there was a Trial x Estrogen interaction 
(F(6,159)=4.47, p<0.001; ηG2=0.04; figure 41c) and a Trial by Progestin interaction 
(F(3,159)=3.93, p<0.01; ηG2=0.02figure 41e), with treatment differences emerging on Trial 4, 
the trial with the highest working memory load. On Trial 4, there was a main effect of 
estrogen (F(2,53)=5.23, p<0.01; ηG2=0.06; figure 41d), with E2-treated animals performing 
better than those treated with vehicle (Fisher, p<0.05) or EE (Fisher, p<0.05), regardless of 
Progestin treatment. There was also a main effect of Progestin on Trial 4 (F(1,53)=5.40, 
p<0.05; ηG2=0.03; figure 41f), with levo-treated animals outperforming animals that did not 
receive levo (Fisher, p<0.05), regardless of Estrogen treatment. 
 There was a Trial x Estrogen x Progestin interaction on Block 3 of WRAM testing 
(days 7-9; F(6,159)=3.66, p<0.01; ηG2=0.04; figure 41g), with group differences on Trial 4, 
the highest working memory load trial. On Trial 4, there was an Estrogen x Progestin 
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interaction (F(2,53)=4.73, p<0.05; ηG2=0.07; figure 41h), whereby treatment with E2 
produced spatial memory impairment in animals that did not receive levo, relative to 
treatment with EE (Fisher, p<0.05) or no estrogen (Fisher, p<0.05). There were no effects 
of Estrogen within the levo-treated groups (Fisher, p>0.05). 
 There were no effects of Estrogen (F(2,53)= 0.46, p>0.05, NS; ηG2<0.01) or Progestin 
(F(1,53)= 2.99, p>0.05, NS; ηG2<0.01) on Block 4 of WRAM testing (days 10-12), and there 
were no effects of Estrogen or Progestin on delayed memory retention (day 13). 
Morris Water Maze 
 There were no effects of Estrogen (F(2,53)= 0.80, p>0.05, NS; ηG2<0.01; figure 42a) 
or Progestin on MM performance (F(1,53)= 0.03, p>0.05, NS; ηG2<0.01; figure 42a). On the 
probe trial, there was a main effect of Quadrant (F(1,53)= 430.58, p≤0.0001; ηG2=0.86), with 
no Estrogen x Quadrant interaction (F(2,53)= 0.20, p>0.05; ηG2<0.01; NS), but there was a 
Progestin x Quadrant interaction (F(1,53)= 3.81, p<0.05; ηG2=0.03). This prompted us to 
analyze the first half of the Probe trial, to determine whether animals began searching in 
other quadrants after a lack of reward in the NE quadrant for the first 30 seconds. Indeed, 
during the first 30 seconds of the probe trial, there was a main effect of Quadrant (F(1,53)= 
261.96, p≤0.0001; ηG2=0.93; figure 42b), with no Estrogen x Quadrant interaction (F(2,53)= 
0.10, p>0.05; ηG2<0.01; NS; figure 42b), and no Progestin x Quadrant interaction (F(1,53)= 
2.44, p>0.05; ηG2=0.03; NS; figure 42b), demonstrating that all treatment groups localized 
the platform by the end of MM testing. 
Visible Platform Task 
 There was no effect of Estrogen on escape latency in the visible platform task 
(F(2,53)= 0.03, p>0.05; ηG2<0.01; NS), but there was a marginal effect of Progestin on 
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escape latency (F(1,53)= 3.19, p<0.10; ηG2=0.01). Animals treated with levo tended to escape 
from the maze faster than those that did not receive Levo (Fisher, p<0.10), indicating that 
this treatment enhanced some procedural aspect of water-maze performance. Although this 
effect was present, all groups exhibited mean escape times of less than 10 seconds across 
all six trials, and the levo-induced benefit on this task amounted to an average escape time 
of less than two seconds faster than that of non-levo treated animals (no levo: M=9.32s, 
SD=7.47s; levo: M=7.95s, SD=7.16s). 
Peripheral Markers of Treatment 
 There was a main effect of Estrogen on Uterine Weights (F(2,53)=8.51, p<0.001; 
ηG2=0.24; figure 43a), with E2-treated animals exhibiting heavier uterine horns at sacrifice 
than animals that received EE or no estrogen, regardless of Progestin treatment. There was 
no impact of Progestin treatment on Uterine Weights (F(1,53)=1.20, p>0.05; ηG2=0.02; figure 
43a). and no Estrogen x Progestin interaction (F(1,53)=0.10, p>0.05; NS; ηG2<0.01; figure 
43a). Relationships between E2 levels and uterine weights by group are shown in figure 44. 
Serum Hormone Levels 
 There was a main effect of Estrogen on circulating serum levels of E2 
(F(2,53)=93.77, p<0.0001; ηG2=0.78; figure 43b), with higher E2 levels in groups given E2 
compared to those given EE or no estrogen, regardless of Progestin treatment. There was 
no impact of Progestin treatment on serum E2 levels (F(1,53)=1.17, p>0.05; ηG2=0.02; figure 
43b). 
Discussion 
 The aim of the current study was to determine whether EE-containing contraceptive 
formulations might serve as cognitively protective HTs during the transition to menopause. 
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I compared tonic EE and E2 treatment, with and without the popular progestin levo, to 
vehicle treatment in animals undergoing the end stages of ovarian follicular depletion, as a 
model of the transition to menopause. I observed a benefit of E2 treatment during the 
middle of WRAM testing, similar to the effects of E2 in post-depletion animals that we 
reported in chapter 7. However, I also observed a negative impact of E2 treatment later in 
testing, which is unique to E2 given during follicular depletion; this negative effect was not 
seen in post-depletion animals with an identical E2 treatment in chapter 7. Of note, the only 
treatment regimens utilized here that are not sufficient to halt ovulation are those for the 
Control and E2 alone groups: the inconsistency in E2’s effects on cognition may reflect the 
inconsistent endogenous hormone levels that this exogenous treatment is added to. In 
support of this hypothesis, the addition of levo, which alone is sufficient to halt ovulation 
and mask the irregular endogenous hormone levels associated with the transition to 
menopause, negates the impairment seen with E2 alone, without negating the benefit of E2 
seen earlier in testing. The addition of levo treatment to E2 treatment does, however, 
induce a deficit on the initial testing block that is not seen with E2 alone. Thus, while it 
seems that treatment with E2 produces a favorable cognitive impact after follicular 
depletion is complete, modeling post-menopause, as we reported in chapter 7, we now 
report that E2 alone produces both cognitive enhancement and impairment when 
administered during the transition to menopause. 
 I saw no cognitive impact of EE alone, relative to no hormone treatment. These 
results are identical to the cognitive profile of the corresponding dose of EE that I reported 
in Ovx animals in chapter 4, and differs from the cognitive impact of a similar dose of EE 
that I observed in regularly cycling, ovary-intact young adult rats in chapter 5. While I did 
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not observe any overt cognitive benefits of EE treatment, I still consider the observed 
neutral cognitive impact to be a positive result; EE produces the same estrogenic 
stimulation that FDA-approved E2 or CEE HTs yield, without the negative cognitive 
impact that we observed with CEE in chapter 6, or with E2 or levo in the current 
experiment.  
 I also conclude that the cognitive impact of levo depends on the estrogen treatment 
that it is administered with. In animals that received no estrogen, and in animals that 
received E2, levo impaired WRAM performance on the first block of testing, but improved 
performance in later testing blocks, relative to animals that did not receive levo. In animals 
that received EE treatment, levo produced a benefit on the second block of WRAM testing, 
with no negative impact on any other blocks. Thus, the treatment utilized here that models 
over 20 different currently available FDA-approved hormonal contraceptives (EE+levo) 
produced the most favorable cognitive profile, relative to no hormone treatment at all, E2 
treatment alone, EE treatment alone, levo treatment alone, or E2 plus levo treatment.  
 Altogether, I report here that treatment with E2 or levo alone, or a combination of 
E2 and levo during the transition to menopause results in mixed cognitive effects, including 
both improved and worsened performance on our WRAM task. Treatment with EE alone 
did not impact performance on any of the tasks utilized here, and treatment with EE plus 
levo produced a modest benefit on our WRAM task. This EE+levo-induced memory 
benefit during the transition to menopause is an incredibly exciting finding, as this 
treatment regimen is widely available, free to most women in the United States, and 
produces all of the non-cognitive benefits of currently approved HTs, in addition to 
pregnancy prevention not offered by traditional HTs. More investigation into the many 
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different variations of contraceptive formulations currently available is sorely needed. The 
results here are specific to tonic treatment regimens, while many of the available 
formulations (and the most popular) are administered in a daily cycle. Previous and 
ongoing work from our lab suggests that the cognitive impact of EE (Mennenga et al., 
2015a) and of levo may vary between tonic and cyclic regimens.  
 Also, the cognitive impacts of each of the numerous available synthetic progestins 
have only just started to be explored. There has been no exploration into the cognitive 
impact of phasic contraceptive formulations, which even more closely model the 
reproductive hormone cycle and may produce an even better cognitive outcome. To my 
knowledge, along with two other reports from our laboratory on the memory effects of 
MPA (Braden et al., 2010, 2011), and ongoing unpublished work from our lab, this is the 
only basic science evaluation of the cognitive impact of any synthetic progestin to date. 
This is also, to my knowledge, the only basic science investigation into various available 
hormone treatments in a model of the transition to menopause. Thus, I am very pleased to 
report that I have discovered a promising new avenue for investigation into cognitively 
protective HTs to be utilized during the transition to menopause. I hope that this work 
opens a new road to safe, affordable, easy-to-access HT options during the transition to 
menopause. 
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CHAPTER 10: GENERAL DISCUSSION 
 Women are exposed to constant shifts in endogenous and exogenous hormones 
throughout life. These exposures have pervasive and interactive impacts on many 
physiological functions, spanning multiple systems. Women’s reproductive hormones, in 
particular, undergo both endogenously- and exogenously- triggered changes, including 
those that happen during perinatal development, puberty, with use of hormonal 
contraceptives, during pregnancy, throughout the transition to menopause, and with 
hormone therapy (HT). Reproductive hormones such as estrogens, androgens, 
progesterone, and others, are responsible for the regulation of many body functions in 
addition to their influence on reproductive functions. Internal hormone secretions serve to 
regulate body temperature, bone density, body fat composition and deposition, metabolism, 
brain function, and much more (Mennenga and Bimonte-Nelson, 2015). Moreover, the 
breadth of the types of hormone exposures women experience is impressive, including both 
natural and synthetic hormones, and several changes in hormone use trends across the last 
few decades may produce a unique generation of aging females.  
 I have studied four distinct types of hormone profiles in this dissertation: the ovary-
intact, reproductively viable hormone profile, which includes several distinct hormonal 
states in a cyclic pattern, the ovariectomy (Ovx) hormone profile, which is void of ovarian 
hormones, the mid-follicular depletion hormone profile, which includes several hormonal 
states that occur in an irregular pattern, and the post-follicular depletion hormone profile, 
which involves low levels of endogenous estrogens and progesterone and moderate levels 
of the androgen androstenedione. Further, I have evaluated individual contributions to 
cognitive ability from several hormones, including androstenedione, several estrogens 
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(ethinyl estradiol, EE; conjugated equine estrogens, CEE; estradiol, E2), and a synthetic 
progestin (levonorgestrel, levo). Results largely indicate that which hormonal treatments 
produce an optimal cognitive impact depends on which of the above hormone profiles is in 
question. Altogether, the data that I have collected for my dissertation indicate that both 
endogenous and exogenous hormonal fluctuations across the lifespan impact specific 
domains of cognition, and are likely to play an important role in shaping the cognitive 
phenotype throughout aging.  
Optimizing Hormonal Contraceptive Use During Young Adulthood 
 I have shown in both humans and rodents that treatment with the estrogen found in 
combined contraceptives (EE) is associated with poorer spatial memory; however, in both 
species, differences only became apparent when working memory demand was highest 
(chapters 3 and 4). In the human radial arm maze (HRAM), which I have demonstrated to 
be a reliable measure of human spatial working memory (chapter 2), I was able to detect 
detriments in performance on the highest working memory trials in women with relatively 
high circulating estrogens (those taking combined contraceptives and those in the follicular 
phase of the menstrual cycle), compared to males (chapter 3).  
 In several follow-up studies, I investigated how the estrogenic component of 
combined oral contraceptives, EE, affects spatial learning and memory in both Ovx and 
ovary-intact young-adult female rats (chapters 4 and 5). In this series of studies, I showed 
that a high dose of EE impaired spatial working memory in Ovx rodents, and both medium 
and high doses of EE reduced the number of ChAT-IR neurons in the basal forebrain 
(chapter 4). Further, the observed behavioral effects correlated with the observed changes 
in the cholinergic system, suggesting that EE may be affecting spatial learning and memory 
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through its impact on this system (chapter 4). I noted a similar pattern of effects in another 
study, in which I administered EE to ovary-intact rats that were actively cycling through 
the estrous cycle. In this study, a low dose of EE, comparable to the doses clinically 
prescribed to women, produced deficits in spatial learning and memory (chapter 5).  
 The findings that I report in chapters 2 through 5 answer many questions about the 
cognitive impact of hormonal contraceptives, but they also raise many new questions. Due 
to the between-subjects nature of the studies utilizing the HRAM in chapters 2 and 3, I 
cannot be sure whether the group differences in visuospatial and spatial working memory 
tasks are due to differences in hormonal profiles, or other subject variables that were not 
accounted for. A within-subjects study is necessary to know whether the differences we 
report here change across time within women. Similarly, the data presented here does not 
allow insight into the permanency of EE’s impact on cognition. Past research from our lab 
found long lasting cognitive impairments with a different synthetic progestin, MPA 
(Braden et al., 2011), raising a possibility that the observed effects might be permanent, or 
long lasting. Finally, while findings from chapter 4 suggest that EE may be exerting its 
cognitive effects through the cholinergic system, we do not know precisely how. 
Additional work is necessary to elucidate the exact mechanisms by which EE impacts 
cognition.  
Optimizing the Cognitive Impact of Hormone Therapy in a Rodent Model of Natural 
Menopause 
 My next series of studies was aimed at optimizing the cognitive impact of HT 
across the transition to menopause. I investigated how various parameters, including timing 
of hormone administration initiation, length of hormone exposure time, and type of 
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estrogen, impacted the cognitive effects of HT during and after VCD-induced follicular 
depletion (chapters 6 and 7). I replicated a previous lab finding, that CEE treatment 
initiated post-depletion produces memory detriments (chapter 6; Acosta et al., 2010). 
Additionally, I extended the previous findings to incorporate multiple administration 
parameters, and discovered that timing of treatment initiation alters the cognitive impact of 
CEE in a model of human menopause. I also reported that post-depletion treatment with 
bioidentical E2 provides a cognitive benefit, akin to that seen with surgical removal of the 
ovaries (chapter 7).  
 These findings have massive clinical implications; beginning with the broad 
message that HT will likely produce optimal benefits with minimal risks only if it is 
tailored to each woman’s personal hormonal makeup. More specifically, I have 
demonstrated that bioidentical E2 as a HT appears to be a more viable option for cognition 
than CEE post-menopause, possibly because of the existing hormonal imbalances created 
by the disruption of the menstrual cycle. Clinical work from the large study of women’s 
health across the nation (SWAN) has detected several distinct hormonal profiles in women 
across the transition to menopause (Tepper et al., 2012). Future research into the individual 
differences in the menopause transition experience is likely to result in further optimization 
of HTs for cognition. Whether the same clusters of hormone profiles are seen across time 
in the VCD model is unknown; collection of circulating hormone levels across time 
following VCD treatment may allow even more refined modeling of natural human 
menopause.  
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Hormonal Mechanisms Underlying the Cognitive Consequences of Natural Hormone 
Loss 
 I utilized pharmacological blockades to investigate the hormonal mechanism by 
which androstenedione may be impairing memory following follicular depletion. The 
results supported our hypothesis, that androstenedione is producing cognitive impairments 
through its conversion to E1, rather than through its actions on the androgen receptor 
(chapter 8). This finding helps to identify exactly which parts of the endogenous hormone 
milieu are negative for cognition. It seems that elevated levels of E1 relative to E2 
negatively impact cognition during and after the transition to menopause.  
 At this point, our lab has identified three different manipulations that each serve to 
alter this hormonal ratio, and that each benefit spatial learning and memory. Surgical 
removal of the follicle-deplete ovaries has now been shown in two separate studies to 
improve aspects of cognition (Acosta et al., 2009b; chapter 7), administration of exogenous 
E2 has also been shown to enhance cognition (experiment 7), and blocking conversion of 
androgens to estrogens via pharmacological inhibition of the aromatase enzyme has also 
now been shown to negate androstenedione-induced cognitive impairments.  Thus, it seems 
likely that there will be multiple ways in which hormone profiles can be altered to benefit 
cognition throughout the transition to menopause, aside from the administration of 
exogenous hormone treatments.  
Modeling Current Trends in Hormone Therapy 
 Finally, I sought to determine whether EE-containing contraceptives might be 
cognitively protective during the transition to menopause. I did this by comparing tonic EE 
and E2 treatment, both with and without the popular progestin levo, to vehicle treatment in 
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animals undergoing the end stages of ovarian follicular depletion, as a model of the 
transition to menopause. I found that E2, levo, and E2 combined with levo each produce 
mixed cognitive effects, which include both benefits and detriments to spatial memory 
(chapter 9). EE alone did not impact cognition, as measured by the WRAM and MM, an 
effect that is promising, given that EE is capable of producing all of the non-cognitive 
benefits of E2 and CEE. Even more exciting was that EE in combination with levo, 
modeling currently available FDA-approved hormonal contraceptive formulations, 
produced a transient benefit on the WRAM (chapter 9). Together, these results indicate that 
currently available, FDA-approved combined contraceptives (containing both EE and a 
synthetic progestin) may serve as a more optimal HT for women that are experiencing the 
transition to menopause than either bioidentical E2 or CEE HT.  
 There are several possible reasons that our EE plus levo treatment produced 
different cognitive effects than either CEE or E2 during the transition to menopause. First, 
the estrogenic component of hormonal contraceptives is unique in several respects: it is not 
converted to other estrogens, and is more resistant to enzymatic degradation in general than 
natural estrogens, conferring a distinct pharmacokinetic profile, and its pharmacodynamic 
profile differs from that of natural E2 and CEE as well. Combined contraceptives are also 
unique candidates for HT due to their ability to halt ovulation, therefore altering 
endogenous production of estrogens and other hormones. Traditional HTs, such as E2 and 
CEE, are not sufficient to halt ovulation, meaning that irregular production of ovarian 
hormones continues in addition to the exogenous administration of these hormone 
treatments. Not only does this distinction mean that traditional HTs do not offer protection 
against unwanted pregnancies, it also means that the endogenous hormone profile likely 
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differs, depending on which exogenous hormone formulation is administered. Thus, a 
treatment that masks irregular endogenous hormone fluctuations in addition to providing 
estrogenic and progestogenic stimulation, such as a combined hormonal contraceptive, may 
be the optimal HT choice for women undergoing the transition to menopause. This 
masking of endogenous hormone fluctuations may not be necessary once follicular 
depletion is complete, and ovulation has ceased.  
General Conclusions 
 Broadly, the goal of my graduate work was to elucidate the parameters that 
determine how endogenous and exogenous hormones impact cognition, particularly spatial 
learning and memory. My conclusions from the completed experiments are that 
endogenous and exogenous hormone treatments have the potential to impact spatial 
memory, and that the direction of these effects largely depends on many individual factors. 
First and foremost, the existing hormone profile of the user determines the cognitive impact 
of hormone exposures. In young adult, naturally-cycling and Ovx organisms, I conclude 
that, although the presence of the ovaries alters the cognitive effects of EE treatment, 
generally, lower doses of EE delivered via tonic regimens (as opposed to daily cyclic 
regimens) produce the best cognitive outcomes. In our model of transitional menopause, I 
established that optimal treatments may vary, depending on which stage of the menopause 
transition the user is in. During follicular depletion, combined contraceptives, specifically 
those containing EE and levo and delivered in a tonic regimen, produce a more favorable 
cognitive profile than bioidentical E2, levo, or E2 combined with levo. Natural, 
bioidentical E2, while producing mixed cognitive results when delivered during follicular 
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depletion, appears to be a viable HT option when delivered after follicular depletion is 
complete.  
 Although the work performed for this dissertation furthered our knowledge of how 
to optimize hormone exposures across the lifespan, several questions remain unanswered. 
First, we do not know whether the cognitive effects of most of the treatments examined 
here are transient or permanent. Major shifts in HT use trends and the fairly recent 
availability of hormonal contraceptives mean that current and future generations have been 
exposed to entirely different hormones throughout their lifespan than any previous 
generation. Work from our laboratory utilizing the synthetic progestin MPA suggests that 
these effects may be long lasting, therefore contributing permanently to the cognitive aging 
profile (Braden et al., 2011). If the treatments investigated in this dissertation do have long-
lasting effects on the brain or body, then current and future generations are likely to 
experience cognitive aging differently than any previous generation. Administration 
parameters, variations in dose and type of hormone, variations in endogenous hormone 
levels, and other factors, such as verbal intelligence, may serve to further impact the 
cognitive effects of any hormone treatment.  
 Thus, much more investigation into the numerous parameters surrounding hormone 
treatment administration is sorely needed. It is my sincere hope that work from this 
dissertation will serve as a starting point from which future studies can be designed to 
continue to elucidate how each of these parameters impact learning and memory 
throughout the entire lifespan. I purposely investigated multiple treatment regimens that are 
already available to women in an effort to minimize the amount of time that the translation 
of my findings to the clinic would take. Contraceptive hormones were initially designed to 
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regulate the menses, providing relief from irregular menstrual cycles. This feature makes 
them an especially interesting candidate for HT. Future studies may allow clinicians to 
develop the optimal transition from the reproductive cycle to reproductive senescence; 
through utilization of cyclic hormonal contraceptive regimens, the menstrual cycle could 
even be simulated through the end of life. We do not yet know enough of the impact that 
such treatments may have on the body as a whole to assert this as a definite possibility, 
however it is possible that the findings from this dissertation lead to revision of hormone 
treatment recommendations, and potentially even re-thinking the type of hormone 
treatments that are delivered. Should the effects reported in this dissertation prove to be 
permanent or long lasting, that means that permanent or long lasting detriments, but also 
benefits, to cognition may be possible to achieve through short-term treatments. Such 
findings could be utilized to improve the way that current and future generations 
experience cognitive aging. 
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PERFECT MARGARITA 
Ingredients 
2 ounces silver/blanco tequila 
1 tablespoon kosher salt 
4 limes 
½ an orange 
2 tablespoons light agave nectar 
¾ cup ice cubes 
Instructions 
 Pour 1/2-ounce of tequila into a small saucer. Spread kosher salt in a separate small 
saucer. Wet the rim of a glass in the tequila. Lift out of the tequila and hold upside down 
for 10 seconds to dry slightly, and then dip the rim of the glass into the salt. Juice two limes 
into the bottom of a cocktail shaker. Cut the remaining two limes and the orange into 
quarters and add them to the shaker. Add agave nectar and muddle. Add the remaining 1 
1/2 ounces of tequila and any remaining on the saucer. Add ice to the shaker, cover and 
shake for 30 seconds. Strain the mixture through a cocktail strainer into the salt-rimmed 
glass, garnish with lime slice, and serve immediately. 
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Figure 1. Experiment 1 schematics and pictures of the human radial arm maze. Depiction 
of the HRAM and surrounding space. 
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Figure 2. Experiment 1 Human and Rodent Radial Arm Maze Performance. There was a 
main effect of Trial [F(10,1520)= 97.19; p< 0.0001] on HRAM Errors, with HRAM Errors 
increasing as trials progressed and working memory load increased. HRAM Errors 
increased from trial 8 to 9 (Trial 8: M= 0.28, SE= 0.04; Trial 9: M= 0.53, SE= 0.06; p< 
0.05), from trial 9 to trial 10 (Trial 10: M=1.03; p<0.0001) and again from trial 10 to trial 
11 (Trial 11: M=2.67, SE=0.11; p<0.0001). This increase in errors occurred when the 
number of arms participants needed to avoid exceeded roughly 8-9 items. HRAM Errors 
declined significantly across Testing Sessions (Both Sessions: M=0.436, SE=0.04, 
Session 1: M=0.51, SE=0.04, Session 2: M= 0.37, SE= 0.04; [F(1,152)= 7.85; p< 0.01]). 
The pattern of performance across trials was the same across Testing Session, (Session x 
Trial interaction: F(10,1520)= 1.80; p>0.05, NS]. Figure 2B shows error patterns observed in 
different versions of the rodent RAM for comparison. 
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Figure 3. Experiment 1 Human Radial Arm Maze Scores as Predicted by Verbal 
Intelligence Measure. WRAT-3 scores did not correlate with HRAM Total Errors.  
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Figure 4. Experiment 1 Human Radial Arm Maze Scores as Predicted by Episodic 
Memory Measures. RAVLT Total Words Learned, Retroactive Interference, and Delayed 
Recall did not correlate with HRAM Total Errors (p>0.05, NS). Regression analysis 
indicated that Total Words Learned, Retroactive Interference, and Delayed Recall trials 
of the RAVLT were not significant predictors of HRAM Total Errors. Combining all 
measures of the RAVLT also did not predict HRAM Total Errors (Adjusted 
R2multiple=0.00, F(3, 151)= 0.88, p>0.05, NS).  
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Figure 5. Experiment 1 Human Radial Arm Maze Scores as Predicted by Visuospatial 
Ability Measures. Both visuospatial tasks, the MRT and JLAP, correlated negatively with 
HRAM Total Errors (p<0.01 and p<0.0001, respectively). For every additional question 
participants answered correctly on the MRT, HRAM errors decreased by 0.40 on 
average; errors decreased by 0.66 for each one point increase in JLAP. The MRT and 
JLAP together predicted HRAM Total Errors (Adjusted R2multiple=0.11, F(2, 152)= 10.29, 
p<0.0001).  
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Figure 6. Experiment 1 Human Radial Arm Maze Scores as Predicted by Working 
Memory Measures. Performance on the working memory capacity tasks, the OSpan, 
Rspan, RotSpan, and SymSpan, correlated negatively with HRAM Total Errors (p<0.001, 
p<0.0001, p<0.05, p<0.05, respectively). For every additional point earned on the Ospan 
or Rspan, HRAM Total Errors decreased by 0.17, on average; HRAM Total Errors 
decreased by 0.19 for each one-point increase in RotSpan or SymSpan scores. The 
Ospan, Rspan, RotSpan, and SymSpan together predicted HRAM Total Errors (Adjusted 
R2multiple=0.09, F(4,146)= 4.80, p<0.001).  
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Figure 7. Experiment 2 Human Radial Arm Maze Performance Across Trials. There was 
a Trial x Hormone Group interaction (F(30,1100)= 1.47, p<0.05) for Total Errors on the 
HRAM, such that as working memory load (trial) increased, group differences began to 
emerge. When trials were grouped into low working memory demand and high working 
memory demand, there were no differences between the Male and Female Follicular 
groups (F(1,67)= 0.12, p>0.05, NS; η2<0.01), Male and Female Luteal groups (F(1,74)= 0.44, 
p>0.05, NS; η2<0.01), or Male and Female Oral Contraceptive groups (F(1,75)= 1.74, 
p>0.05, NS; η2=0.02) for trials 2 through 6, which required participants to remember 1-5 
previously visited spatial locations. There was a difference on Total Errors between the 
Male and Female Follicular groups (F(1,67)= 4.38, p<0.05; η2=0.06), and between the 
Male and Female Oral Contraceptive groups  (F(1,75)= 6.17, p<0.05; η2=0.08), but not 
between the Male and Female Luteal groups (F(1,74)= 0.14, p>0.05, NS; η2<0.01), for 
trials 7 through 11, which corresponded to a demand of 6-10 previously visited spatial 
locations.  
 
  
184 
 
  
185 
Figure 8. Experiment 2 Reading Proficiency Task. We found a difference in WRAT-3 
scores between the Male and Female Follicular (F(1,60)= 6.95, p<0.05; η2=0.10), but not 
between the Male and Female Luteal (F(1,67)= 1.54, p>0.05, NS; η2=0.02) groups, or the 
Male and Female Oral Contraceptive groups (F(1,71)= 2.26, p>0.05, NS; η2=0.03). Mean 
scores on the WRAT-3 for each group were as follows: men (M=109.6; SD=7.2), 
contraceptive users (M=106.7; SD=9.0), follicular phase (M=103.3; SD=6.0), and luteal 
phase (M=103.7; 13.5).  
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Figure 9. Experiment 2 Episodic Memory Tasks. There were no differences between 
Male and Female Follicular (F(1,67)= 1.06, p>0.05, NS; η2=0.02), Male and Female Luteal 
(F(1,74)= 0.71, p>0.05, NS; η2=0.01), or Male and Female Oral Contraceptive (F(1,75)= 
1.82, p>0.05, NS; η2=0.02) on Total Words Learned (trials A1-A5). There were no 
differences between Male and Female Follicular (F(1,66)= 1.08, p>0.05, NS; η2=0.02), 
Male and Female Luteal (F(1,73)= 0.38, p>0.05, NS; η2=0.01), or Male and Female Oral 
Contraceptive (F(1,74)= 0.99, p>0.05, NS; η2=0.01) on number of words recalled on the 
retroactive interference trial (trial A6). There were no differences between Male and 
Female Follicular (F(1,67)= 2.29, p>0.05, NS; η2=0.03), Male and Female Luteal (F(1,74)= 
0.85, p>0.05, NS; η2=0.01), or Male and Female Oral Contraceptive (F(1,75)= 2.05, 
p>0.05, NS; η2=0.03) on number of words recalled following a 20-minute delay (trial 
A7).  
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Figure 10. Experiment 2 Visuospatial Ability Tasks. There were differences in MRT 
scores between the Male and Female Follicular groups (F(1,67)= 11.57, p<0.01; η2=0.15), 
the Male and Female Luteal groups (F(1,74)= 6.09, p<0.05; η2=0.08), and the Male and 
Female Oral Contraceptive groups (F(1,75)= 8.91, p<0.01; η2=0.11). There was also a 
marginal difference in JLAP scores between the Male and Female Follicular groups 
(F(1,67)= 3.54, p<0.10; η2=0.05), and a significant difference between the Male and 
Female Oral Contraceptive groups (F(1,75)= 5.73, p<0.05; η2=0.07), but not between the 
Male and Female Luteal groups (F(1,74)= 1.67, p>0.05, NS; η2=0.02). 
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Figure 11. Experiment 2 Working Memory Capacity Tasks. There were no differences 
between groups on the OSpan (Male versus Female Follicular: F(1,65)= 0.28, p>0.05, NS; 
η2<0.01; Male versus Female Luteal: F(1,72)= 0.02, p>0.05, NS; η2<0.01; Male versus 
Female Oral Contraceptive: F(1,73)= 0.65, p>0.05, NS; η2<0.01), RSpan (Male versus 
Female Follicular: F(1,65)= 0.10, p>0.05, NS; η2<0.01; Male versus Female Luteal: F(1,72)= 
2.31, p>0.05, NS; η2=0.03; Male versus Female Oral Contraceptive: F(1,73)= 0.06, p>0.05, 
NS; η2<0.01), RotSpan (Male versus Female Follicular: F(1,65)= 0.20, p>0.05, NS; η2<0.01; 
Male versus Female Luteal: F(1,72)= 0.57, p>0.05, NS; η2<0.01; Male versus Female Oral 
Contraceptive: F(1,73)= 0.43, p>0.05, NS; η2<0.01), or SymSpan (Male versus Female 
Follicular: F(1,65)= 0.03, p>0.05, NS; η2<0.01; Male versus Female Luteal: F(1,72)= 0.57, 
p>0.05, NS; η2<0.01; Male versus Female Oral Contraceptive: F(1,73)= 0.87, p>0.05, NS; 
η2=0.01) tasks.  
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Figure 12. Experiment 3 Water Radial Arm Maze Performance. When delivered via daily 
subcutaneous injection, there were no effects of EE treatment on WMC, WMI, or RM 
during the learning portion of testing. During the asymptotic phase of testing, similar to 
effects seen previously in our lab with tonic EE treatment (Mennenga et al., 2015), there 
was a Trial x Treatment interaction for WMC errors [F(6,64)= 2.82; p<0.05] with a planned 
comparison showing that the high EE treated animals made more errors than vehicle 
treated animals as working memory load increased [F(2,32)= 5.78; p<0.01]. Post-hoc 
analyses also showed that the high EE group committed more WMC errors than the low 
EE (Fisher, p<0.05) and medium EE (Fisher, p<0.05) animals at the highest working 
memory load.  
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Figure 13. Experiment 3 Morris Water Maze Performance. There was a marginal 
Treatment x Day interaction for MM testing [F(6,64)=2.21; p=0.05]. Further analyses 
revealed a main effect of Treatment [F(3,32)= 3.22; p<0.05] for Day 1 of MM, whereby the 
vehicle group performed better than the low EE [F(1,16)= 6.84; p<0.05], medium EE 
[F(1,16)= 8.51; p<0.05], and high EE [F(1,16)= 9.47; p<0.01] groups. There was no 
Treatment x Trial interaction for Day 1, indicating that this effect was present across all 
trials and was not carried by the initial exposure to the task on trial 1. There were no 
effects of Treatment for Days 2 or 3 of MM testing. A higher percent distance was spent 
in the previously platformed quadrant versus the opposite quadrant [F(1,32) =374.33; 
p<0.0001] for the probe trial, with no quadrant by Treatment interaction, indicating that 
all groups spatially localized the platform quadrant by the end of testing. 
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Figure 14. Experiment 3 ChAT Cell Population Estimates. For wet uterine weight, there 
was a significant effect of Treatment [F(3,31)=29.88; p<0.0001], with uteri of vehicle-
treated rats weighing less than low EE- [F(1,15)= 62.17; p <0.0001], medium EE- [F(1,16)= 
117.36; p <0.0001], and high EE- [F(1,16)= 109.10; p <0.0001] treated rats. 
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Figure 15. Experiment 3 Uterine Weights. There was a main effect of Treatment 
[F(3,12)=3.66; p<0.05] in the VDB, whereby ChAT-IR cell counts were lower in the 
medium EE group (Fisher, p<0.05), and lower in the high EE group (Fisher, p=0.05), 
than those in the vehicle group. ChAT-IR cell counts in the low EE group did not differ 
from the vehicle group. Post-hoc tests indicate that the ChAT-IR cell counts were lower 
in the medium EE group (Fisher, p<0.05) and marginally lower in the high EE group 
(Fisher, p=0.09), than the low EE group. There were no effects of Treatment on ChAT-IR 
cell counts in the MS. The MS had a lower ChAT-IR cell count than the VDB 
(F(1,12)=96.49, p<0.001). There was also a positive correlation between ChAT-IR cell 
counts in the VDB and MS of the basal forebrain (r=0.56, p<0.05), indicating that 
animals with higher ChAT-IR cell counts in the MS tended to also have higher cell 
counts in the VDB. There was a negative correlation between ChAT-IR cell counts in the 
VDB and number of WMC errors on the highest load trial (trial 4) during the asymptotic 
portion of WRAM testing [r= -0.55; p<0.05], such that animals with lower ChAT-IR cell 
counts committed more WMC errors.  
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Figure 16. Experiment 4 Timeline and Depiction of Behavioral Tasks. Depiction of 
temporal relations between experimental manipulations.  
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Figure 17. Experiment 5 Water Radial Arm Maze Performance. There was a main effect of 
Treatment on Total Errors made on days 2-7 of WRAM testing, which is considered the 
learning phase of testing (F(1,16)= 4.80, p<0.05), with the EE-treated group committing 
more errors across all trials than the vehicle-treated animals. There was no interaction 
between Treatment and Trial (F(3,48)= 1.59, p=0.20, NS), indicating that this difference was 
not specific to any trial. This difference was no longer apparent during the asymptotic 
portion of testing, days 8-12 (F(1,16)= 1.94, p=0.18, NS) and there was no interaction 
between Treatment and Trial for this portion of testing (F(3,48)= 0.70, p=0.56, NS).  
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Figure 18. Experiment 4 Morris Water Maze Performance. There were no main effects of 
Treatment on Total Swim Distance (cm) for the MM (F(1,16)= 1.08, p=0.31, NS), but there 
was a Day x Treatment interaction (F(4,64)= 3.32, p<0.05). Further analyses revealed that 
there was an effect of Treatment on Total Swim Distance on Day 1 of testing (F(1,16)= 5.25, 
p<0.05), with the EE-treated animals swimming a shorter distance than the vehicle-treated 
animals across all four trials, suggesting that they covered a shorter distance during the 
allotted trial time. For the probe trial, there was a main effect of Quadrant (F(1,16)= 173.00, 
p<0.0001), indicating that all animals preferred the previously-platformed quadrant over 
the diagonally opposite quadrant and were therefore likely employing a spatial strategy. 
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Figure 19. Experiment 4 Morris Water Maze Day 1 Performance. There was no 
difference on any trial of Day 1 when only successful trials were included (Trial 1: no 
animals found the platform; Trial 2: F(1,5)=0.05, p>0.05, NS; Trial 3: F(1,7)=1.61, p>0.05, 
NS; Trial 4: F(1,8)=0.47, p>0.05, NS). Further, mean swim velocity (cm/s) was marginally 
decreased in the EE group (F(1,16)=3.93, p<0.10).  
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Figure 20. Experiment 4 Markers of Peripheral Stimulation. There was a main effect of 
Treatment on androstenedione levels (F(1,14)= 11.99, p<0.01), E2 levels (F(1,16)= 5.54, 
p<0.05), and FSH levels (F(1,17)= 8.32, p<0.05), such that EE treatment increases 
androstenedione levels, decreases E2 levels, and increased FSH levels, relative to vehicle 
treatment.  
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Figure 21. Experiment 5 Timeline and Depiction of Behavioral Tasks Used. Depiction of 
temporal relations between experimental manipulations.  
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Figure 22. Experiment 5 Water Radial Arm Maze Performance. For Block 3, there was a 
main effect of Treatment, such that the Post group made more errors than the Control group 
(F(1,15)=3.22, p≤0.05, ηG2=0.01), as expected (Acosta et al., 2010) (F(1,15)=3.22, p≤0.05, 
ηG2=0.01). The Post group also made more error than the Peri-ST group (F(1,14)=6.20, 
p≤0.05, ηG2=0.03) across all trials, indicating a benefit of early treatment, but did not differ 
from the Peri-LT group (F(1,17)=1.20, p>0.05, NS, ηG2=0.01), indicating that the benefit of 
early initiation is restricted to short-term treatment.  
 
  
214 
 
 
  
215 
Figure 23. Experiment 5 Morris Water Maze Performance. We did not observe an effect 
of Wave (F(1,26)= 1.22; p>0.05, NS, ηG2=0.02), nor a Wave x Treatment interaction 
(F(3,26)= 1.42; p>0.05, NS, ηG2=0.04) for MM swim distance, therefore analyses were 
collapsed across wave. There were no differences in swim distance on Days 1-3 between 
the Post and Control groups (F(1,15)=0.36, p>0.05, ηG2=0.01; NS), the Post and Peri-LT 
groups (F(1,17)=2.29, p>0.05, ηG2=0.02; NS), nor the Post and Peri-ST groups 
(F(1,14)=1.21, p>0.05, ηG2=0.03; NS). For the probe trial, there was a main effect of 
Quadrant (F(1,30)=353.88, p≤0.0001, ηG2=0.90) in the absence of a Quadrant x Treatment 
interaction (F(3,30)=1.38, p>0.05, ηG2=0.10; NS).  
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Figure 24. Experiment 5 Delay-Match-to-Sample Asymmetrical Three-Choice Task 
Performance. We did not observe an effect of Wave (F(1,26)= 0.47; p>0.05, NS, ηG2<0.01), 
nor a Wave x Treatment interaction (F(3,26)= 2.35; p>0.05, NS, ηG2=0.01) for DMS errors, 
therefore both waves are presented together. There was a Trial x Treatment interaction for 
the Control versus the Post group (F(4, 60)=6.22; p≤0.001, ηG2=0.08), whereby the Post 
group made fewer errors on Trial 2, the working memory trial (F(1,15)=16.26, p≤0.01, 
ηG2=0.14), during the learning phase of testing (Days 1-3). There were no differences 
between the Post and Peri-LT groups (F(1,17)=0.66, p>0.05, ηG2=0.01; NS) or Post and Peri-
ST groups (F(1,14)=0.03, p>0.05, ηG2=0.04; NS) for the learning portion of testing (Figure 
24a). There were no effects of Treatment for the asymptotic portion of DMS testing (Days 
4-6), and there were no effects of Treatment on errors following a 6- or 8-hour delay 
between trials 1 and 2.  
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Figure 25. Experiment 5 Peripheral Markers of Treatment Verification. There was a main 
effect of Treatment on uterine weights (F(3, 30)=4.44; p≤0.05, η2=0.31), such that the 
Control group had lower uterine weights than all CEE-treated groups (Post: Fisher, 
p≤0.05; Peri-LT: Fisher p≤0.05; Peri-ST: Fisher, p≤0.01). There was also a main effect of 
Treatment on corpora lutea counts (F(3, 30)=8.91; p≤0.001, η2=0.47), such that animals in 
the Peri-ST group had more corpora lutea than the Control (Fisher, p≤0.01), Post (Fisher, 
p≤0.001), and Peri-LT (Fisher, p≤0.0001) animals. 
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Figure 26. Experiment 5 Serum Levels of Androstenedione. There were no group 
differences in serum levels of androstenedione (F(3,29)=0.13; p>0.05, η2=0.02 NS).  
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Figure 27. Experiment 5 Correlations Between Behavioral Scores and Serum 
Androstenedione Levels. In all treatment groups, androstenedione levels positively 
correlated with total WRAM errors on Trials 1-4 across all days of testing (r=0.51, 
p≤0.05), as well as on Trial 4 alone, the trial with the highest working memory load, 
(r=0.58, p≤0.01). 
  
224 
 
  
225 
Figure 28. Experiment 6 Timeline and Depiction of Behavioral Tasks Used. Depiction of 
temporal relations between experimental manipulations.  
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Figure 29. Experiment 6 Water Radial Arm Maze Performance. On the first block of 
WRAM testing, days 2-4, there was a Trial x Treatment interaction for the VCD and VCD-
Ovx groups (F(3,60)= 2.52, p<0.05; ηG2=0.04), such that on trial 4, the trial with the highest 
working memory load, the VCD animals made more errors than the Ovx animals (F(1,20)= 
2.96, p<0.05; ηG2=0.06). There was also a marginal Trial x Treatment interaction for the 
VCD and VCD-E2 groups (F(3,60)= 2.48, p<0.10; ηG2=0.04), such that on trial 4, the trial 
with the highest working memory load, the VCD animals made marginally more errors 
than the VCD-E2 animals (F(1,20)= 2.94, p<0.10; ηG2=0.06). On the second testing block, 
days 5-8, there was a Trial x Treatment interaction for the VCD and VCD-E2 groups 
(F(3,60)= 3.70, p<0.05; ηG2<0.01). On Trial 4, the trial with the highest working memory 
load, E2 treatment enhanced performance; the E2 animals made fewer errors than the VCD 
group (F(1,20)= 4.68, p<0.05; ηG2=0.04). There were no effects of Treatment on Days 9-12 
of testing.  
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Figure 30. Experiment 6 Follicle Counts, Corpora Lutea Counts and Uterine Weights. 
There were no differences in total number of follicles present in the ovaries of the E2 and 
Vehicle groups at sacrifice (F(1,20)= 0.93, p= 0.35; η2=0.04; NS), or the number of corpora 
lutea (F(1,20)= 0.46, p= 0.51; η2=0.02; NS). There was a main effect of Treatment on wet 
uterine weights (F(2,30)= 14.93, p<0.0001; η2=0.50), with E2-treated animals having heavier 
uterine horns than vehicle-treated or Ovx animals (Fisher, p<0.0001). There was no 
difference between the Vehicle and Ovx groups in uterine weight, indicating a lack of 
uterine stimulation in the Vehicle-treated VCD animals.  
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Figure 31. Experiment 6 Serum Levels of E2, Estrone, and Androstenedione. There was a 
main effect of treatment on serum E2 levels (F(2,30)= 17.85, p<0.0001; η2=0.54), with the 
E2-treated group showing higher circulating levels of E2 than both the Ovx and Vehicle 
groups (Fisher, p<0.0001). There was no difference in serum E2 levels between the Ovx 
and Vehicle groups at sacrifice (Fisher, p=0.76; NS; Vehicle M=5.42pg/ml, Ovx 
M=1.45pg/ml). 
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Figure 32. Experiment 7 Timeline and Depiction of Behavioral Tasks Used. Depiction of 
temporal relations between experimental manipulations.  
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Figure 33. Experiment 7 Water Radial Arm Maze Performance. For Block 3 of WRAM, 
there was a Treatment x Trial interaction for WMC errors [F(8,88) =3.05, p<0.01]. For Trial 
4, there was a main effect of Treatment [F(4,44) =4.31, p<0.01]; the Androstenedione group 
did worse than the Vehicle group (Fisher, p<0.001); the addition of anastrozole treatment 
reversed this androstenedione-induced impairment (Fisher, p<0.01). On Trial 4, the 
Androstenedione group also did worse than the Anastrozole group (Fisher, p<0.01) group, 
and the Androstenedione+Flutamide group did worse than the Vehicle group (Fisher, 
p<0.05). There was also an effect on Block 3 for WMI, with a Treatment x Trial interaction 
for WMI errors [F(12,132) =5.36, p<0.0001]. For Trial 4, there was a main effect of 
Treatment [F(4,44) =5.90, p<0.001]; the Androstenedione group committed more WMI 
errors than Vehicle (Fisher, p<0.01). The addition of anastrozole reversed the impairing 
effect of andostenedione on Trial 4 (Fisher, p<0.01), and the Androstenedione group made 
more errors than the Anastrozole group (Fisher, p<0.01). The Androstenedione+Flutamide 
group committed more WMI errors on Trial 4 than the Vehicle (Fisher, p<0.01), 
Androstenedione+Anastrozole (Fisher, p<0.01), and Anastrozole (Fisher, p<0.01) groups. 
There was a main effect of Treatment for RM errors [F(4,44) =6.30, p<0.001] for Block 3 of 
WRAM testing. The Androstenedione group committed more RM errors than the Vehicle 
group (Fisher, p<0.001), and anastrozole reversed reference memory impairments induced 
by androstenedione (Fisher, p<0.05). The Androstenedione group also made more RM 
errors than the Anastrozole group (Fisher, p<0.05), and the Androstenedione+Flutamide 
group made more RM errors than Vehicle (Fisher, p<0.001), Androstenedione+Anastrozole 
(Fisher, p<0.01), and Anastrozole (Fisher, p<0.05) groups. 
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Figure 34. Experiment 7 Delay Match-to-Sample Performance. There was a main effect of 
Day [F(6,264) =17.17, p<0.0001] with Total Errors decreasing as days progressed. There 
were no Treatment effects for Total Errors (Days 1-7), nor was there a Treatment x Day 
interaction.  
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Figure 35. Experiment 7 Morris Water Maze Performance. Analyses revealed a main effect 
of Block [F(5,220) =150.06, p<0.0001], with swim distance decreasing across blocks 
showing learning. There was a Treatment x Block interaction for Morris water maze testing 
[F(20,220)=1.84; p<0.05]. For Block 1, there was a main effect of Treatment [F(4,44)=2.96; 
p<0.05]; post hoc analyses revealed that the Androstenedione+Anastrozole group swam a 
shorter distance to the platform than the Vehicle (Fisher, p<0.05), Androstenedione (Fisher, 
p<0.05), and the Androstenedione+Flutamide group (Fisher, p<0.01). For the probe trial, 
there was a main effect of Quadrant [F(1,44)=982.20; p<0.0001] in the absence of a Quadrant 
x Treatment interaction [F(4,44)=2.30; p>0.05, NS], indicating that all groups equally 
localized the platform using spatial navigation by the end of Morris water maze testing.  
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Figure 36. Experiment 7 Visible Platform Performance. There was a main effect of Trial 
[F(5,220) =9.32, p<0.0001], with latency decreasing as trials progressed within the day of 
visible platform testing. There were no Treatment main effects [F(4,44)=1.49, p<0.05, NS] 
on latency to escape for the visible platform task. However, there was a Treatment x Trial 
interaction [F(20,220) =2.35, p<0.01], such that there was a main effect of Treatment on 
Trial 1 [F(4,44) =3.65, p<0.05]. Further analyses indicated that the Vehicle group took a 
longer time to reach the platform than the Androstenedione (Fisher, p<0.05), 
Androstenedione+Anastrozole (Fisher, p<0.01), and Anastrozole (Fisher, p<0.001) 
groups; no hormone treated group differed from any other hormone treated group. There 
were no effects of Treatment on any of the remaining trials (Trials 2-6). 
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Figure 37. Experiment 7 Uterine Weights. There was a main effect of Treatment for uterine 
weights [F(4,43)=13.03; p<0.0001]. The Androstenedione group had higher uterine weights 
than the Vehicle (Fisher, p<0.0001), Androstenedione+Anastrozole (Fisher, p<0.001), 
Androstenedione+Flutamide (Fisher, p<0.0001), and Anastrozole (Fisher, p<0.0001) 
groups. The Androstenedione+Anastrozole group also had higher uterine weights than the 
Anastrozole group (Fisher, p<0.05).  
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Figure 38. Experiment 7 Serum Hormone Levels. There was a main effect of Treatment for 
serum androstenedione [F(4,31)=6.04; p<0.01]. Androstenedione increased serum 
androstenedione levels in all groups receiving this androgen, relative to vehicle treatment 
[Vehicle vs. Androstenedione (Fisher, p<0.01), Vehicle vs. Androstenedione+Flutamide 
(Fisher, p<0.05), Vehicle vs. Androstenedione+ Anastrozole (Fisher, p<0.01)], and relative 
to treatment with anastrozole alone [Anastrozole group vs. Androstenedione group (Fisher, 
p<0.001), Anastrozole vs. Androstenedione+Flutamide group (Fisher, p<0.05), Anastrozole 
vs. Androstenedione+ Anastrozole group (Fisher, p<0.01)]. There was a main effect of 
Treatment for serum testosterone [F(4,28)=4.60; p<0.01]. The Androstenedione group had 
higher testosterone serum levels than Vehicle (Fisher, p<0.01) and Anastrozole (Fisher, 
p<0.01) groups, and the Androstenedione+Anastrozole group also had higher serum 
testosterone levels than Vehicle (Fisher, p<0.05) and Anastrozole (Fisher, p<0.05) groups. 
The analysis of serum estrone revealed a main effect of Treatment as well [F(4,26)=96.67; 
p<0.0001]. The Androstenedione group had higher serum estrone levels than the Vehicle 
group (Fisher, p<0.001), and the addition of anastrozole decreased estrone levels 
(Androstenedione vs. Androstenedione+Anastrozole Fisher, p<0.05). The Androstenedione 
group had higher serum levels than the Anastrozole group (Fisher, p<0.001), and the 
Androstenedione+ Flutamide group had higher serum estrone levels than the Vehicle 
(Fisher, p<0.0001), Anastrozole (Fisher, p<0.0001), Androstenedione (Fisher, p<0.0001), 
and Androstenedione+Anastrozole groups (Fisher, p<0.0001). The 
Androstenedione+Anastrozole group tended to have higher serum estrone levels than the 
Vehicle (p=0.05), and Anastrozole (p=0.05) groups. 
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Figure 39. Experiment 7 Correlations Between Serum Estrone Levels and Cognitive 
Performance. Serum estrone levels correlated with average Total Errors on Block 3 of 
WRAM testing across all four trials (r=0.39; p<0.05), as well as on Trial 4, the trial with 
the highest working memory load (r=0.36; p<0.05). Because we found a clear bimodal 
distribution in estrone levels, whereby the Androstenedione+Flutamide group had higher 
estrone levels than all other groups and therefore held the potential to exert a large amount 
of influence over these analyses, we also assessed each of these correlations excluding the 
Androstenedione+Flutamide group. With the Androstenedione+Flutamide group excluded, 
we found that serum estrone levels still correlated with average Total Errors on Block 3 of 
WRAM testing across all four trials (r=0.58; p<0.01), as well as on Trial 4, the trial with 
the highest working memory load (r=0.62; p<0.01).  
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Figure 40. Experiment 8 Timeline and Depiction of Behavioral Tasks Used. Depiction of 
temporal relations between experimental manipulations. 
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Figure 41. Experiment 8 Water Radial Arm Maze Performance. For Block 1 (days 2-3) of 
WRAM testing, there was a Trial x Estrogen x Progestin interaction (F(6,159)=2.33, p<0.05; 
ηG2=0.04), with group differences appearing on Trial 4, the trial with the highest working 
memory load. On Trial 4, there was a Estrogen x Progestin interaction (F(2,53)=3.39, p<0.05; 
ηG2=0.05), whereby levo treatment produced impairments relative to no levo treatment in 
animals treated with no estrogen (Fisher, p<0.05), and in animals treated with E2 (Fisher, 
p<0.05), but not in animals treated with EE (Fisher, p>0.05). On Block 2 of WRAM testing 
(days 4-6), there was a Trial x Estrogen interaction (F(6,159)=4.47, p<0.001; ηG2=0.04) and a 
Trial by Progestin interaction (F(3,159)=3.93, p<0.01; ηG2=0.02), with treatment differences 
emerging on Trial 4, the trial with the highest working memory load. On Trial 4, there was 
a main effect of estrogen (F(2,53)=5.23, p<0.01; ηG2=0.06), with E2-treated animals 
performing better than those treated with vehicle (Fisher, p<0.05) or EE (Fisher, p<0.05), 
regardless of Progestin treatment. There was also a main effect of Progestin on Trial 4 
(F(1,53)=5.40, p<0.05; ηG2=0.03), with levo-treated animals outperforming animals that did 
not receive levo (Fisher, p<0.05), regardless of Estrogen treatment. There was a Trial x 
Estrogen x Progestin interaction on Block 3 of WRAM testing (days 7-9; F(6,159)=3.66, 
p<0.01; ηG2=0.04), with group differences on Trial 4, the highest working memory load 
trial. On Trial 4, there was an Estrogen x Progestin interaction (F(2,53)=4.73, p<0.05; 
ηG2=0.07), whereby treatment with E2 produced spatial memory impairment in animals 
that did not receive levo, relative to treatment with EE (Fisher, p<0.05) or no estrogen 
(Fisher, p<0.05). There were no effects of Estrogen within the levo-treated groups (Fisher, 
p>0.05).
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Figure 42. Experiment 8 Morris Water Maze Performance. There were no effects of 
Estrogen (F(2,53)= 0.80, p>0.05, NS; ηG2<0.01) or Progestin on MM performance (F(1,53)= 
0.03, p>0.05, NS; ηG2<0.01). On the probe trial, there was a main effect of Quadrant 
(F(1,53)= 430.58, p≤0.0001; ηG2=0.86), with no Estrogen x Quadrant interaction (F(2,53)= 
0.20, p>0.05; ηG2<0.01; NS), but there was a Progestin x Quadrant interaction (F(1,53)= 3.81, 
p<0.05; ηG2=0.03). This prompted us to analyze the first half of the Probe trial, to 
determine whether animals began searching in other quadrants after a lack of reward in the 
NE quadrant for the first 30 seconds. Indeed, during the first 30 seconds of the probe trial, 
there was a main effect of Quadrant (F(1,53)= 261.96, p≤0.0001; ηG2=0.93), with no 
Estrogen x Quadrant interaction (F(2,53)= 0.10, p>0.05; ηG2<0.01; NS), and no Progestin x 
Quadrant interaction (F(1,53)= 2.44, p>0.05; ηG2=0.03; NS), demonstrating that all treatment 
groups localized the platform by the end of MM testing. 
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Figure 43. Experiment 8 Uterine Weights and Serum Hormone Levels. There was a main 
effect of Estrogen on Uterine Weights (F(2,53)=8.51, p<0.001; ηG2=0.24), with E2-treated 
animals exhibiting heavier uterine horns at sacrifice than animals that received EE or no 
estrogen, regardless of Progestin treatment. There was no impact of Progestin treatment 
on Uterine Weights (F(1,53)=1.20, p>0.05; ηG2=0.02). There was no Estrogen x Progestin 
interaction (F(1,53)=0.10, p>0.05; NS; ηG2<0.01).  
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Figure 44. Experiment 8 Relations Between Uterine Weights and Serum Hormone 
Levels. Scatterplot of serum E2 levels (pg/ml) by uterine weights (g), split by group. 
Lowess smooth line fitting 66% of the points is shown by group. 
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